NOVEL ADENINE COMPOUND AND USE THEREOF

Information

  • Patent Application
  • 20120178743
  • Publication Number
    20120178743
  • Date Filed
    February 22, 2012
    12 years ago
  • Date Published
    July 12, 2012
    12 years ago
Abstract
An antiallergic agent for topical administration containing an adenine compound of general formula (1):
Description
TECHNICAL FIELD

The present invention relates to a novel adenine compound which is useful as a prophylactic or therapeutic agent for viral diseases, allergic diseases, etc.


BACKGROUND ART

Interferon is an endogenous protein which plays an important role in mammalian immune system, takes a part of nonspecific defensive mechanism in vivo and greatly participates also to specific defensive mechanism in vivo. In fact, interferon has been used in the clinical field as a therapeutic agent for viral diseases, such as hepatitis B and C, etc. Low molecular weight organic compounds which induce biosynthesis of said interferon (interferon inducers) have been developed as an interferon preparation in next generation. Imidazoquinoline derivatives (see European Patent Publication A 145340), adenine derivatives (see WO 98/01448 and WO 99/28321), etc. are illustrated. For example, Imiquimod, an imidazoline derivative is used in the clinical field as an external antiviral agent for genital verruca.


By the way, T cells which play the key role of the immunological response in vivo are classified into two kinds, Th1 cells and Th2 cells. In the body of patients suffering from allergic disease, cytokines such as interleukin 4 (IL-4), interleukin 5 (IL-5), etc. are excessively secreted from TH2 cells and therefore, it is expected that the compound which suppresses immune response of Th2 cells becomes a therapeutic agent for allergic diseases.


It is known that the above imidazoquinoline derivatives and adenine derivatives have not only the interferon inducing activity, but also have the activity suppressing the production of interleukin 4 (IL-4) and interleukin 5 (IL-5). In fact it is known that these derivatives are effective for allergic diseases on animal model.


However, there is anxiety for systemic adverse-effects due to the interferon inducing activity such as fever, interferon-like diseases when these derivatives are administered as an antiallergic agent.


DISCLOSURE OF INVENTION

The problem to be solved by the present invention is to provide a topically administrable medicament which is characterized in suppressing the systemic adverse effect caused by interferon inducing activity.


That is, the present invention provides a novel adenine compound which is characterized in being quickly metabolized to change a less active compound when it is topically administered, and a topically administrable medicament containing this compound as an active ingredient, which is used as the therapy for viral diseases, cancer or allergic diseases, whose systemic pharmacological activity is lessened.


The present inventors have been extensively studied in order to obtain a therapeutic and prophylactic agent for immune deficiency such as allergic diseases which shows excellent effect in the applied area and does not show the systemic adverse effect, when it is externally used in the form of liniments or aerosols useful for diseases such as asthma, etc. and as a result have found that the adenine compounds of the present invention show surprisingly excellent effect on pathologically modeled animals and is characterized in being quickly metabolized in the applied area or the body to change into a less active compound. Namely, the compounds of the present invention are reduced in the systemically pharmacological activity and are useful as a therapeutic or prophylactic agent for viral diseases, cancer, allergic diseases, etc. The present invention was completed based on the above findings.





BRIEF DESCRIPTION OF FIGURES


FIG. 1 shows anti-HSV activity on a compound of Example 20 against a pathologic modeled-animal infected with HSV-2 in its vagina.





Compound A was spread to a vagina of a female mouse (BALB/c) to which previously Depo-Provera was administered, and on next day, HSV-2 was infected to the vagina. Nine days later, the rate of survival or death of mice was observed and compared.


BEST MODE FOR CARRYING OUT THE INVENTION

The present invention relates to


[1] A topically administrable medicament containing an adenine compound represented by a general formula (1):




embedded image


wherein


Ring A is a 6 to 10 membered mono or bicyclic aromatic hydrocarbon ring or a 5 to 10 membered mono or bicyclic heteroaromatic ring containing 1 to 3 hetero atoms selected from the group of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom and 0 or 1 sulfur atom,


n is an integer selected from 0 to 2, m is an integer selected from 0 to 2,


R is halogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkoxy group, or substituted or unsubstituted amino group, and when n is 2, R(s) may be the same or different,


X1 is oxygen atom, sulfur atom, NR1 (wherein R1 is hydrogen atom or alkyl group) or a single bond,


Y1 is a single bond, alkylene which may be substituted by oxo group, or divalent group of the formula below:




embedded image


(wherein r1 and r2 are independently an integer selected from 1 to 3),


Y2 is a single bond, alkylene optionally substituted by hydroxy group or oxo group, oxyalkylene, cycloalkylene, oxycycloalkylene, divalent group of a monocyclic hetero ring containing 1 or 2 hetero atoms selected from the group consisting of 1 or 2 nitrogen atoms wherein said nitrogen atom may be substituted, oxygen atoms and sulfur atoms wherein said sulfur atom(s) may be oxidized by 1 to 2 oxygen atoms, or divalent group of the formula below:




embedded image


(wherein A′ is cycloalkylene, s1 is an integer selected from 1 to 3),


Z is alkylene,


Q1 is hydrogen atom, halogen atom, hydroxy group, alkoxy group, or a group selected from the group consisting of Substituents illustrated below,


Q2 is a group selected from the group consisting of Substituents illustrated below,


R10 or R11 in Q2 may be taken with R to form a 9 to 14 membered fused bi or tricyclic ring together with the adjacent Ring A,


when m is 0, Q1 is a group selected from the group consisting of Substituents illustrated below,


Substituents: —COOR10; —COSR10; —OCOOR10; —OCOR10; —CONR11R12; —OCONR11R12


(wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkeny group, substituted or unsubstituted cycloalkeny group, or substituted or unsubstituted alkynyl group, R11 and R12 are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkeny group, substituted or unsubstituted cycloalkeny group, or substituted or unsubstituted alkynyl group, or R11 and R12 may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s));


and any group selected from the following formulas (3)˜(6):




embedded image


(wherein M is a single bond, oxygen atom or sulfur atom, and q is an integer selected from 1 to 3),


and when m is 2, (Y2-Q2)(s) may be the same or different,


or a pharmaceutically acceptable salt thereof as an active ingredient;


[2] The topically administrable medicament containing an adenine compound described in the above [1], wherein in the general formula (1), at least one of Q1 and Q2 is —COOR10, —COSR10, —OCOR10, —OCOOR10 or —CONR11R12;


[3] The topically administrable medicament containing an adenine compound described in the above [1] or [2]: wherein in the general formula (1), the substituent(s), by which alkyl group, alkeny group or alkynyl group in R10, R11 and R12 is substituted, are the same or different and at least one substituent selected from the group consisting of halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heterocyclic group;


[4] The topically administrable medicament containing an adenine compound described in any one of the above [1] to [3]: wherein in the general formula (1), Z is methylene and Ring A is benzene;


[5] The topically administrable medicament containing an adenine compound described in the above [4]: wherein in the general formula (1), Y1 is C1-5 alkylene, Q1 is hydrogen atom, hydroxy group or alkoxy group, Y2 is a single bond, and Q2 is —COOR10;


[6] The topically administrable medicament containing an adenine compound described in the above [5]: wherein in the general formula (1), Z is methylene, Ring A is benzene, R10 is alkyl group substituted by hydroxy group, amino group, alkylamino group or dialkylamino group, and m is 1;


[7] The topically administrable medicament containing an adenine compound described in the above [4]: wherein in the general formula (1), Y1 is C1-5 alkylene, Q1 is hydrogen atom, hydroxy group or alkoxy group, Y2 is C1-3 alkylene, Q2 is —COOR10, and m is 1;


[8] The topically administrable medicament containing an adenine compound described in the above [4]: wherein in the general formula (1), m is 0, Y1 is C1-6 alkylene which may be substituted with oxo group, and Q1 is —COOR10, —COSR10, —OCOR10, —OCOOR10, —CONR11R12 or —OCONR11R12;


[9] The topically administrable medicament containing an adenine compound described in any one of the above [1] to [8]: wherein in the general formula (1), and X1 is oxygen atom, sulfur atom or NR1 (wherein R1 is hydrogen atom or alkyl group);


[10] The topically administrable medicament containing an adenine compound described in any one of the above [1] to [4]: wherein in the general formula (1), m is 0, X1 is a single bond, Y1 is C1-4 alkylene which may be substituted by oxo group, and Q1 is —COOR10;


[11] The topically administrable medicament containing an adenine compound described in any one of the above [1] to [10]: wherein in the general formula (1), the limitation is either 1) or 2) below:


1) n is 0;


2) n is 1 or 2, and R is alkyl group, alkoxy group or halogen atom;


[12] The adenine compound or its pharmaceutically acceptable salt described in the above [1]: wherein in the general formula (1), at least one of Q1 and Q2 is a substituent selected from the following formulae (3)˜(6):




embedded image


(M is a single bond, oxygen atom or sulfur atom, and q is an integer selected from 1 to 3);


[13] The adenine compound or its pharmaceutically acceptable salt described in the above [1]: wherein in the general formula (1), at least one of Q1 and Q2 is —COSR10, —OCOOR10, —OCOR10 or —OCONR11R12 (wherein, R10, R11 and R12 are the same as defined in [1]);


[14] The adenine compound or its pharmaceutically acceptable salt described in the above [1]: wherein in the general formula (1), Q1 is —COOR20 (R20 is substituted or unsubstituted alkeny group or substituted or unsubstituted alkynyl group);


[15] The adenine compound or its pharmaceutically acceptable salt described in the above [1]: wherein in the general formula (1), Q1 is —CONR21R22 (R21 and R22 are independently, substituted or unsubstituted alkeny group or substituted or unsubstituted alkynyl group, or R21 and R22 are taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocyclic ring containing a nitrogen atom represented by the formula (2):




embedded image


wherein Y3 is a single bond, methylene, oxygen atom, sulfur atom, SO, SO2, NR14 (wherein R14 is hydrogen atom, C1-4 alkyl group, C2-4 alkylcarbonyl group, C2-4 alkoxycarbonyl group or C1-4 alkylsulfonyl group),


q1 is an integer selected from 0 to 4, and


R13 is hydroxy group, carboxy group, C1-4 alkyl group, C1-4 alkoxy group or C2-4 alkoxycarbonyl group;


[16] The adenine compound or its pharmaceutically acceptable salt described in the above [1]: wherein in the general formula (1), Z is methylene, and Ring A is naphthalene;


[17] The adenine compound or its pharmaceutically acceptable salt described in the above [1]: wherein in the general formula (1), Z is methylene, Ring A is a 5 to 10 membered mono or bicyclic hetero ring containing 1 to 3 heteroatoms selected from the group consisting of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom;


[18] The adenine compound or its pharmaceutically acceptable salt described in the above [1,7]: wherein in the general formula (1) in the above [1], the heteroaromatic ring in Ring A is furan, thiophene, or pyridine;


[19] The adenine compound or its pharmaceutically acceptable salt described in any one of the above described [16] to [18]: wherein in the general formula (1) in the above [1], Q1 is hydrogen atom, hydroxy group or alkoxy group, Y1 is C1-5 alkylene, Q2 is —COOR10 (wherein R10 is the same as defined in claim 1), and m is 1;


[20] The adenine compound or its pharmaceutically acceptable salt described in the above [19]; wherein in the general formula (1) in the above [1], Y2 is a single bond;


[21] The adenine compound, its tautomer or its pharmaceutically acceptable salt described in any one of the above described [16] to [18]: wherein in the general formula (1) in the above [1], m is 0, Y1 is C1-6 alkylene which may be substituted by oxo group, and Q1 is —COOR10, —COSR10, —OCOR10, —OCOOR10, —CONR11R12 or —OCONR11R12 (wherein R10, R11 and R12 are the same as defined in [1]);


[22] The adenine compound or its pharmaceutically acceptable salt described in the above [1]: wherein in the general formula (1), Y2 is alkylene or oxyalkylene, and Q2 is —COSR10 or —CONR11R12 (R10, R11, and R12 is the same as defined in [1]);


[23] The adenine compound or its pharmaceutically acceptable salt described in the above [1]: wherein in the general formula (1), Y2 is divalent group of a saturated monocyclic heteroring containing 1˜2 hetero atoms selected from substituted or unsubstituted 1˜2 nitrogen atoms, oxygen atoms and sulfur atoms (said sulfur atom may be oxidized by 1 or 2 oxygen atoms);


[24] The adenine compound or its pharmaceutically acceptable salt described in the above [23]: wherein divalent group of the saturated monocyclic heteroring is piperazin-1,4-diyl;


[25] The adenine compound or its pharmaceutically acceptable salt described in the above [23] or [24]: wherein in the general formula (1), Q2 is —COOR10 (wherein R10 is the same as defined in [1]);


[26] The adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [25], wherein in the general formula (1), the substituent(s) by which alkyl group, alkeny group or alkynyl group in R10, R11, R12, R20, R21 and R22 is substituted, are at least one substituent selected from the group consisting of halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heterocyclic group;


[27] The adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [25], wherein R is hydrogen atom, alkyl group, alkoxy group, or halogen atom;


[28] The adenine compound or its pharmaceutically acceptable salt described in the above [1], wherein in the general formula (1), Z is methylene, Ring A is benzene, Q1 is hydrogen atom, hydroxy group or alkoxy group, Y1 is C1-5 alkylene, Y2 is a single bond, Q2 is —COOR23 (wherein R23 is alkyl group substituted by amino group, alkylamino group or dialkylamino group), and m is 1;


[29] The adenine compound or its pharmaceutically acceptable salt described in the above [1], wherein in the general formula (1), Z is methylene, Ring A is benzene, Q1 is hydrogen atom, hydroxy group or alkoxy group, Y1 is C1-5 alkylene, Y2 is a single bond, and Q2 is —COSR24 (wherein R24 is hydroxy group or alkyl group which is substituted by substituted or unsubstituted amino group);


[30] The adenine compound or its pharmaceutically acceptable salt described in the above [1], wherein in the general formula (1), Z is methylene, Ring A is benzene, Q1 is hydrogen atom, hydroxy group or alkoxy group, Y1 is C1-5 alkylene, Y2 is a single bond, and Q2 is —CONR25R26 (wherein R25 is hydrogen atom, alkyl group, alkeny group, or alkynyl group, and R26 is hydroxy group, or alkyl group which is substituted by substituted or unsubstituted amino group);


[31] The adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [30], wherein in the general formula (1), X1 is oxygen atom, sulfur atom or NR1 (R1 is hydrogen atom or alkyl group);


[32] A medicament containing the adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [30] as an active ingredient;


[33] A pharmaceutical composition containing the adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [31] as an active ingredient;


[34] An immunoregulating agent containing the adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [31] as an active ingredient;


[35] A prophylactic or therapeutic agent for viral diseases containing the adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [31] as an active ingredient;


[36] A prophylactic or therapeutic agent for allergic diseases containing the adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [31] as an active ingredient;


[37] A prophylactic or therapeutic agent for allergic diseases described in [36] wherein the disease is asthma or atopic dermatosis;


[38] A prophylactic or therapeutic agent for cancer diseases containing the adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [31] as an active ingredient;


[39] A topically administrable preparation containing the adenine compound or its pharmaceutically acceptable salt described in any one of the above [12] to [31] as an active ingredient;


[40] The topically administrable preparation described in any one of the above [1] to [11], wherein the preparation is a prophylactic and therapeutic agent for viral diseases, dermal diseases or allergic diseases;


[41] The topically administrable preparation described in the above [40] wherein the allergic disease is asthma;


[42] The topically administrable preparation described in the above [40] wherein the allergic disease is atopic dermatosis;


[43] The topically administrable preparation described in any one of the above [1] to [11], and [39] to [42] wherein the half-life in serum on the compound of the general formula (1) is less than 1 hour;


[44] The topically administrable preparation described in any one of the above [1] to [11], and [39] to [42] wherein the half-life in liver S9 on the compound of the general formula (1) is less than 1 hour;


[45] The topically administrable preparation described in any one of the above [1] to [11], and [39] to [42] wherein the interferon concentration in serum is less than 10 IU/ml after said compound is topically administered; and


[46] The topically administrable preparation described in any one of the above [1] to [11], and [39] to [42] wherein the preparation is an inhalation formulation.


The mode of the present invention is described in detail below.


“Halogen” includes fluorine atom, chlorine atom, bromine atom and iodine atom, especially preferably fluorine atom and chlorine atom.


“Alkyl group” includes C1-10 straight or branched alkyl group, such as methyl group, ethyl group, propyl group, 1-methylethyl group, butyl group, 2-methylpropyl group, 1-methylpropyl group, 1,1-dimethylethyl group, pentyl group, 3-methylbutyl group, 2-methylbutyl group, 2,2-dimethylpropyl group, 1-ethylpropyl group, 1,1-dimethylpropyl group, hexyl group, 4-methylpentyl group, 3-methylpentyl group, 2-methylpentyl group, 1-methylpentyl group, 3,3-dimethylbutyl group, 2,2-dimethylbutyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, heptyl group, 1-methylhexyl group, 1-ethylpentyl group, octyl group, 1-methylheptyl group, 2-ethylhexyl group, nonyl group, decyl group, etc., preferably C1-6 alkyl group, more preferably C1-4 alkyl group.


Alkyl moiety in “alkylcarbonyl group”, “alkylsulfonyl group”, “alkylamino group” and “dialkylamino group” includes the same as the above alkyl group. Two alkyl moieties in the above dialkylamino group may be the same or different.


“Cycloalkyl group” includes a 3 to 8 membered mono cycloalkyl group, such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cycloheptyl group, cyclooctyl group, etc.


“Alkoxy group” includes C1-10 straight or branched alkoxy group, such as methoxy group, ethoxy group, propoxy group, 1-methylethoxy group, butoxy group, 2-methylpropoxy group, 1-methylpropoxy group, 1,1-dimethylethoxy group, pentoxy group, 3-methylbutoxy group, 2-methylbutoxy group, 2,2-dimethylpropoxy group, 1-ethylpropoxy group, 1,1-dimethylpropoxy group, hexyloxy group, 4-methylpentyloxy group, 3-methylpentyloxy group, 2-methylpentyloxy group, 1-methylpentyloxy group, 3,3-dimethylbutoxy group, 2,2-dimethylbutoxy group, 1,1-dimethylbutoxy group, 1,2-dimethylbutoxy group, heptyloxy group, 1-methylhexyloxy group, 1-ethylpentyloxy group, octyloxy group, 1-methylheptyloxy group, 2-ethylhexyloxy group, nonyloxy group, decyloxy group, etc., preferably C1-6 alkoxy group, more preferably C1-4 alkoxy group.


Alkoxy moiety in “alkoxycarbonyl group” is the same as in the above alkoxy group.


“Alkenyl group” includes, C2-8 straight or branched alkenyl group having 1 to 3 double bonds, such as ethenyl group, 1-propenyl group, 2-propenyl group, 1-methylethenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 2-methyl-2-propenyl group, 1-pentenyl group, 2-pentenyl group, 4-pentenyl group, 3-methyl-2-butenyl group, 1-hexenyl group, 2-hexenyl group, 1-octenyl group, etc., preferably C2-4 alkeny group.


“Cycloalkeny group” includes a 3 to 8 membered monocycloalkeny group having 1 or 2 double bonds, such as cyclobutenyl group, cyclopentenyl group, cyclopentadienyl group, cyclohexenyl group, cyclohexadienyl group, cycloheptenyl group, cycloheptadienyl group, cyclooctenyl group, etc.


“Alkynyl group” includes C2-8 straight or branched alkynyl group having 1 or 2 triple bonds, such as ethynyl group, 1-propynyl group, 2-propynyl group, 1-butynyl group, 2-butynyl group, 3-butynyl group, 1-methyl-2-propynyl group, 1-pentynyl group, 2-pentynyl group, 3-pentynyl group, 5-pentynyl group, 1-methyl-3-butynyl group, 1-hexynyl group, 2-hexynyl group, etc., preferably C2-4 alkynyl group.


“Aryl group” includes phenyl group, 1-naphthyl group or 2-naphthyl group.


“Heterocyclic group” includes a heteroaromatic group or an aliphatic heterocyclic group.


“The heteroaromatic group” includes a 5 to 10 membered mono or bicyclic heteraromatic group containing 1 to 3 hetero atoms selected from 0 to 3 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom, such as furyl group, thienyl group, pyrrolyl group, pyridyl group, indolyl group, isoindolyl group, quinolyl group, isoquinolyl group, pyrazolyl group, imidazolyl group, pyrimidinyl group, pyrazinyl group, pyridazinyl group, thiazolyl group, oxazolyl group, etc. The binding position on said heteroaromatic group is not limited and said heteroaromatic group may be bound via an optional carbon atom or nitrogen atom thereof.


“The aliphatic heterocyclic group” includes a 5 to 8 membered monocyclic aliphatic heterocyclic group containing 1 to 3 hetero atoms selected from 0 to 3 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom, such as pyrrolidinyl group, piperazinyl group, piperidinyl group, morpholinyl group, thiomorpholinyl group, 1-oxothiomorpholinyl group, 1,1-dioxothiomorpholinyl group, etc. The binding position on said aliphatic heterocyclic group is not limited and said aliphatic heterocyclic group may be bound via an optional carbon atom or nitrogen atom thereof.


“Alkylene” includes C1-6 straight or branched alkylene, such as, methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, 1-methylmethylene, 1-ethylmethylene, 1-propylmethylene, 1-methylethylene, 2-methylethylene, 1-methyltrimethylene, 2-methyltrimethylene, 2-methyltetramethylene, 3-methylpentamethylene, etc.


“Oxyalkylene” includes C1-6 straight or branched oxyalkylene, such as a divalent group shown as —OCH2—, —O(CH2)2—, —O(CH2)3—, O(CH2)4—, —O(CH2)5—, —O(CH2)6—, —OCH(CH3)—, —OCH(CH2CH3)—, —O—CH(CH2CH2CH3)—, —OCH(CH3)CH2—, —OCH2CH(CH3)—, —OCH(CH3)CH2CH2—, —OCH2CH(CH3)CH2—, —OCH2CH(CH3)CH2CH2—, or OCH2CH2CH(CH3)CH2CH2—,


“Cycloalkylene” includes a 4 to 7 membered monocyclic cycloalkylene, such as 1,3-cyclobutandiyl, 1,3-cyclopentandiyl, 1,3-cyclohexandiyl, 1,4-cyclohexandiyl, 1,3-cycloheptandiyl, 1,5-cycloheptandiyl, etc.


“Oxycycloalkylene” includes oxy a 4 to 7 membered monocyclic alkylene, such as a divalent group selected from the following formulas (7)˜(9):




embedded image


“A 6 to 10 membered mono or bicyclic aromatic hydrocarbon ring” in Ring A includes benzene ring or naphthalene ring.


“A 5 to 10 membered monocyclic or bicyclic heteroaromatic ring containing 1 to 3 hetero atoms selected from 0 to 2 nitrogen atoms, 0 or 1 oxygen atom and 0 or 1 sulfur atom” in Ring A includes pyrrole ring, pyridine ring, furan ring, thiophene ring, pyrimidine ring, pyridazine ring, pyrazine ring, triazine ring, indole ring, benzofuran ring, benzothiophene ring, benzimidazole ring, benzothiazole ring, quinoline ring, quinazoline ring, purine ring, etc., preferably pyridine ring, furan ring and thiophene ring.


“The divalent group of a monocyclic 5 to 7 membered saturated heterocycle containing 1 or 2 hetero atoms selected from 1 or 2 nitrogen atoms, oxygen atom, and sulfur atom (said sulfur atom may be oxidized by 1 or 2 oxygen atoms.)” in Y2 includes pyrrolidindiyl group, piperidindiyl group, piperazindiyl group, morpholindiyl group, thiomorpholindiyl group, 1-oxothiomorpholindiyl group, 1,1-dioxothiomorpholindiyl group, etc. and the ring may bind via an optional carbon atom or nitrogen atom with the adjacent Ring A and Q2. Preferable divalent groups of said saturated heterocycle containing a nitrogen atom(s) are 1,3-pyrrolidindiyl group, 1,4-piperazindiyl group, 1,3-piperazindiyl group, 1,4-piperidindiyl group, 1,3-piperidindiyl group, 2,4-morpholindiyl group, 2,4-thiomorpholindiyl group, 1-oxo-2,4-thiomorpholindiyl group, 1,1-dioxo-2,4-thiomorpholindiyl group, etc.


The substituent by which alkyl group, cycloalkyl group, or alkoxy group is substituted in R includes halogen atom, hydroxy group, alkoxy group, amino group, alkylamino group, dialkylamino group, etc. The substituent(s) are the same or different and the number of the substituent(s) are 1 or plural, preferably 1 to 5. The substituent(s) include chlorine atom, fluorine atom, methoxy group, ethoxy group, propoxy group, dimethylamino group, ethylamino group, etc.


Alkyl group in R includes preferably C1-3 alkyl group, such as methyl group, ethyl group, propyl group, 1-methylethyl group, etc. Substituted alkyl group in R includes preferably, trifluoromethyl group, 2,2,2-trifluoroethyl group, 2-methoxyethyl group, 2-hydroxyethyl group, 2-dimethylaminoethyl group, etc. Alkoxy group in R includes preferably C1-3 alkoxy group, such as methoxy group, ethoxy group, propoxy group, 1-methylethoxy group. Substituted alkoxy group in R includes preferably trifluoromethoxy group, 2,2,2-trifluoroethoxy group, 2-methoxyethoxy group, 2-hydroxyethoxy group, 2-dimethylaminoethoxy group, etc.


The substituents of the substituted amino group in R include alkyl group, alkyl group substituted by hydroxy group, or alkyl group substituted by alkoxy group. The substituent(s) are the same or different, and the number of the substituent(s) is 1 or 2. The substituents) include methyl group, ethyl group, propyl group, 1-methylethyl group, 2-ethoxyethyl group, 2-hydroxyethyl group, 2-ethoxyethyl group, etc. Two substituents of the substituted amino group in R may be taken together to form with the adjacent carbon atom a 5 to 7 membered heterocycle containing a nitrogen atom(s), and said heterocycle containing a nitrogen atom(s) includes the same rings as in the heterocycle containing a nitrogen atom(s) which R11 and R12 are taken to form, as mentioned below. Examples thereof are pyrrolidine, N-methylpiperazine, piperidine, morpholine, etc.


Alkylene in Y1 includes preferably C1-3 alkylene, such as methylene, methylmethylene, ethylene, 1-methylethylene, 2-methylethylene, trimethylene, etc.


Alkylene substituted by oxo group in Y1 means divalent group in which an optional methylene constituting of the alkylene is substituted by carbonyl group, and includes preferably —COCH2—, —CH2COCH2—, and —CH2CO—.


Alkylene in Y2 includes, preferably C1-3 alkylene, such as methylene, ethylene, trimethylene, etc.


Alkylene substituted by hydroxy group or oxo group in Y2 means a divalent group in which an optional methylene constituting of the alkylene is substituted by hydroxy group or carbonyl group, and includes preferably, —CHOHCH2—, —CH2CHOHCH2—, —CH2CHOH—, —COCH2—, —CH2COCH2—, and —CH2CO—.


Oxyalkylene in Y2 includes a divalent group, preferably, such as —OCH2—, —O(CH2)2—, or —O(CH2)3— and the oxygen atom in said divalent group is bound to Ring A.


When Y2 is divalent group of the following formula:




embedded image


it may bind in the optional direction.


Alkylene in Z includes preferably C1-3 alkylene, such as methylene, methylmethylene, etc.


Alkoxy group in Q1 includes preferably, straight or branched C1-4 alkoxy group, such as methoxy group, ethoxy group, propoxy group, etc.


When Q1 or Q2 is a substituent group selected from the group consisting of the following groups:


—COOR10; —COSR10; —OCOOR10; —OCOR10; —CONR11R12; —OCONR11R12 (wherein, R10, R11 and R12 are the same as defined above.); and a group selecting from the group of the following formulas (3)˜(6):




embedded image


wherein M and q are the same as defined above,


the substituent group by which alkyl group, alkeny group, alkynyl group, cycloalkyl group or cycloalkeny group in R10, R11 and R12 is substituted includes halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, or substituted or unsubstituted heteroaromatic group, etc. The substituents are the same or different and the number of the substituent(s) is 1 or plural, preferably 1 to 5.


The substituent group of the above mentioned substituted amino group includes alkyl group, alkyl group substituted by hydroxy group, or alkyl group substituted by alkoxy group. The substituent(s) are the same or different and the number of the substituent(s) is 1 or 2. Said two substituents may be taken to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s). Said heterocycle containing a nitrogen atom(s) includes the same rings as in the heterocycle containing a nitrogen atom(s) which R11 and R12 are taken to form, as mentioned below.


The aryl group mentioned above includes phenyl group, 1-naphthyl group, and 2-naphthyl group. The heteroaromatic group mentioned above includes 2-pyridyl group, 3-pyridyl group, 4-pyridyl group, 2-furyl group, 3-furyl group, etc.


The substituent group on the above substituted aryl group or the above substituted heteroaromatic group includes halogen atom such as chlorine atom, fluorine atom, etc.; hydroxy group; alkyl group such as methyl group, ethyl group, etc.; alkoxy group, such as methoxy group, ethoxy group, etc.; amino group; alkylamino group; dialkylamino group; alkyl group substituted by 1 to 3 halogen atoms such as trifluoromethyl group, etc.


The substituent group of the above substituted alkoxy group includes halogen atom, such as chlorine atom, fluorine atom, etc.; hydroxy group; alkoxy group, such as methoxy group, ethoxy group, propoxy group. etc.; substituted or unsubstituted aryl group; substituted or unsubstituted heteroaromatic group, etc. The substituent group of said aryl group or said heteroaromatic group is the same as the substituent of alkyl group, etc. in the above R10, R11, and R12.


The 5 to 7 membered heterocycle containing a nitrogen atom(s) which R11 and R12 are taken to form with the adjacent nitrogen atom includes a 5 to 7 membered saturated heterocycle containing a nitrogen atom(s) containing 1 to 3 hetero atoms selected from 1 or 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom and said sulfur atom may be oxidized by 1 or 2 oxygen atoms. Examples thereof are pyrrolidine, piperazine, piperidine, morpholine, thiomorpholine, 1-oxothiomorpholine, 1,1-dioxothiomorpholine, etc. and each of them may be substituted by hydroxy group, carboxy group, alkyl group, alkylcarbonyl group, alkylsulfonyl group, alkoxy group or alkoxycarbonyl group. Said heterocycle containing a nitrogen atom(s) includes preferably a saturated heterocycle containing a nitrogen atom(s) of the formula (2):




embedded image


wherein Y3 is a single bond, methylene, oxygen atom, sulfur atom, SO, SO2, NR14 (wherein R14 is hydrogen atom, C1-4 alkyl group, C2-4 alkylcarbonyl group, C2-4 alkoxycarbonyl group, or C1-4 alkylsulfonyl group),


q1 is an integer selected from 0˜4, and


R13 is hydroxy group, carboxy group, C1-4 alkyl group, C1-4 alkoxy group, or C2-4 alkoxycarbonyl group.


R10 is preferably substituted or unsubstituted straight or branched C1-6 alkyl group. Said substituent includes halogen atom, hydroxy group, alkoxy group, substituted or unsubstituted aryl group, and substituted or unsubstituted amino group. Examples of R10 are methyl group, ethyl group, propyl group, 1-methylethyl group, butyl group, 2-methylpropyl group, 1-methylpropyl group, 1,1-dimethylethyl group, 2,2-difluoroethyl group, 2,2,2-trifluoroethyl group, 2-hydroxyethyl group, 3-hydroxypropyl group, 2-methoxyethyl group, 2-ethoxyethyl group, 2-benzyloxyethyl group, 2-dimethylaminoethyl group, 2-morpholinoethyl group, etc.


R11 and R12 are preferably, substituted or unsubstituted straight or branched C1-6 alkyl group. Said substituent group includes hydroxy group, alkoxy group, etc. Examples of R11 and R12 are methyl group, ethyl group, propyl group, 1-methylethyl group, butyl group, 2-methylpropyl group, 1-methylpropyl group, 1,1-dimethylethyl group, 2-hydroxyethyl group, 3-hydroxypropyl group, 2-methoxyethyl group, 2-ethoxyethyl group, etc. Furthermore, a 5 to 7 heterocycle containing a nitrogen atom(s) which R11 and R12 are taken to form with the adjacent nitrogen atom is one of preferable modes, such as pyrrolidine, piperazine, N-methylpiperazine, piperidine, morpholine, etc.


When Q1 or Q2 is an optional substitution group selected from the above substituent groups, it is preferably —COOR10, —COSR10, —OCOOR10, or —CONR11R12, more preferably —COOR10. In addition m is preferably 1.


The 9 to 14 membered bi or tricyclic fused ring which R10 or R11 are taken to form with the adjacent Ring A in Q2 is preferably the group selected from the following formulas:




embedded image


wherein Ring A″ is the same as Ring A, and q is an integer selected from 1 to 3, more preferably the group of the following formulas:




embedded image


wherein q is the same as defined above.


The adenine compound of the present invention, according to the kinds of substituents, may include a tautomer, a geometrical isomer, a stereoisomer or a mixture thereof.


Namely when at least one asymmetrical carbon atom presents in a compound of the general formula (1), a diastereomer or an enantiomer exists and these isolated isomers or a mixture thereof are included in the present invention.


In addition, the adenine compound of the general formula (1) and its tautomer are chemically equivalent and the adenine compound of the present invention includes the tautomer. Said tautomer is illustratively an oxo compound of the general formula (1′):




embedded image


wherein Ring A, m, n, R, X1, Y1, Y2, Z, Q1, and Q2 are the same as defined above.


The pharmaceutically acceptable salt includes acid addition salts or base addition salts. The acid addition salt includes for example, inorganic salts such as hydrochloride, hydrobromide, hydrosulfate, hydroiodide, nitrate, phosphate, etc., organic salts, such as citrate, oxalate, acetate, formate, propionate, benzoate, trifluoroacetate, maleate, tartarate, methanesulfonate, benzenesulfonate, para-toluenesulfonate, etc. The base addition salt includes inorganic base salts such as sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt, etc., organic base salts, such as triethylammonium salt, triethanolammonium salt, pyridinium salt, diisopropylammonium salt, and amino acid salts formed with basic or acidic amino acids such as arginine, aspartic acid, glutamic acid, etc. The compound of the general formula (1) may form a hydrate(s) or a solvate(s) with ethanol, etc.


The compound of the general formula (1) can be prepared by the following methods. The starting materials which are not described below are prepared in accordance with the method described below or the known methods described, for example, in WO 98/01448 or WO 99/28321 or in accordance with the known methods.


Process 1:



embedded image


wherein in the above formulas, Q3 is Q1, or carboxy group, Q4 is Q2, carboxy group, or hydroxy group, L is a leaving group, and Ring A, m, n, R, X1, Y1, Y2, Z, Q1 and Q2 are the same as defined above.


A compound (II) is obtained by reacting a compound (I) and a compound (VIII) in the presence of a base.


The base used in this reaction is an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., a metal hydroxide such as sodium hydroxide, potassium hydroxide, etc., a metal hydride such as sodium hydride, etc., or a metal alkoxide such as potassium t-butoxide, etc. The solvent used in this reaction is a halogenated hydrocarbon-solvent such as carbon tetrachloride, chloroform, methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, etc., an aprotic solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, etc. The reaction is carried out, for example at the range from about 0° C. to around boiling point of the solvent.


The compound (IV) is obtained by reaction a compound (II) and a compound (IX).


When X1 is NR1, the reaction is carried out in the presence or absence of a base. The base includes for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., a metal hydroxide such as sodium hydroxide, potassium hydroxide, etc., an organic base such as triethylamine, diisopropylethylamine, 4-dimethylaminopyridine, etc. The solvent used in this reaction is an ether-solvent such as tetrahydrofuran, 1,4-dioxane, diglyme, etc., an alcohol-solvent such as propanol, butanol, etc., an aprotic solvent such as dimethylformamide, etc. The reaction may be carried out in the absence of a solvent. The reaction is carried out, for example at the range from about 50° C. to 200° C.


When X1 is oxygen atom or sulfur atom, the reaction is carried out in the presence of a base. The base includes for example, an alkali metal such as sodium, potassium, etc., an alkali metal hydride such as sodium hydride, etc. The solvent used in this reaction is an ether-solvent such as tetrahydrofuran, 1,4-dioxane, diglyme, etc., an aprotic solvent such as dimethylformamide, dimethyl sulfoxide, etc. The reaction may be carried out in the absence of a solvent. The reaction is carried out, for example at the range from about 50° C. to 200° C.


Furthermore, in the step from a compound (I) to a compound (IV), first a compound (III) can be synthesized in the same manner as the above method and then the product (III) can be reacted with a compound (VIII) to give a compound (IV).


A compound (V) can be prepared by brominating a compound (IV). The brominating agent is bromine, hydrobromic acid perbromide, N-bromo succinimide, etc. Sodium acetate may be added as a reaction promoter in this reaction. The solvent is a halogenated hydrocarbon-solvent such as carbon tetrachloride, methylene chloride, dichloroethane, etc., an ether-solvent such as diethyl ether, etc., acetic acid, carbon disulfide, etc. The reaction is carried out, for example at the range from about 0° C. to around boiling point of the solvent.


A compound (VI) is obtained by reacting a compound (V) with a metal alkoxide such as sodium methoxide, etc.


The solvent is an ether-solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, etc., an aprotic solvent such as dimethylformamide, etc., an alcohol solvent such as methanol corresponding to the metal alkoxide used in this reaction and so on. The reaction is carried out, for example at the range of from room temperature to around boiling point of the solvent.


A compound (VII) is obtained by treating a compound (VI) or a compound (V) in an acidic condition.


The acid is for example, an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, etc., an organic acid such as trifluoroacetic acid, etc. The solvent is for example, water, a mixture of water and an organic solvent. Said organic solvent includes an ether-solvent such as diethyl ether, tetrahydrofuran, etc., an aprotic solvent such as dimethylformamide, acetonitrile, etc., an alcohol-solvent such as methanol, ethanol, etc. The reaction is carried out, for example at the range from room temperature to around boiling point of the solvent.


The compound wherein X1 is a single bond in a compound of the general formula (1) can be prepared by the method described in the examples of the present specification. The intermediates corresponding to a compound (III) can be prepared in accordance with the method described in the above WO 98/01448.


Process 2



embedded image


wherein Ring A, m, n, R, X1, Y1, Y2, Z, Q3 and Q4 are the same as defined above, X is amino group, hydroxy group, or mercapto group and L is a leaving group.


A compound (XII) is obtained by reacting a compound (X) and a compound (XI) in the presence of a base.


The base is for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., a metal hydroxide, such as sodium hydroxide, potassium hydroxide, etc., an organic base such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, etc., a metal alkoxide such as sodium methoxide, etc. The solvent is for example, a halogenated hydrocarbon-solvent such as methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, etc., an alcohol-solvent such as methanol, ethanol, etc., an aprotic solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, etc. The reaction is carried out, for example at the range from about 0° C. to around boiling point of the solvent.


A compound (XIV) is obtained by reacting a compound (XII) and a compound (XIII) in the presence or absence of a base.


The base is for example, an inorganic base such as an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., a metal hydroxide such as sodium hydroxide, potassium hydroxide, etc., an organic base such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, etc., a metal alkoxide such as sodium methoxide, etc. The solvent used in this reaction are an ether-solvent such as tetrahydrofuran, 1,4-dioxane, diglyme, etc., an alcohol-solvent such as methanol, ethanol, etc., an aprotic solvent such as toluene, dimethylformamide, dimethyl sulfoxide, etc. The reaction may be carried out in the absence of a solvent. The reaction is carried out, for example at the range from room temperature to around boiling point of the solvent.


In the step from a compound (XII) to a compound (XIV), compound (XV) can be synthesized and the product (XV) can be reacted to give a compound (XIV).


A compound (XV) wherein X is amino group is obtained by reacting a compound (XII) and guanidine in the presence or absence of a base. The base is, for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., a metal hydroxide, such as sodium hydroxide, potassium hydroxide, etc., an organic base such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, etc., a metal alkoxide such as sodium methoxide, etc. The solvent used in this reaction are an ether-solvent such as tetrahydrofuran, 1,4-dioxane, diglyme, etc., an alcohol-solvent such as methanol, ethanol, etc., an aprotic solvent such as toluene, dimethylformamide, dimethyl sulfoxide, etc. The reaction may be carried out in the absence of a solvent. The reaction is carried out, for example at the range from room temperature to around boiling point of the solvent.


A compound (XV) wherein X is hydroxy group is obtained by reacting a compound (XII) and urea in the presence or absence of a base. The base is, for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., a metal hydroxide, such as sodium hydroxide, potassium hydroxide, etc., an organic base such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, etc., a metal alkoxide such as sodium methoxide, etc. The solvent used in this reaction is an ether-solvent such as tetrahydrofuran, 1,4-dioxane, diglyme, etc., an alcohol solvent such as methanol, ethanol, etc., an aprotic solvent such as toluene, dimethylformamide, dimethyl sulfoxide, etc. The reaction may be carried out in the absence of a solvent. The reaction is carried out, for example at the range from about room temperature to around boiling point of the solvent.


A compound (XV) wherein X is mercapto group is obtained by reacting a compound (XII) and benzoylisocyanate in the presence or absence of a base and then, subjecting the product to cyclization reaction. The base used in the reaction with benzoisocyanate is for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., an organic base such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, etc. The solvent used in this reaction is a halogenated hydrocarbon such as methylene chloride, etc., an ether-solvent such as tetrahydrofuran, 1,4-dioxane, etc., an aprotic solvent such as dimethylformamide, dimethyl sulfoxide, etc. The reaction is carried out, for example at the range from about 0° C. to around boiling point of the solvent.


The base used in the cyclization reaction is an alkali metal hydroxide, such as sodium hydroxide, potassium hydroxide, etc., a metal alkoxide, such as sodium methoxide, potassium t-butoxide, etc. The solvent is an ether-solvent such as tetrahydrofuran, etc., an alcohol-solvent such as ethanol, 2-propanol, etc., an aprotic solvent such as, dimethylformamide, dimethyl sulfoxide, etc. The reaction is carried out, for example at the range from about room temperature to around boiling point of the solvent.


A compound (XIV) is obtained by reacting a compound (XV) and a compound (XVI) in the presence of a base.


The base is for example, an alkali metal hydrogencarbonate such as sodium hydrogencarbonate, etc., an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., a metal hydroxide, such as sodium hydroxide, potassium hydroxide, etc., a metal hydride such as sodium hydride, etc., an organic base such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, etc., a metal alkoxide such as potassium t-butoxide, etc. The solvent used in this reaction is a halogenated hydrocarbon such as carbon tetrachloride, chloroform, methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, etc., an aprotic solvent such as, dimethylformamide, dimethyl sulfoxide, acetonitrile, etc. The reaction is carried out, for example from the range from about 0° C. to around boiling point of the solvent.


Process 3

When Q3 or Q4 is carboxy group or hydroxy group in the above general formulas (II)˜(XVI), it can be converted to Q1 or Q2, respectively in the known method to the skilled person in the art or the similar method, for example, the method described in R. C. Larock “Comprehensive Organic Transformation (VCH Publishers, Inc, 1989)”.


The reaction is concretely explained below.





When Q1 or Q2 is —COOR10  (1)


After an intermediate of the compound of the present invention, namely a carboxylic acid is converted to an acid halide, the acid halide is reacted with R10OH to give an ester. The halogenating agent is for example, thionyl chloride, phosphoryl chloride, phosphorus pentachloride, phosphorus trichloride, etc. The solvent is for example, a halogenated hydrocarbon such as carbon tetrachloride, chloroform, methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, 1,4-dioxane, etc., an aprotic solvent such as, toluene, xylene, etc. The reaction is carried out, for example from the range from about 0° C. to around boiling point of the solvent. The base used in the esterification reaction is for example, an organic base such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, etc. The solvent is for example, a halogenated hydrocarbon such as methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, etc., an aprotic solvent such as, dimethylformamide, dimethyl sulfoxide, etc. The reaction is carried out, for example from the range from about 0° C. to around boiling point of the solvent.





When Q1 or Q2 is —CONR11R12  (2)


After an intermediate of the compound of the present invention, namely a carboxylic acid is converted to an acid halide, the acid halide is reacted with R11R12NH to give an amide. The carboxylic acid and R11R12NH can be condensed to give the amide, too. The base used in the reaction with the acid halide is for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate, etc., an alkaline earth metal carbonate such as calcium carbonate, etc., a metal hydroxide, such as sodium hydroxide, potassium hydroxide, etc., a metal hydride such as sodium hydride, etc., an organic lithium compound such as butyllithium, an organic base such as triethylamine, diisopropyl ethylamine, pyridine, 4-dimethylaminopyridine, etc. The solvent used in this reaction is a halogenated hydrocarbon such as methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, etc., an aprotic solvent such as, dimethylformamide, dimethyl sulfoxide, etc. The reaction is carried out, for example at the range from about 0° C. to around boiling point of the solvent.


The condensation reaction may be carried out in the presence of an active esterification agent. The condensing agent is, for example, a carbodiimide compound such as 1-ethyl-3-(3-dimethylaminopropylcarbodiimide hydrochloride, dicyclohexylcarbodiimide, etc. The esterification agent is, for example, N-hydroxybenztriazole, N-hydroxysuccinimide, etc. The solvent is a halogenated hydrocarbon such as chloroform, methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, etc., an aprotic solvent such as, dimethylformamide, dimethyl sulfoxide, etc. The reaction is carried out, for example at the range from about 0° C. to around boiling point of the solvent.





When Q1 or Q2 is —OCOOR10, —OCOR10 or —OCONR11R12  (3)


The intermediate of the compound of the present invention, namely a hydroxy group and L1COOR10, L1COR10, or L1CONR11R12 (wherein L1 is a leaving group, preferably halogen atom, R10, R11 and R12 are the same as defined above.) are reacted in the presence of a base to give a carbonate derivative, an acyl compound and a urethane derivative, respectively. The base is, for example, an organic base such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine. The solvent is a halogenated hydrocarbon such as methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, etc., an aprotic solvent such as dimethylformamide, dimethyl sulfoxide, etc. The reaction is carried out, for example, at the range from about 0° C. to around boiling point of the solvent.





When Q1 or Q2 is any one of the formulas (3)˜(6):  (4)


In case of the formula (3) or (4) being a lactone ring, said compound is prepared by treating a hydroxycarboxylic acid with an acid. The acid is an inorganic acid such as, hydrochloric acid, hydrobromic acid, sulfuric acid, etc., or an organic acid such as methanesulfonic acid, p-toluenesulfonic acid, etc. An acid anhydride such as acetic acid anhydride can be also used. The solvent is water, an organic solvent or a mixture of water and the organic solvent. The organic solvent is an ether-solvent such as diethyl ether, tetrahydrofuran, etc., an aprotic solvent such as benzene, acetonitrile, etc. The reaction is carried out, for example at the range from about room temperature to around boiling point of the solvent.


In case of the formula (5) or (6) being a cyclic carbonate, said compound is prepared by reacting a dihydroxy compound with tri phosgene in the presence of a base. The base is an organic base, such as triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine, etc. The solvent is a halogenated hydrocarbon such as chloroform, methylene chloride, etc., an ether-solvent such as diethyl ether, tetrahydrofuran, etc., an aprotic solvent such as, benzene, toluene, etc. The reaction is carried out, for example at the range from about 0° C. to around boiling point of the solvent.


Any compound used in process 1 or 2 can use as a starting material in each step described in process 3 and each step described in process 3 may use any steps described in process 1 or 2, as long as it does not influence the reaction in the post process.


When the adenine compound of the present invention, its intermediate or its starting material has a functional group, the introduction of the substituent group or the conversion reaction into the functional group can be carried out in accordance of the conventional method known in the art, if necessary, in an appropriate step, namely a step in the middle of process 1 or 2. These methods are described in Jikken Kagaku Koza edited by Nippon Kagakukai, Maruzen, or Comprehensive Organic Transformations, by R. C. Lalock (VCH Publishers, Inc, 1989), etc. As the conversion reaction into the functional group, acylation or sulfonylation by using an acid halide, an sulfonyl halide, etc., alkylation by using an alkyl halide, etc., hydrolysis, Friedel-Crafts Reaction or C to C bond-formation reaction such as Wittig reaction, etc., oxidization or reduction reaction, etc. are illustrated.


Furthermore, when the compound of the present invention or the intermediate thereof has a functional group such as amino group, carboxy group, hydroxy group, oxo group, etc., the compound may be subjected to protection or deprotection reaction, if necessary. The preferable protecting groups, the protecting methods and the deprotecting methods are in detail explained in Protective Groups in Organic Synthesis 2nd Edition (John Wiley 86 Sons, Inc.; 1990) and so on.


The compound of the general formula (1) of the present invention and the intermediate for preparing it can be purified by the method known in the art such as column chromatography (e.g., silica gel chromatography, ion exchange chromatography), recrystallization, etc. The solvent for recrystallization includes an alcohol-solvent such as methanol, ethanol, 2-propanol, etc., an ether-solvent such as ethyl ether, etc., an ester-solvent such as ethyl acetate, etc., an aromatic hydrocarbon solvent such as benzene, toluene, etc., a ketone-solvent such as acetone, etc., a hydrocarbon-solvent such as hexane etc., an aprotic solvent such as dimethylformamide, acetonitrile, water or a mixture thereof. Other purification methods are explained in Jikken Kagaku Koza Vol. 1 (edited by Nippon Kagaku Kai, Maruzen).


The compound of the general formula (1) of the present invention which has one or more asymmetric centers can be prepared by the conventional method by using a starting material having an asymmetric carbon atom(s), or otherwise in a way of the process for the preparation by introducing the asymmetric center(s). For example, the enantiomer compound can be prepared by using an optically active compound as a starting compound or by optical resolution in an appropriate way of the process for the preparation. The optical resolution is carried out by the diastereomar method, namely by salt-forming the compound of the general formula (1) of the present invention or an intermediate thereof with an optically active acid such as a monocarboxylic acid (e.g., mandelic acid, N-benzyloxyalanine, lactic acid, etc.), a dicarboxylic acid (e.g., tartaric acid, o-diisopropylidene tartaric acid, malic acid, etc.), a sulfonic acid (e.g., camphorsulfonic acid, bromocamphorsulfonic acid, etc.) in an inert solvent such as an alcohol-solvent (e.g., methanol, ethanol, 2-propanol, etc.), an ether-solvent (e.g., diethyl ether, etc.), an ester solvent (e.g., ethyl acetate, etc.), a hydrocarbon-solvent (e.g., toluene, etc.), an aprotic solvent (e.g., acetonitrile, etc.), or a mixture thereof.


The compound of the general formula (1) of the present invention or an intermediate thereof which has an acidic functional group such as carboxy group, can be prepared by salt-forming with an optically active amine (an organic amine such as α-phenethylamine, kinin, quinidine, cinchonidine, cinchonine, strychnine, etc.).


The salt formation is carried out at the range from room temperature to the boiling temperature of the solvent. In order to promote the optical purity of the object compound, it is preferable to raise once the temperature to around the boiling point of the solvent. The yield can be raised by cooling the reaction mixture, if necessary, before filtrating a crystallized precipitate. The amount of the optically active acid or amine is preferably about 0.5 to about 2.0 moles per a substrate, more preferably around 1 mole. The precipitate is, if necessary, recrystallized from an inert solvent such as an alcohol-solvent (e.g., methanol, ethanol, 2-propanol, etc.), an ether-solvent (e.g., ethyl ether, etc.), an ester-solvent (e.g., ethyl acetate, etc.), a hydrocarbon-solvent (e.g., toluene, etc.), an aprotic solvent (e.g., acetonitrile, etc.), a mixture thereof to give an optically purified compound. Furthermore, if necessary, an optically resolved salt is treated with an acid or a base by the conventional method to give a free form.


The adenine compound of the present invention, and a tautomer thereof, or a pharmaceutically acceptable salt thereof shows interferon inducting activity, and/or IL-4 and IL-5 production suppressing activity, and therefore, is effective as a prophylactic or therapeutic agent for viral diseases, allergic diseases, or dermatosis. Furthermore, the adenine compound of the present invention, a tautomer thereof, or a pharmaceutically acceptable salt thereof is characterized in, when topically administered, showing an medical effect at the applied lesion, but in systematically showing none of the pharmacological activity because the compound is converted by an enzyme in vivo to other compound (degraded compound) having substantially reduced medical effect and therefore, is useful as a topically administered agent. The medical effect used herein means a pharmacological activity of the compound, such as interferon inducing activity, IL-4 production suppressing activity and/or IL-5 production suppressing activity, etc.


The medical effect of the degraded compound is preferably 10 times, more preferably 100 times, further more preferably 1000 times reduced comparing with that of the parent compound.


Said pharmacological activities can be evaluated by the conventional measuring method known in the art, preferably by the measuring method in vitro. For example, there are illustrated methods described in Method in ENZYMOLOGY (Academic press), etc. or the method by using the commercialized ELISA Kit (e.g., AN′ ALYSA (Immunoassay System), etc.), or the method described in Example of the present specification, etc.


For example, by measuring interferon inducing activity with bioassay using cells of mouse spleen, the amount of each interferon induction (IU)/ml at the same concentration of the parent compound (the compound of the present invention) and the degraded compound can be compared. In addition, each concentration showing the definite amount of interferon production can be compared with the parent compound and its degraded compound, too.


As a pharmacological activity, the activity in vivo caused by interferon inducing activity, etc. is illustrated. Said activity in vivo includes immune activating activity, influenza-like symptom, etc. The immune activating activity includes the induction of cytotoxic activity such as NK cells, etc. The influenza-like symptom includes fever, etc. The fever means the rise of the body temperature of a mammalian, for example, in case of human, the fever means that the body temperature rises more than normal temperature. The topical administration method is not limited, and the administration is done in case of administration via nasal cavity, alveolus or air way, by aeration or inhalation, in case of administration to skin, by spreading on the skin, and in case of administration to eye, by eye dropping, etc. Preferable administration is done by aeration or inhalation.


It can be also confirmed that the compound of the present specification, when it is topically administered, is converted to a degraded compound in the blood, etc. in human or animal for example, by its half life in the serum or in liver S9 in vitro. The test method to determine the half life of the compound of the present invention in vitro is known.


The above “degraded compound” means a compound having carboxy group or hydroxy group which is prepared by hydrolyzing the amide bond or ester bond contained in the subsistent(s), Q1 and/or Q2 in the general formula (1).


The measuring method of the half life in liver S9 of the compound of the present invention is as follows:


The compound of the present invention is added to liver S9 solution, and the mixture is incubated at 37±0.5° C. for 5 minutes to 2 hours. By quantitatively analyzing at the definite interval the amount of the compound of the present invention remaining in the liver S9 solution with HPLC (high performance liquid chromatography), etc., the constant of quenching velocity is calculated and the half life is calculated. The liver S9 means the supernatant prepared by the liver of mammalian being homogenated in an aqueous solution, such as physiological saline, sucrose solution, KCl solution, etc., the homogenate being centrifuged at 9000×g and its supernatant fraction being collected. The aqueous solution is usually used 2 to 4 times as much as the amount of liver. The liver of human, dog, rabbit, guinea pig, rat, mouse, etc. are used. The liver S9 diluted with buffer, etc., if necessary can be used.


The measuring method of the half life in the serum of the compound of the present invention is as follows:


The compound of the present invention is added to the serum solution, and the mixture is incubated at 37±0.5° C. for 5 minutes to 2 hours. By quantitatively analyzing at the definite interval the amount of the compound of the present invention remaining in the serum solution with HPLC (high performance liquid chromatography), etc., the constant of quenching velocity calculated and the half life is calculated. The method described in Example is illustrated.


The serum herein means the supernatant fraction obtained by excluding hemocytes and blood coagulation factor from blood by centrifugation, etc. The serum diluted with buffer, etc. can be used.


The compound of the present invention is not limited as long as the compound is formed into the preparation for topical administration. The preparation is prepared by the conventional known method and the preparation may contain ordinal carriers, excipients, binders, stabilizers, buffer, solubilizing agents, isotonic agents, etc.


Examples of the preparation for topical administration are ointments, lotion, creams, gels, tapes, dermal patches, poultices, sprays, aerosols, or aqueous solutions/suspensions for spray used for inhalator or cartridge for insufflator, eye drops, nose drops, powders for topical administration, etc.


The ointments, creams and gels usually contain 0.01 to 10 w/w % of the compound of the present invention. An aqueous or oil base used in them may contain suitable viscosity-increasing agents and/or gelling agents and/or solvents. Said base includes for example, water and/or liquid paraffin or an oil such as squalane, various fatty acid esters, vegetable oils such as arachis oil, castor oil, animal oils such as squalene or polyethylene glycol. The viscosity-increasing agent and gelling agent include soft paraffin, aluminium stearate, cetostearyl alcohol, polyethylene glycol, sheep wool fat, beeswax, carboxy methylene and cellulose derivative and/or non-ionic emulsifying agent such as glycerin monostearate.


The lotion usually contains 0.01 to 10 w/w % of the compound of the present invention and the lotion preparation may be formulated by an aqueous or oil base and may usually contain an emulsifying agent, a stabilizer, a dispersion agent, a suspension agent, or a viscosity-increasing agent.


The powder for external administration usually contains 0.01 to 10 w/w % of the compound of the present invention and may be made of suitable bases such as talc, lactose or starch.


The eye drop preparation may be formed by an aqueous or nonaqueous base and may contain a dispersing agent, a solubilizing agent, a suspending agent or a preservative.


The splay may be formed into an aqueous solution or suspension by for example, using a suitable liquid jet, or into aerosols distributed from a pressured bag such as a measuring inhalator.


The aerosol suitable for inhalation is either a suspension or a solution and may usually contain the compound of the present invention and a suitable jet such as fluorocarbon, hydrogen-containing chlorofluorocarbon or a mixture thereof, especially hydrofluoroalkane, more especially 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro n-propane or a mixture thereof. The aerosol may further contain, if necessary, excipients well known in the art, such as a surfactant such as oleic acid or lecithin and a co-solvent such as ethanol.


A gelatin capsule or cartridge used for inhalator or for insufflator may be formed by using a powdered mixture and a suitable powdered base such as lactose or starch, etc., for inhalating the compound of the present invention. Each capsule or cartridge may usually contain 20 μg˜10 mg of the compound of the present invention. As another method, the compound of the present invention may be administered without any excipients such as lactose.


The amount of the compound of the present invention contained in the preparation for external administration depends on the kind of preparations, but is generally 0.001 to 10% by weight, preferably 0.005 to 1% by weight. In case of the powder for inhalation, the amount of the compound of the present invention is a range of 0.1 to 5% by weight.


In regard to the aerosol each a measured amount or one blown (splayed) amount of the compound of the present invention is preferably 20 μg to 2000 μg, preferably about 20 μg to 500 μg. The dosage is once or several times (for example, 2 to 4 or 8 times) a day. One to three dose units are administered per each time.


The composition of the present invention may be administered in combination with other therapeutically effective medicament. When administered as an antiasthma, the composition of the present invention can be used in a combination with a β2-adrenaline receptor agonist, an antihistamine or an antiallergic agent, especially a β2-adrenaline receptor agonist. The each medicament used in a combination may be administered at the same time or different time separately or in the form of a mixture thereof.


EXAMPLE

The present invention is explained in detail by illustrating Examples and Reference examples below, but should not be limited by them.


Reference Example 1
2-Butoxyadenine

After sodium (13.56 g, 590 mmol) was dissolved in n-butanol (480 ml), 2-chloroadenine (4.0 g, 23.59 mmol) was added thereto and the mixture was stirred at 140° C. for 19 hours. After the mixture was allowed to cool, water (400 ml) was added thereto and the mixture was stirred for 30 minutes. And then the organic layer was separated and concentrated. Water (400 ml) was added to the residue and the solution was neutralized with concentrated hydrochloric acid. The resulting precipitate was filtered and washed with ethanol to give the captioned compound (3.72 g, 17.97 mmol, yield 76%) as a white solid.


Reference Example 2
Methyl 3-bromomethylbenzoate

3-Bromomethylbenzoyl chloride (1.96 g, 10.37 mmol) was dissolved in methanol (20 ml), and triethylamine (1.5 ml) was added thereto. The mixture was stirred at room temperature for 1 hour. The mixture was poured into a saturated sodium hydrogencarbonate solution and was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated to give the captioned compound (1.90 g, 10.29 mmol, yield: 97%) as a colorless oil.


Reference Example 3
2-Butoxy-9-(3-methoxycarbonylbenzyl)adenine

After 2-butoxyadenine (0.66 g, 3.19 mmol) obtained by Reference example 1 and potassium carbonate (0.80 g, 5.79 mmol) were added to DMF (40 ml), the compound (1.99 g, 10.78 mmol) obtained by Reference example 2 was added thereto and the mixture was stirred at room temperature for 18 hours. After removing the solvent the residue was poured into water and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH 300/1˜50/1) to give the captioned compound (0.50 g, 1.41 mmol, yield: 44%) as a white solid.


Reference Example 4
8-Bromo-2-butoxy-9-(3-methoxycarbonylbenzyl)adenine

After 2-butoxy-9-(3-methoxycarbonylbenzyl)adenine (0.41 g, 1.54 mmol) obtained by Reference example 3, and sodium acetate (1.14 g, 13.90 mmol) were dissolved in acetic acid (50 ml), bromine (0.1 ml, 7.7 mmol) was added thereto. The mixture was stirred at room temperature for 5 hours. After removing the solvent the residue was poured into water and extracted with dichloromethane. After the organic layer was washed with a saturated sodium hydrogencarbonate solution, a saturated sodium hydrogensulfite solution and saturated brine in that order, the organic layer was dried over anhydrous magnesium sulfate and concentrated to give the captioned compound (0.45 g, 1.04 mmol, yield: 90%) as a yellow tar.


Reference Example 5
2-Butoxy-9-(3-carboxybenzyl)-8-methoxyadenine

After sodium (0.49 g, 21.30 mmol) was dissolved in methanol (50 ml), 8-bromo-2-butoxy-9-(3-methoxycarbonylbenzyl)adenine (0.22 g, 0.51 mmol) obtained by Reference example 4 was added thereto and the mixture was refluxed for 30 hours. After being allowed to cool, the solution was neutralized with concentrated hydrochloric acid and concentrated. The residue was poured into water. The resulting precipitate was filtered and washed with methanol to give the captioned compound (0.13 g, 0.35 mmol, yield: 69%) as a white solid.


Reference Example 6
2-n-Butylaminoadenine

2-Chloroadenine (6.0 g, 35.4 mmol) and n-butylamine (30 ml) were reacted in an autoclave (200 ml) at 130° C. for 150 hours. After the reaction mixture was concentrated under reduced pressure, the residue was poured into water to precipitate the solid. The precipitated solid was successively washed with methylene chloride and methanol to give the captioned compound (2.08 g, yield 30%) as a yellowish orange powdered solid.


Reference Example 7
9-Benzyl-2-(2-hydroxyethylamino)adenine

9-Benzyl-2-chloroadenine (1.0 g, 3.8 mmol) was stirred in 2-aminoethanol (8 ml) at 110° C. for 4 hours. Water (100 ml) was added to the reaction mixture and the resulting precipitate was filtered to give the captioned compound (1.1 g, 3.8 mmol, yield: 100%) as a white solid.


Reference Example 8
9-Benzyl-8-bromo-2-(2-hydroxyethylamino)adenine

9-Benzyl-2-(2-hydroxyethylamino)adenine (100 mg, 0.35 mmol) obtained by Reference example 7 was dissolved in acetic acid and thereto was added 2.0 M bromine/acetic acid (0.18 ml, 0.36 mmol). The mixture was stirred at room temperature for 3 hours. After adding water (3 ml) to the reaction mixture, the solution was neutralized with 40% sodium hydroxide solution under ice cooling and the resulting precipitate was filtered to give the captioned compound (130 mg, 0.36 mmol, yield: 100%) as a white solid.


Reference Example 9
2-(2-Hydroxyethylamino)-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was prepared in accordance with the method of Reference example 7.


Reference Example 10
8-Bromo-2-(2-hydroxyethylamino)-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was prepared in accordance with the method of Reference example 8.


Reference Example 11
2-(2-Hydroxyethoxy)-9-{(6-methyl-3-pyridyl)methyl}adenine)

After sodium (2.1 g, 91 mmol) was dissolved in ethylene glycol (30 ml), 2-chloro-9-{(6-methyl3-pyridyl)methyl}adenine (3.0 g, 11 mmol) was added thereto and the mixture was stirred at 100° C. for 3 hours. After the mixture was allowed to cool, water (80 ml) was added thereto and the resulting precipitate was filtered to give the captioned compound (3.1 g, 10 mmol, yield: 94%) as a white solid.


Reference Example 12
8-Bromo-2-(2-hydroxyethoxy)-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was prepared in accordance with the method of Reference example 8.


Reference Example 13
2-(2-Hydroxyethoxy)-8-methoxy-9-{(6-methyl-3-pyridyl)methyl}adenine

After 8-bromo-2-(2-hydroxyethoxy)-9-{(6-methyl-3-pyridyl)methyl}adenine (2.3 g, 7.7 mmol) obtained by Reference example 12 was suspended in a mixture of 1N sodium hydroxide solution (30 ml) and methanol (30 ml), the mixture was stirred at 100° C. for 10 hours. Water was added to the reaction mixture and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated to give the captioned compound (670 mg, 2.0 mmol, yield: 26%) as a pale yellow solid.


Reference Example 14
2-{2-(N,N-Dimethylaminocarbonyloxy)ethoxy}-8-methoxy-9-{(6-methyl-3-pyridyl)methyl}adenine

2-(2-Hydroxyethoxy)-8-methoxy-9-{(6-methyl-3-pyridyl)methyl}adenine (200 mg, 0.61 mmol) obtained by Reference example 13, dimethylaminopyridine (5 mg, 0.4 mmol) and N,N-diisopropylethylamine (0.32 mmol, 1.8 mmol) were dissolved in a mixed solvent of pyridine (2 ml) and dimethylformamide (2 ml), and thereto was added under ice cooling N,N-dimethylcarbamoyl chloride (1.1 ml, 12 mmol). The mixture was stirred for 21 hours. Water was added to the reaction mixture and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography to give the captioned compound (66 mg, 0.16 mmol, yield: 27%) as a white solid.


Reference Example 15
9-Benzyl-8-hydroxy-2-thioadenine

After aminomalononitrile p-toluenesulfonate (45 g, 178 mmol) was added to tetrahydrofuran, thereto were added benzylisocyanate (25 g, 188 mmol) and N,N-diisopropylethylamine (23.5 ml, 130 mmol). The mixture was stirred at room temperature for 14 hours. After removing the solvent, the residue was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated. To the residue were added tetrahydrofuran and 1N sodium hydroxide solution. The mixture was stirred at 50° C. for 20 minutes and neutralized with 15% potassium hydrogensulphate. The resulting precipitate was filtered, added to tetrahydrofuran and thereto was dropped benzoylisothiocyanate (41 ml, 305 mmol). The mixture was stirred at room temperature over a night and the solvent was removed. The precipitate was collected by adding ether to the residue, refluxed in a mixed solvent of tetrahydrofuran and 2N sodium hydroxide solution for 50 hours and neutralized with 10% potassium hydrogensulfate solution. The resulting precipitate was collected and recrystallized from ethyl acetate to give the captioned compound as a white powdered solid.


Reference Example 16
2-(2,3-Dihydroxypropylamino)-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was prepared in accordance with the method of Reference example 7.


Reference Example 17
8-Bromo-2-(2,3-dihydroxypropylamino)-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was prepared in accordance with the method of Reference example 10.


Reference Example 18
2-(2,3-Dihydroxypropylamino)-8-methoxy-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was prepared in accordance with the method of Reference example 13.


Reference Example 19
8-Methoxy-9-{(6-methyl-3-pyridyl)methyl}-2-{(2-oxo-1,3-dioxolan-4-yl)methylamino}adenine

2-(2,3-Dihydroxypropylamino)-8-methoxy-9-{(6-methyl-3-pyridyl)methyl}adenine (230 mg, 0.64 mmol) obtained by Reference example 18, 4-dimethylaminopyridine (5 mg, 0.04 mmol) and triethylamine (0.02 ml, 0.14 mmol) were dissolved in dimethylformamide (2 ml). Thereto was added di-t-butyl dicarbonate (410 mg, 1.9 mmol) in the oil bath kept at 50° C. and the mixture was stirred for 14 hours. The reaction mixture was concentrated and the residue was purified by preparative thin layer chromatography to give the captioned compound (64 mg, 0.17 mmol, yield 26%) as a white solid.


Reference Example 20
9-Benzyl-2-methoxycarbonylmethoxyadenine

9-Benzyl-8-hydroxy-2-(2-hydroxyethoxy)adenine (0.39 g, 1.37 mmol) and pyridinium dichromate (5.28 g, 14.03 mmol) were dissolved in DMF (14 ml) and the solution was stirred at room temperature for 23 hours. The reaction mixture was poured into an aqueous saturated ammonium chloride solution, and extracted with chloroform. The organic layer was concentrated and the resulting residue was added to methanol (100 ml). Thereto was added sulfuric acid (5 ml) and the mixture was refluxed under stirring for 3 hours. The mixture was neutralized with sodium hydrogencarbonate in an ice bath and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH 300/1˜100/1) to give the captioned compound (0.12 g, 0.38 mmol) as a white solid.


Reference Example 21
9-Benzyl-8-bromo-2-methoxycarbonylmethoxyadenine

9-Benzyl-2-methoxycarbonylmethoxyadenine (0.12 g, 0.38 mmol) obtained by Reference example 20 and sodium acetate (57 mg, 0.69 mmol) were dissolved in chloroform (6 ml), and thereto was added bromine (92 mg, 0.58 mmol) in an ice bath. The mixture was stirred at room temperature for 5 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was successively washed with a saturated sodium hydrogencarbonate and 10% sodium thiosulfate, dried over anhydrous magnesium sulfate and then concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=200/1) to give the captioned compound (0.10 g, 0.25 mmol) as a white solid.


Reference Example 22
2-(2-Methoxycarbonylethyl)adenine

9-Benzyl-2-(2-methoxycarbonylethyl)adenine (0.29 g, 0.93 mmol) obtained by Example 61 and 20% Pd(OH)2/C (0.32 g) were added to a mixed solvent of isopropanol (8 ml) and formic acid (8 ml), and the mixture was stirred at a pressure of 2 atmosphere of hydrogen at 70° C. for 40 hours. After filtration, the filtrate was concentrated to give the captioned compound (0.23 g, 0.86 mmol) as a white solid.


Reference Example 23
2-(2-Methoxycarbonylethyl)-9-{(6-methyl-3-pyridyl)methyl}adenine

2-(2-Methoxycarbonylethyl)adenine (313 mg, 1.51 mmol) obtained by Reference example 22 and potassium carbonate (0.44 g, 3.18 mmol) were added to DMF (40 ml). The mixture was at 70° C. for 1 hour and then cooled to room temperature. Thereto was added 6-methyl-3-pyridylmethyl chloride hydrochloride (0.38 g, 2.13 mmol) and the mixture was stirred at room temperature for 15 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1-30/1) to give the captioned compound (358 mg, 1.15 mmol) as a white solid.


Reference Example 24
8-Bromo-2-(2-methoxycarbonylethyl)-9-{(6-methyl-3-pyridyl)methyl}adenine

After 2-(2-methoxycarbonylethyl)-9-{(6-methyl-3-pyridyl)methyl}adenine (70 mg, 0.21 mmol) obtained by Reference example 23 and sodium acetate (0.35 g, 4.27 mmol) were dissolved in acetic acid (8 ml), thereto was added bromine (0.34 g, 2.13 mmol) and the mixture was stirred at 70° C. for 9 hours. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The organic layer was washed with saturated sodium hydrogencarbonate, saturated sodium thiosulfate, and saturated brine in that order and then dried over anhydrous magnesium sulfate. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜40/1) to give the captioned compound (31 mg, 0.076 mmol) as a pale yellow solid.


Reference Example 25
2-Butoxy-8-hydroxy-9-(5-methoxycarbonylfurfuryl)adenine

Lithium aluminium hydride (54 mg, 1.42 mmol) was added to THF (4 ml), and thereto butoxy-8-hydroxy-9-(5-methoxycarbonylfurfuryl)adenine (62 mg, 0.17 mmol) obtained by Example 15 in THF (10 ml) was dropped in an ice bath. The mixture was stirred at room temperature for 1 hour. Thereto were added water (54 μl), 1N sodium hydroxide (162 μl) and water (162 μl) in that order in an ice bath. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=30/1˜20/1) to give the captioned compound (50 mg, 0.15 mmol) as a white solid.


Reference Example 26
2-Butoxy-9-(5-cyanomethylfurfuryl)-8-hydroxyadenine

After 2-butoxy-8-hydroxy-9-(5-hydroxymethylfurfuryl)adenine (42 mg, 0.13 mmol) obtained by Reference example 25 was dissolved in chloroform (10 ml), thereto was added thionyl chloride (0.2 ml) and the mixture was refluxed for 2 hours. After removing the solvent, the residue was dissolved in DMF (5 ml). Thereto was added sodium cyanide (35 mg, 0.71 mmol) and the mixture was stirred at room temperature for 4 hours. After removing the solvent, the residue was poured into water, neutralized with 1N hydrochloric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=50/1˜30/1) to give the captioned compound (31 mg, 0.091 mmol) as a white solid.


Reference Example 27
3,4-Dimethoxycarbonylbenzyl bromide

After 3,4-dimethoxycarbonyltoluene (5.28 g, 25.36 mmol) was added to carbon tetrachloride (250 ml), thereto were added N-bromosuccinimide (6.33 g, 35.56 mmol) and benzoylperoxide (0.53 g, 2.19 mmol) and the mixture was refluxed for 10 hours under stirring. After removing the solvent, the residue was poured into water and extracted with ether. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 250 g, eluting solvent: Hexane/CHCl3=10/1˜CHCl3 only) to give the captioned compound (2.05 g, 7.14 mmol) as a colorless transparent oil.


Reference Example 28
2-Butoxy-9-(3,4-dimethoxycarbonylbenzyl)adenine

2-Butoxyadenine (0.50 g, 2.41 mmol) obtained by Reference example 1 and potassium carbonate (0.25 g, 1.81 mmol) were added to DMF (12 ml) and the mixture was stirred at 70° C. for 1 hour. After the mixture was cooled to room temperature, 4-dimethoxycarbonylbenzyl bromide obtained by Reference example 27 (1.99 g, 10.78 mmol) was added thereto and the mixture was stirred at room temperature for 9 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=300/1˜100/1) to give the captioned compound (775 mg, 1.88 mmol) as a pale yellow solid.


Reference Example 29
2-Butoxy-8-methoxy-9-{(6-methoxycarbonyl-3-pyridyl)methyl}adenine

2-Butoxy-9-{(6-carboxyl-3-pyridyl)methyl}-8-methoxyadenine (87 mg, 0.23 mmol), potassium carbonate (32 mg, 0.24 mmol) and methyl iodide (66 mg, 0.46 mmol) were added in DMF (10 ml), and the mixture was stirred at room temperature for 3 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1) to give the captioned compound (78 mg, 0.20 mmol) as a yellow tar.


Reference Example 30
2-Butoxy-9-{6-thio-3-pyridyl}methyl) adenine

2-Butoxy-9-{6-chloro-3-pyridyl}methyl}-8-hydroxyadenine (1.00 g, 3.00 mmol) and 70% NaSH nH2O (3.40 g) were added to DMF (35 ml) and the mixture was stirred at 120° C. for 9 hours. After removing the solvent, the residue was poured into water and neutralized with concentrated hydrochloric acid. The resulting precipitate was filtered, successively washed with water and chloroform and dried in vacuo under heating to give the captioned compound (0.98 g, 2.97 mmol) as a yellow solid.


Reference Example 31
2-Butoxy-9-{6-(γ-butyrolactonyl)thio-3-pyridyl}methyl)adenine

2-Butoxy-9-{6-thio-3-pyridyl}methyl)adenine (0.25 g, 0.76 mmol) obtained by Reference example 30, potassium carbonate (78 mg, 0.51 mmol) and α-bromo-γ-butyrolactone (190 mg, 1.15 mmol) were added to DMF (18 ml), and the mixture was stirred at room temperature for 17 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 10 g, eluting solvent: CHCl3/MeOH=200/1˜50/1) to give the captioned compound (0.31 g, 0.75 mmol) as a white solid.


Reference Example 32
8-Bromo-2-butoxy-9-{4-(γ-butyrolactonyloxy)benzyl}adenine

8-Bromo-2-butoxy-9-(4-hydroxybenzyl)adenine (0.20 g, 0.51 mmol), cesium carbonate (0.42 g, 1.29 mmol) and α-bromo-γ-butyrolactone (0.42 g, (2.55 mmol) were added to DMF (7 ml), and the mixture was stirred at room temperature for 55 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 10 g, eluting solvent: CHCl3/MeOH=300/1˜100/1) to give the captioned compound (0.19 g, 0.40 mmol) as a yellow tar.


Reference Example 33
2-(2-Methoxyethoxy)adenine

After sodium (3.00 g, 130 mmol) was dissolved in 2-methoxyethanol (150 ml), thereto was added 2-chloroadenine (3.00 g, 17.69 mmol) and the mixture was refluxed for 8 hours. After the mixture was allowed to cool, water (400 ml) was added thereto and neutralized with concentrated hydrochloric acid. The resulting precipitate was filtered and washed with methanol to give the captioned compound (3.06 g, 14.48 mmol, yield 73%) as a white solid.


Reference Example 34
(9-(3-Methoxycarbonylmethylbenzyl)-2-(2-methoxyethoxy)adenine

2-(2-Methoxyethoxy)adenine (0.19 g, 0.90 mmol) obtained by Reference example 33 and potassium carbonate (0.87 g, 6.30 mmol) were added to DMF (10 ml) and the mixture was stirred at 60° C. for 1.5 hours. After cooling to room temperature, methyl 3-bromo methylphenylacetate (0.44 g, 1.80 mmol) was added thereto and the mixture was stirred at room temperature for 1.5 hours. After removing the solvent, the residue was poured into 5% citric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 6.0 g, eluting solvent: CHCl3/MeOH 200/1˜50/1) to give the captioned compound (0.23 g, 0.63 mmol, yield; 70%) as a pale yellow solid.


Reference Example 35
8-Bromo-9-(3-methoxycarbonylmethylbenzyl)-2-(2-methoxyethoxy)adenine

After 9-(3-methoxycarbonylmethylbenzyl)-2-(2-methoxyethoxy)adenine (0.23 g, 0.63 mmol) obtained by Reference example 34 and sodium acetate (0.093 g, 1.13 mmol) were dissolved in chloroform (10 ml), bromine (0.15 g, 0.95 mmol) was added thereto and the mixture was stirred at room temperature for 3 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was washed with saturated sodium hydrogencarbonate, saturated sodium hydrogen sulfite, and saturated brine in that order and dried over anhydrous magnesium sulfate. The residue was purified by column chromatography (SiO2 7.0 g, eluting solvent: CHCl3/MeOH=100/0˜200/1) to give the captioned compound (0.22 g, 0.50 mmol, yield: 79%) a brown solid.


Reference Example 36
2-Butylamino-9-(3-methoxycarbonylmethylbenzyl)adenine

2-Butylaminoadenine (0.21 g, 1.00 mmol) obtained by Reference example 6 and potassium carbonate (0.69 g, 5.00 mmol) were added to DMF (7 ml), and thereto was added methyl 3-bromomethylphenylacetate (0.49 g, 2.00 mmol). The mixture was stirred at room temperature for 2 hours. After removing the solvent, the residue was poured into 5% citric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 6.3 g, eluting solvent: CHCl3/MeOH=100/0˜50/1) to give the captioned compound (0.23 g, 0.61 mmol, yield: 61%) as a white solid.


Reference Example 37
8-Bromo-2-butylamino-9-(3-methoxycarbonylmethylbenzyl)adenine

After 2-butylamino-9-(3-methoxycarbonylmethylbenzyl)adenine obtained by Reference example 36 (0.23 g, 0.61 mmol) was dissolved in chloroform (10 ml), bromine (0.15 g, 0.92 mmol) was added thereto and the mixture was stirred at room temperature for 1 hour. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was washed with saturated sodium hydrogencarbonate, saturated sodium hydrogensulfite and saturated brine in that order, dried over anhydrous magnesium sulfate and concentrated to give the captioned compound (0.23 g, 0.51 mmol, yield: 83%) as a pale yellow solid.


Reference Example 38
2-Chloro-9-(3-methoxycarbonylmethylbenzyl)adenine

2-Chloroadenine (1.70 g, 10.0 mmol) and potassium carbonate (9.67 g, 70.0 mmol) were added to DMF (35 ml) and the mixture was stirred at 60° C. for 1.5 hours. After cooling to room temperature, methyl 3-bromomethylphenylacetate (3.16 g, 13.0 mmol) was added thereto and the mixture was stirred at room temperature for 1.5 hours. After removing the solvent, thereto was added chloroform (50 ml) and the resulting solid was washed with water to give the captioned compound (2.13 g, 6.41 mmol, yield: 64%) as a pale yellow solid.


Reference Example 39
8-Bromo-2-chloro-9-(3-methoxycarbonylmethylbenzyl)adenine

After 2-chloro-9-(3-methoxycarbonylmethylbenzyl)adenine obtained by Reference example 38 (2.00 g, 6.03 mmol) and sodium acetate (2.95 g, 36.0 mmol) were dissolved in chloroform (100 ml), bromine (4.79 g, 30.0 mmol) was added thereto and the mixture was stirred at room temperature for 5 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was washed with saturated sodium hydrogencarbonate, saturated sodium hydrogensulfite and saturated brine in that order, dried over anhydrous magnesium sulfate and concentrated to give the captioned compound (1.78 g, 4.34 mmol, yield: 72%) as a brown solid.


Reference Example 40
Methyl 2-(4-bromomethyl)phenylpropionate

Thionyl chloride (5.80 ml, 80 mmol) was added to methanol (100 ml) under ice cooling and the mixture was stirred for 1 hour. Thereto was dropped 2-(4-bromomethyl)phenylpropionic acid (4.86 g, 20 mmol) in methanol (30 ml). After stirring at room temperature for 2 hours, the solvent was removed. Water was added to the residue and the mixture was extracted with ethyl acetate. The organic layer was washed with 5% sodium carbonate and 5% brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (hexane-ethyl acetate) to give the captioned compound (4.71 g, 18.3 mmol, yield: 92%) as a colorless oil.


Reference Example 41
Ethyl α,α-dimethyl-m-tolylacetate

After potassium t-butoxide (11.22 g, 50 mmol) was added to ethyl m-tolylacetate (7.12 g, 40 mmol) and iodomethane (14.20 g, 100 mmol) in THF solution (300 ml) at −80° C., the mixture was stirred at room temperature for 3 hours. After saturated ammonium chloride solution (200 ml) was added thereto, the solvent was removed and the residue was extracted with chloroform. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (hexane-ethyl acetate) to give the captioned compound (4.92 g, 23.9 mmol, yield: 84%) as a colorless oil.


Reference Example 42
Ethyl α,α-dimethyl-m-bromomethylphenylacetate

To ethyl α,α-dimethyl-m-tolylacetate (4.12 g, 20 mmol) obtained by Reference example 41 in carbon tetrachloride (140 ml) were added N-bromosuccinimide (3.56 g, 20 mmol) and benzoylperoxide (100 mg, 0.41 mmol) and the mixture was refluxed for 3 hours. To the reaction mixture was 5% sodium hydrogensulfite and the organic layer was separated. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (hexane-ethyl acetate) to give the captioned compound (4.62 g) as a colorless oil.


Reference Example 43
Methyl 4-(2-bromoethyl)benzoate

Thionyl chloride (5.80 ml, 80 mmol) was added to methanol (100 ml) under ice cooling. The mixture was stirred for 1 hour and thereto was dropped 2-(4-bromoethyl)benzoic acid (4.58 g, 20 mmol) in methanol (30 ml). After stirring at room temperature for 2 hours, the solvent was removed. Water was added to the residue and mixture was extracted with ethyl acetate. The organic layer was washed with 5% sodium carbonate and 5% brine, dried over anhydrous magnesium sulfate and concentrated to give the captioned compound (4.79 g, 18.3 mmol, yield: 99%) as a colorless oil.


The compounds of Reference examples 44˜46 below were obtained in accordance with the method of Reference example 40.


Reference Example 44
Methyl o-tolylacetate (4.36 g, 26.6 mmol, yield: 89%)
Reference Example 45
Methyl p-tolylacetate (4.42 g, 27.0 mmol, yield: 90%)
Reference Example 46
Methyl 2-fluoro-5-methylbenzoate (3.07 g, 18.3 mmol, yield: 91%)
Reference Example 47
Methyl 2-methoxy-5-methylbenzoate

To 5-methylsalicylic acid (3.04 g, 20 mmol) in DMF (100 ml) were added potassium carbonate (8.28 g, 60 mmol) and iodomethane (6.24 g, 44 mmol) under ice cooling and then the mixture was stirred at room temperature for 12 hours. The mixture were extracted by adding 5% sodium hydrogensulfite and ethyl acetate, and the extracted organic layer was washed with 5% citric acid and 5% brine. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (hexane-ethyl acetate) to give the captioned compound (3.43 g, 19.1 mmol, yield: 95%) as a colorless oil.


Reference Example 48
Methyl α,α-dimethyl-p-tolylacetate

The captioned compound was obtained in accordance with the method of Example 41 (2.26 g, 11.8 mmol, yield: 75%).


Reference Example 49
Ethyl (2R,S)-3-methylphenylpropionate

To ethyl m-tolylacetate (3.56 g, 20 mmol) in THF (300 ml) was added iodomethane (3.12 g, 22 mmol). Thereto at −80° C. was added potassium t-butoxide (2.47 g, 22 mmol) and the mixture was stirred at room temperature for 3 hours. After saturated ammonium chloride (200 ml) was added thereto at −80° C., THF was removed and the residue was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, concentrated and purified by column chromatography (hexane-ethyl acetate) to give the captioned compound (2.97 g, 15.5 mmol, yield: 77%) as a colorless oil.


The compounds of Reference examples 50˜54 below were prepared in accordance with the method of Reference example 42.


Reference Example 50
Methyl o-bromomethylphenylacetate
Reference Example 51
Methyl 3-bromomethyl-6-fluorobenzoate
Reference Example 52
Methyl 3-bromomethyl-6-methoxybenzoate
Reference Example 53
Methylα,α-dimethyl-p-bromomethylphenylacetate
Reference Example 54
Ethyl (2R,S)-3-bromomethylphenylpropionate
Reference Example 55
Methyl dimethoxy(3-methylphenyl)acetate

To 3-methylacetophenone (5.0 g, 37 mmol) in pyridine (50 ml) was added selenium dioxide (7.44 g, 67 mmol), and the mixture was refluxed for 3.5 hours. The resulting black solid was filtered off. The filtrate was neutralized with concentrated hydrochloric acid and extracted with ether to give 3-methylphenylglyoxylic acid (6.12 g, 37 mmol, yield: 100%). Then to the obtained 3-methylphenyloxoacetic acid (4.0 g, 24 mmol) in methanol (250 ml) was added concentrated sulfuric acid (13 ml), and the mixture was refluxed for 5 hours. After being neutralized with saturated sodium hydrogencarbonate, the solution was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 170 g, eluting solvent: Hex/AcOEt=200/1˜0/1) to give the captioned compound (3.75 g, 16.7 mmol, yield: 69%) as a pale yellow oil.


Reference Example 56
Methyl dimethoxy(3-bromomethylphenyl)acetate

The captioned compound was obtained in accordance with the method of Reference example 27. Yield: 69% Reference example 57


2-Butoxy-9-[3-(1,1,2-trimethoxy-2-oxoethyl)benzyl]adenine

The captioned compound as a yellow solid was obtained in accordance with the method of Reference example 3, yield: 75%.


Reference Example 58
8-Bromo-2-butoxy-9-[3-(1,1,2-trimethoxy-2-oxoethyl)benzyl]adenine

The captioned compound was obtained in accordance with the method of Reference example 21, yield: 95%.


Example 1
2-Butoxy-8-hydroxy-9-(3-methoxycarbonylbenzyl)adenine

After 2-butoxy-8-methoxy-9-(3-carboxybenzyl)adenine (0.60 g, 1.61 mmol) obtained by Reference example 5 was dissolved in methanol (20 ml), thereto was added sulfuric acid (1 ml) and the solution was refluxed for 1 hour under stirring. After the reaction mixture was neutralized with saturated sodium hydrogencarbonate solution in an ice bath, the resulting precipitate was filtered and washed with methanol to give the captioned compound (0.48 g, 1.29 mmol, yield: 80%) as a white solid.


The compounds of Examples 2˜4 below were obtained in accordance with the method of Example 1.


Example 2
2-Butoxy-8-hydroxy-9-(3-ethoxycarbonylbenzyl)adenine
Example 3
2-Butoxy-8-hydroxy-9-(3-isopropoxycarbonylbenzyl)adenine
Example 4
2-Butoxy-8-hydroxy-9-{3-(2,2,2-trifluoroethoxycarbonyl)benzyl}adenine
Example 5
2-Butoxy-8-hydroxy-9-{3-(2-benzyloxyethoxycarbonyl)benzyl}adenine

After 2-butoxy-9-(3-carboxybenzyl)-8-methoxyadenine (0.06 g, 0.16 mmol) obtained by Reference example 5 and triethylamine (0.03 g, 0.28 mmol) were added to acetonitrile (10 ml), benzyl 2-bromoethyl ether (0.06 g, 0.28 mmol) was added thereto, and the mixture was refluxed for 50 hours under stirring. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The solid was added to methanol (10 ml) and concentrated hydrochloric acid (10 ml), and the mixture was stirred at room temperature for 18 hours. After neutralizing with saturated sodium hydrogencarbonate solution, the solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, concentrated and washed with methanol to give the captioned compound (0.03 g, 0.06 mmol, yield: 38%) as a white solid.


Example 6

2-Butoxy-8-hydroxy-9-{3-(2-hydroxyethoxycarbonyl)benzyl}adenine 2-Butoxy-8-hydroxy-9-{3-(2-benzyloxyethoxycarbonyl)benzyl}adenine (0.03 g, 0.06 mmol) obtained by Example 5, 5% Pd/C (60 mg) and concentrated hydrochloric acid (0.1 ml) were added to a mixed solvent of THF (30 ml) and methanol (30 ml), and the mixture was stirred under hydrogen atmosphere at room temperature for 60 hours. The reaction mixture was filtered, neutralized with saturated sodium hydrogencarbonate solution and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜50/1) and washed with methanol to give the captioned compound (0.01 g, 0.02 mmol, yield: 42%) as a white solid.


The compounds of Examples 7˜9 below were obtained in accordance with the method of Example 5.


Example 7
2-Butoxy-8-hydroxy-9-{3-(2-dimethylamino ethoxycarbonyl)benzyl}adenine
Example 8
2-Butoxy-8-hydroxy-9-{3-(2-morpholino ethoxycarbonyl)benzyl}adenine
Example 9
2-Butoxy-8-hydroxy-9-{3-(3-pyridylmethoxycarbonyl)benzyl}adenine
Example 10
2-Butoxy-8-hydroxy-9-{3-(S-methylthiocarbonyl)benzyl}adenine

After 2-butoxy-9-(3-carboxybenzyl)-8-methoxyadenine (0.06 g, 0.16 mmol) obtained by Reference example 5 and triethylamine (0.02 g, 0.19 mmol) were added to DMF (10 ml), methanesulfonyl chloride (0.02 g, 0.19 mmol) was added thereto in an ice bath, and the mixture was stirred for 1 hour. Methanethiol (0.1 ml, 1.43 mmol) was added thereto and the mixture was stirred at room temperature for 8 hours. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The solid was added to methanol (10 ml) and concentrated hydrochloric acid (10 ml) and the mixture was refluxed under stirring at room temperature for 18 hours. After being neutralized with saturated sodium hydrogencarbonate solution, the solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=80/1˜20/1) and washed with methanol to give the captioned compound (0.01 g, 0.03 mmol, yield: 16%) as a white solid.


The compounds of Examples 11˜12 below were obtained in accordance with the method of Example 1.


Example 11
2-Butoxy-8-hydroxy-9-(4-methoxycarbonylbenzyl)adenine
Example 12
2-Butoxy-8-hydroxy-9-(4-isopropoxycarbonylbenzyl)adenine
Example 13
2-Butoxy-8-hydroxy-9-{4-(3-pyridylmethoxycarbonyl)benzyl}adenine

After 2-butoxy-9-(4-carboxybenzyl)-8-methoxyadenine (0.05 g, 0.13 mmol) prepared in accordance with the method of Reference example 5 and potassium carbonate (0.03 g, 0.22 mmol) were added to DMF (10 ml), 3-chloromethylpyridine hydrochloride (0.03 g, 0.18 mmol) was added thereto, and the mixture was stirred at room temperature for 18 hours. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=300/1˜30/1) and the resulting solid was added to methanol (10 ml) and concentrated hydrochloric acid (10 ml). The mixture was stirred at room temperature for 18 hours. After being neutralized with saturated sodium hydrogencarbonate, the solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, concentrated and washed with methanol to give the captioned compound (0.03 g, 0.07 mmol, yield: 52%) as a white solid.


Example 14
2-Butoxy-8-hydroxy-9-(4-benzyloxycarbonylbenzyl)adenine

The captioned compound was prepared in accordance with the method of Example 13.


The compounds of Examples 15˜18 below were prepared in accordance with the method of Example 1.


Example 15
2-Butoxy-8-hydroxy-9-(5-methoxycarbonylfurfuryl)adenine
Example 16
2-Butoxy-8-hydroxy-9-(5-isopropoxycarbonylfurfuryl)adenine
Example 17
2-Butoxy-8-hydroxy-9-{(6-methoxycarbonyl-3-pyridyl)methyl}adenine
Example 18
2-Butoxy-8-hydroxy-9-{6-isopropoxycarbonyl-3-pyridyl)methyl}adenine
Example 19
2-Butoxy-8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)adenine

Lithium aluminium hydride (0.08 g, 2.15 mmol) was added to THF (10 ml), and thereto was dropped 2-butoxy-9-(3-methoxycarbonyl)benzyladenine (0.20 g, 0.56 mmol) obtained by Reference example 3 in THF (10 ml) in an ice bath, and the mixture was stirred at room temperature for 2 hours. Thereto were dropped water (0.1 ml), 5% sodium hydroxide solution (0.3 ml) and water (0.3 ml) in that order in an ice bath. After the reaction mixture was filtered, the filtrate was concentrated and the residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜30/1) to give 2-butoxy-9-(3-hydroxymethylbenzyl)adenine (0.18 g, 0.55 mmol, yield: 98%) as a white solid.


2-Butoxy-9-(3-hydroxymethylbenzyl)adenine (0.09 g, 0.27 mmol), triethylamine (0.20 g, 1.98 mmol), tosyl chloride (0.30 g, 1.57 mmol) and pyridine (0.4 ml) were added to DMF (10 ml), and the mixture was stirred at room temperature for 24 hours. To the reaction mixture was added sodium cyanide (0.40 g, 9.16 mmol), and the mixture was stirred at 80° C. for 18 hours. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1) to give 2-butoxy-9-(3-cyanomethylbenzyl)adenine (0.04 g, 0.12 mmol, yield: 44%) as a white solid.


2-Butoxy-9-(3-cyanomethylbenzyl)adenine (0.04 g, 0.12 mmol) was added to a mixed solvent of 5% sodium hydroxide solution (10 ml) and methanol (10 ml), and the mixture was stirred at 80° C. for 19 hours. After extracting with dichloromethane, the aqueous layer was neutralized with concentrated hydrochloric acid, and concentrated. The residue and sulfuric acid (1 ml) were added to methanol (50 ml), and the mixture was refluxed under stirring for 1 hour. After being neutralized with saturated sodium hydrogencarbonate solution in an ice bath, the solution was extracted with dichloromethane. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated to give 2-butoxy-8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)adenine (0.04 g, 0.11 mmol, yield: 92%) as a pale yellow solid. And then the captioned compound was obtained in accordance with the method of Example 1, yield (three steps): 71%.


The compounds of Examples 20˜21 below were obtained in accordance with the method of Example 1.


Example 20
2-Butoxy-8-hydroxy-9-(4-methoxycarbonylmethylbenzyl)adenine
Example 21
2-Butoxy-8-hydroxy-9 (4-isoprop oxycarbonylmethylbenzyl)adenine
Example 22
2-Butoxy-8-hydroxy-9-(4-methoxycarbonylmethoxybenzyl)adenine

8-Bromo-2-butoxy-9-(4-acetoxybenzyl)adenine (0.29 g, 0.67 mmol) obtained in accordance with the method of Reference example 4 was added to methanol (10 ml) and 5% sodium hydroxide solution (10 ml), and the mixture was stirred at room temperature for 4 hours. After the mixture was neutralized with concentrated hydrochloric acid, the resulting solid was filtered and washed with methanol to give 8-bromo-2-butoxy-9-(4-hydroxybenzyl)adenine (0.19 g, 0.49 mmol, yield: 73%) as a white solid. Thus obtained 8-bromo-2-butoxy-9-(4-hydroxybenzyl)adenine (0.05 g, 0.13 mmol) and potassium carbonate (0.02 g, 0.14 mmol) were added to DMF (10 ml), and then thereto was added ethyl bromoacetate (0.04 g, 0.24 mmol). The mixture was stirred at room temperature for 18 hours. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The combined organic layer was dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜50/1) to give 8-bromo-2-butoxy-9-(4-ethoxycarbonylmethoxybenzyl)adenine (0.06 g, 0.12 mmol, yield: 96%) as a white solid. And then the captioned compound was obtained in accordance with the method of Example 1, Yield: 80%.


Example 23
2-Butoxy-8-hydroxy-9-{3-bromo-4-(methoxycarbonylmethoxy)benzyl}adenine

After 2-butoxyadenine (0.11 g, 0.53 mmol) obtained by Reference example 1 and potassium carbonate (0.05 g, 0.36 mmol) were added to DMF (10 ml), 4-(chloromethyl)phenol acetate (0.12 g, 6.50 mmol) was added thereto, and the mixture was stirred at room temperature for 18 hours. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=300/1˜30/1) to give 2-butoxy-9-(4-acetoxybenzyl)adenine (0.08 g, 1.41 mmol, yield: 42%) as a white solid. Thus obtained solid was added to methanol (10 ml) and 5% sodium hydroxide solution (10 ml), and the mixture was stirred at room temperature for 2 hours. After being neutralized with concentrated hydrochloric acid, the solution was extracted with dichloromethane. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated to give 2-butoxy-9-(4-hydroxybenzyl)adenine (0.06 g, 0.19 mmol. yield: 86%) as a white solid. Thus obtained solid and potassium carbonate (0.02 g, 0.14 mmol) were added to DMF (10 ml), and then thereto was added ethyl bromoacetate (0.04 g, 0.24 mmol). The mixture was stirred at room temperature for 18 hours. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The combined organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜50/1) to give 2-butoxy-9-{4-(ethoxycarbonyl methoxy)benzyl}adenine (0.06 g, 0.15 mmol, yield: 79%) as a white solid. And then the captioned compound was obtained in accordance with the method of Example 1.


Example 24
2-Butoxy-8-hydroxy-9-{6-(4-ethoxycarbonyl-1-piperidyl)-3-pyridylmethyl}adenine

2-Butoxy-9-(6-chloro-3-pyridylmethyl)-8-methoxyadenine (0.28 mg, 0.77 mmol) was added to 4-ethoxycarbonylpiperidine (10 ml), and the mixture was refluxed under stirring for 8 hours. After the mixture was allowed to cool, ethanol was added thereto. The resulting solid was filtered and purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=80/1˜20/1) to give the captioned compound (0.15 g, 1.41 mmol, yield: 44%) as a white solid.


Example 25
2-Butoxy-8-hydroxy-9-{6-(3-ethoxycarbonyl-1-piperidyl)-3-pyridylmethyl}adenine

The captioned compound was obtained in accordance with the method of Example 24.


Example 26
2-Butoxy-8-hydroxy-9-{(6-ethoxycarbonylmethoxy-2-naphthyl)methyl}adenine)

The captioned compound was obtained in accordance with the method of Example 5.


The compounds of Examples 27˜28 below were obtained in accordance with the method of Example 1.


Example 27
2-Butylamino-8-hydroxy-9-(4-methoxycarbonylbenzyl)adenine
Example 28
2-Butylamino-8-hydroxy-9-(5-ethoxycarbonylfurfuryl)adenine
Example 29
9-Benzyl-8-hydroxy-2-methoxycarbonylmethyladenine

After sodium cyanide (0.20 g, 4.08 mmol) and 9-benzyl-2-chloromethyl-8-hydroxyadenine (0.20 g, 0.69 mmol) were added to DMF (10 ml), the mixture was stirred at 80° C. for 7 hours. After removing the solvent, the residue was poured into water and the solution was neutralized with concentrated hydrochloric acid. The solution was extracted with dichloromethane, and the organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜50/1) and washed with methanol to give 9-benzyl-2-cyanomethyl-8-hydroxyadenine (0.16 g, 0.57 mmol) as a pale yellow solid. Thus obtained 9-benzyl-2-cyanomethyl-8-hydroxyadenine (0.08 g, 0.29 mmol) was added to a mixed solvent of 5% sodium hydroxide solution (20 ml) and methanol (10 ml), and the mixture was stirred at 60° C. for 8 hours. After the mixture was neutralized with concentrated hydrochloric acid, the solvent was removed. The residue and sulfuric acid (1 ml) were added to methanol (50 ml), and the mixture was refluxed for 3 hours under stirring. After being neutralized with saturated sodium hydrogencarbonate solution in an ice bath, the solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified with column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜30/1) and washed with methanol to give the captioned compound (0.02 g, 0.06 mmol) as a white solid.


Example 30
9-Benzyl-2-ethoxycarbonylmethyl-8-hydroxyadenine

The captioned compound was obtained in accordance with the method of Example 29.


Example 31
9-Benzyl-8-hydroxy-2-methoxycarbonylmethylaminoadenine

9-Benzyl-2-chloroadenine (0.30 g, 1.12 mmol), glycine methyl ester hydrochloride (0.72 g, 5.73 mmol) and diisopropylethylamine (1.48 g, 11.47 mmol) were added to n-butanol (10 ml), and the mixture was stirred in an autoclave at 150° C. for 19 hours. The solvent was removed and the residue was poured into water. The solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by column chromatography to give 9-benzyl-2-methoxycarbonylmethylaminoadenine (0.06 g) as a brown tar. Thus obtained 9-benzyl-2-methoxycarbonylmethylaminoadenine was dissolved in dichloromethane (10 ml) and to the solution was added bromine (0.05 ml) in an ice bath. The mixture was stirred at room temperature for 1 hour. After removing the solvent, the residue was poured into water and extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by column chromatography to give 9-benzyl-8-bromo-2-methoxycarbonylmethylaminoadenine (0.06 g) as a yellow solid.


Thus obtained 9-benzyl-8-bromo-2-methoxycarbonylmethylaminoadenine was added to concentrated hydrochloric acid (10 ml), and the mixture was stirred for 8 hours at 100° C. The mixture was neutralized in an ice bath with 5% sodium hydroxide solution (pH 7) and the solvent was removed. To the residue were added methanol (30 ml) and sulfuric acid (1 ml), and the mixture was refluxed for 4 hours. After being neutralized (pH 6) in an ice bath with saturated sodium hydrogencarbonate solution, the solution was extracted with dichloromethane. The organic layer was dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by column chromatography and the obtained compound was washed with methanol to give the captioned compound (0.02 g) as a white solid.


Example 32
8-Hydroxy-2-methoxycarbonylmethylamino-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was obtained in accordance with the method of Example 31.


Example 33
2-(2-Acetoxyethylamino)-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine

To 8-hydroxy-2-(2-hydroxyethylamino)-9-{(6-methyl-3-pyridyl)methyl}adenine (100 mg, 0.32 mmol) prepared by Comparative example 10 in pyridine (1 ml) was added under ice cooling acetic anhydride (0.033 ml, 0.35 mmol), and the mixture was stirred for 3 hours. To the reaction mixture was added sodium hydrogen carbonate solution, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by preparative thin-layer chromatography to give the captioned compound (14 mg, 0.039 mmol, yield: 12%) as a white solid.


The compounds of Examples 3435 below were obtained in accordance with the method of Example 33.


Example 34
8-Hydroxy-2-(2-methoxycarbonyloxyethylamino)-9-{(6-methyl-3-pyridyl)methyl}adenine
Example 35
2-(2-Acetoxyethylamino)-9-benzyl-8-hydroxyadenine
Example 36
2-(2-Acetoxyethoxy)-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine

To 8-hydroxy-2-(2-hydroxyethoxy)-9-{(6-methyl-3-pyridyl)methyl}adenine (90 mg, 0.29 mmol) obtained by Comparative example 11 and dimethylaminopyridine (5 mg, 0.4 mmol) in pyridine (2 ml) was added under ice cooling acetic anhydride (0.027 ml, 0.29 mmol), and the mixture was stirred for 15 hours. To the reaction mixture was added water, and the solution was extracted with chloroform. The combined organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by silica gel column chromatography to give the captioned compound (11 mg, 0.031 mmol, yield: 11%) as a white solid.


Example 37
8-Hydroxy-9-(6-methyl-3-pyridyl)methyl-2-{2-(propionyloxy)ethoxy}adenine

The captioned compound was obtained in accordance with the method of Example 36.


Example 38
2-{2-(Methoxycarbonyloxy)ethoxy}-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine

To 8-hydroxy-2-(2-hydroxyethoxy)-9-{(6-methyl-3-pyridyl)methyl}adenine (90 mg, 0.29 mmol) obtained by Comparative example 11 in pyridine (2 ml) was added under ice cooling methyl chloroformate (0.022 ml, 0.29 mmol), and the mixture was stirred for 3 hours. To the reaction mixture was added water, and the solution was extracted with chloroform. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated to give the captioned compound (68 mg, 0.18 mmol, yield: 63%) as a white solid.


Example 39
2-{2-(N,N-Dimethylaminocarbonyloxy)ethoxy}-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was obtained in accordance with the method of Comparative example 11.


Example 40
9-Benzyl-8-hydroxy-2-(methoxycarbonylmethyl)thioadenine

After 9-benzyl-8-hydroxy-2-thioadenine (200 mg, 0.73 mmol) obtained by Reference example 7 was dissolved in dimethylformamide (8 ml), thereto were added potassium carbonate (150 mg, 1.1 mmol) and methyl bromoacetate (0.1 ml, 1.1 mmol) in that order, and the mixture was stirred at room temperature for 2 hours. After removing the solvent, the residue was poured into water and the solution was extracted with chloroform. The combined organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by silica gel column chromatography to give the captioned compound (173 mg, yield: 69%) as a white solid.


The compounds of Examples 41˜59 below are obtained in accordance with the method of Example 40.


Example 41
9-Benzyl-2-(ethoxycarbonylmethyl)thio-8-hydroxyadenine
Example 42
9-Benzyl-8-hydroxy-2-(octyloxycarbonylmethyl)thioadenine
Example 43
9-Benzyl-2-(t-butoxycarbonylmethyl)thio-8-hydroxyadenine
Example 44
2-(Allyloxycarbonylmethyl)thio-9-benzyl-8-hydroxyadenine
Example 45
2-(Benzyloxycarbonylmethyl)thio-9-benzyl-8-hydroxyadenine
Example 46
9-Benzyl-2-(2-fluoroethoxycarbonylmethyl)thio-8-hydroxyadenine
Example 47
9-Benzyl-2-(2,2-difluoroethoxycarbonylmethyl)thio-8-hydroxyadenine
Example 48
9-Benzyl-2-(2,2,2-trifluoroethoxycarbonylmethyl)thio-8-hydroxyadenine
Example 49
9-Benzyl-8-hydroxy-2-(2-methoxyethoxycarbonylmethyl)thioadenine
Example 50
9-Benzyl-2-(ethylcarbamoylmethyl)thio-8-hydroxyadenine
Example 51
9-Benzyl-8-hydroxy-2-(1-piperidinocarbonylmethyl)thioadenine
Example 52
9-Benzyl-8-hydroxy-2-(morphorinocarbonylmethyl)thioadenine
Example 53
9-Benzyl-8-hydroxy-2-(1-ethoxycarbonylethyl)thioadenine
Example 54
9-Benzyl-8-hydroxy-2-(2-methoxycarbonylethyl)thioadenine
Example 55
9-Benzyl-2-(2-ethoxycarbonylethyl)thio-8-hydroxyadenine
Example 56
9-Benzyl-2-(3-ethoxycarbonylpropyl)thio-8-hydroxyadenine
Example 57
9-Benzyl-2-(4-ethoxycarbonylbutyl)thio-8-hydroxyadenine
Example 58
9-Benzyl-2-(ethoxycarbonylmethylcarbonylmethyl)thio-8-hydroxyadenine
Example 59
9-Benzyl-2-(2-butyrolactino)thio-8-hydroxyadenine
Example 60
8-Hydroxy-9-{(6-methyl-3-pyridyl)methyl}-2-{(2-oxo-1,3-dioxolan-4-yl)methylamino}adenine

8-Methoxy-9-{(6-methyl-3-pyridyl)methyl}-2-{(2-oxo-1,3-dioxolan-4-yl)methylamino}adenine (65 mg, 0.17 mmol) obtained by Reference example 19 was added to concentrated hydrochloric acid, and the solution was stirred under ice cooling for 15 hours. The solution was neutralized under ice cooling with 40% sodium hydroxide solution, and the resulting white crystals were purified by preparative thin-layer chromatography to give the captioned compound (18 mg, 0.049 mmol, yield: 29%) as a white solid.


Example 61
9-Benzyl-8-hydroxy-2-(2-methoxycarbonylethyl)adenine

After 9-benzyl-2-(2-carboxyethyl)-8-hydroxyadenine (100 mg, 0.32 mmol) obtained by Comparative example 15 was added to methanol (20 ml), sulfuric acid (2 ml) was added thereto, and the mixture was refluxed for 4 hours under stirring. After being neutralized in an ice bath with saturated sodium hydrogencarbonate solution, the solution was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜30/1) and the obtained compound was washed with methanol to give the captioned compound (74 mg, 0.23 mmol) as a white solid.


Example 62
9-Benzyl-2-ethoxycarbonylethyl-8-hydroxy adenine

The captioned compound was obtained in accordance with the method of Example 61.


Example 63
9-Benzyl-8-hydroxy-2-(S-methylthiocarbonyl ethyladenine

To DMF (3 ml) were added 9-benzyl-2-(2-carboxyethyl)-8-hydroxyadenine (49 mg, 0.16 mmol) obtained by Comparative example 15, N-hydroxybenzotriazole (47 mg, 0.35 mmol), methanethiol, aqueous 15% sodium salt solution (161 mg, 0.34 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (66 mg, 0.34 mmol), and the mixture was stirred at room temperature for 30 hours. After removing the solvent, the residue was poured into water and the solution was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜30/1) and the obtained compound was washed with methanol to give the captioned compound (17 mg, 0.050 mmol) as a white solid.


Example 64
9-Benzyl-8-hydroxy-2-methoxycarbonylmethoxyadenine

After sodium (0.30 g, 13.04 mmol) was dissolved in methanol (30 ml), thereto was added 9-benzyl-8-bromo-2-methoxycarbonylmethoxyadenine (0.10 g, 0.25 mmol) obtained by Reference example 21, and the mixture was refluxed for 7 hours under stirring. After being allowed to cool, the solution was neutralized with concentrated hydrochloric acid and concentrated. After the residue was dissolved in methanol (30 ml), thereto was added sulfuric acid (2 ml) and the solution was stirred for 7 hours. After being neutralized in an ice bath with saturated sodium hydrogencarbonate solution, the solution was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜30/1) and the obtained compound was washed with methanol to give the captioned compound (62 mg, 0.19 mmol) as a white solid.


Example 65
9-Benzyl-2-ethoxycarbonylmethoxy-8-hydroxyadenine

The captioned compound was obtained in accordance with the method of Example 61.


Example 66
8-Hydroxy-2-methoxycarbonylethyl-9-{(6-methyl-3-pyridyl)methyl}adenine

8-Bromo-2-(2-methoxycarbonylethyl)-9-{(6-methyl-3-pyridyl)methyl}adenine (31 mg, 0.076 mmol) obtained by Reference example 24 was added to concentrated hydrochloric acid (5 ml), and the mixture was stirred at 100° C. for 4 hours. The solution was neutralized in an ice bath with 1N sodium hydroxide solution, concentrated and the residue was dissolved in methanol (70 ml). Thereto was added sulfuric acid (7 ml) and the mixture was refluxed for 2 hours under stirring. After being neutralized in an ice bath with saturated sodium hydrogencarbonate solution, the solution was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=50/1˜20/1), the obtained compound was washed with chloroform and dried in vacuo under heating to give the captioned compound (12 mg, 0.035 mmol) as a white solid.


Example 67
8-Hydroxy-2-(2-methoxycarbonylethyl)-9-(4-methoxycarbonylmethylbenzyl)adenine

The captioned compound was obtained in accordance with the method of Example 66.


Example 68
2-Butoxy-8-hydroxy-9-(4-ethoxycarbonylmethylbenzyl)adenine

The captioned compound was obtained in accordance with the method of Example 61.


Example 69
2-Butoxy-8-hydroxy-9-{3-(2,2,2-trifluoroethoxycarbonyl)methylbenzyl}adenine

To DMF (3 ml) were added 2-butoxy-9-(4-carboxylmethylbenzyl)-8-methoxyadenine (40 mg, 0.10 mmol) obtained in accordance with the method of Reference example 5, N-hydroxybenzotriazole (31 mg, 0.23 mmol), 2,2,2-trifluoroethanol (23 mg, 0.23 mmol), diisopropylethylamine (59 mg, 0.46 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (44 mg, 0.23 mmol), and the mixture was stirred at room temperature for 17 hours. After removing the solvent, the residue was poured into water and the solution was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=200/1˜100/1). The resulting residue was added to THF (5.5 ml) and thereto was added concentrated hydrochloric acid (0.5 ml). The mixture was stirred at room temperature for 1 hour and neutralized with saturated sodium hydrogencarbonate solution. The mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=200/1˜40/1) and the obtained compound was washed with methanol to give the captioned compound (10 mg, 0.022 mmol) as a white solid.


The compounds of Examples 70˜71 below were obtained in accordance with the method of Example 69.


Example 70
2-Butoxy-8-hydroxy-9-{3-(2-fluoroethoxycarbonyl)methylbenzyl}adenine
Example 71
2-Butoxy-8-hydroxy-9-{4-(2-hydroxyethoxycarbonyl)methylbenzyl}adenine
Example 72
2-Butoxy-8-hydroxy-9-{4-(2-dimethylaminoethoxycarbonyl)methylbenzyl}adenine hydrochloride

2-Butoxy-9-(4-carboxylmethylbenzyl)-8-methoxyadenine (84 mg, 0.22 mmol) and potassium carbonate (133 mg, 0.96 mmol) were added to DMF (4 ml), and thereto was added 2-(dimethylamino)ethyl chloride hydrochloride (94 mg, 0.65 mmol). The mixture was stirred at room temperature for 16 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, concentrated and purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/1˜30/1). The resulting residue was added to THF (5.5 ml), and thereto was added concentrated hydrochloric acid (0.5 ml). The mixture was stirred at room temperature for 1 hour. The solution was neutralized with sodium hydrogencarbonate solution, extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=200/1˜40/1). The resulting residue was dissolved into THF (3 ml) and thereto was added concentrated hydrochloric acid (5.5 μl). The mixture was stirred at room temperature for 30 minutes. The precipitated solid was filtered and dried in vacuo under heating to give the captioned compound (16 mg, 0.033 mmol) as a white solid.


Example 73
2-Butoxy-8-hydroxy-9-{4-(2-morpholinoethoxycarbonyl)methylbenzyl}adenine

The captioned compound was obtained in accordance with the method of Example 72.


Example 74
2-Butoxy-8-hydroxy-9-{4-(S-methylthiocarbonyl)methylbenzyl}adenine

The captioned compound was obtained in accordance with the method of Example 63.


The compounds of Examples 75˜79 below were obtained in accordance with the method of Example 69.


Example 75
2-Butoxy-9-{4-(8-ethylthiocarbonyl)methylbenzyl}-8-hydroxyadenine
Example 76
2-Butoxy-8-hydroxy-9-(4-carbamoylmethylbenzyl)adenine
Example 77
2-Butoxy-8-hydroxy-9-(4-methylcarbamoylmethylbenzyl)adenine
Example 78
2-Butoxy-8-hydroxy-9-(4-dimethylcarbamoylmethylbenzyl)adenine
Example 79
2-Butoxy-8-hydroxy-9-(4-morpholinomethylbenzyl)adenine
Example 80
2-Butoxy-9-(3-ethoxycarbonylmethylbenzyl)-8-hydroxyadenine

The captioned compound was obtained in accordance with the method of Example 61.


Example 81
2-Butoxy-8-hydroxy-9-(5-methoxycarbonylmethylfurfuryl)adenine

2-Butoxy-9-(5-cyanomethylfurfuryl)-8-hydroxyadenine (29 mg, 0.085 mmol) obtained by Reference example 26 was added to a mixed solvent of 4N sodium hydroxide solution (3 ml) and methanol (3 ml), and the mixture was refluxed for 4 hours. The solution was neutralized in an ice bath with concentrated hydrochloric acid. After removing the solvent in vacuo, the residue and sulfuric acid (3 ml) were added to methanol (30 ml). The mixture was refluxed for 2 hours under stirring. The solution was neutralized in an ice bath with saturated sodium hydrogencarbonate solution, and extracted with chloroform. The combined organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=70/1˜40/1), and the obtained compound was washed with methanol and dried in vacuo under heating to give the captioned compound (16 mg, 0.091 mmol) as a white solid.


Example 82
2-Butoxy-8-hydroxy-9-{(6-S-methylthiocarbonyl-3-pyridyl)methyl}adenine

The captioned compound was obtained in accordance with the method of Example 63.


Example 83
2-Butoxy-9-{(6-carbamoyl-3-pyridyl)methyl}-8-hydroxyadenine

The captioned compound was obtained in accordance with the method of Example 69.


Example 84
2-Butoxy-8-hydroxy-9-(3-methoxycarbonylethylbenzyl)adenine

2-Butoxy-9-(3-methoxycarbonylethylbenzyl)adenine was obtained in accordance with the method of Example 81. And then the captioned compound was obtained in accordance with the method of Example 1.


Example 85
2-Butoxy-8-hydroxy-9-(4-methoxycarbonylethylbenzyl)adenine

The captioned compound was obtained in accordance with the method of Example 84.


Example 86
2-Butoxy-9-(4-ethoxycarbonylethylbenzyl)-8-hydroxyadenine

The captioned compound was obtained in accordance with the method of Example 61.


The compounds of Examples 87˜89 below were obtained in accordance with the method of Example 1.


Example 87
2-Butoxy-8-hydroxy-9-{6-(4-methoxycarbonyl-1-piperidyl)-3-pyridylmethyl}adenine
Example 88
2-Butoxy-8-hydroxy-9-{6-(3-methoxycarbonyl-1-piperidyl)-3-pyridylmethyl}adenine
Example 89
2-Butoxy-8-hydroxy-9-{(6-methoxycarbonylmethoxy-2-naphthyl)methyl}adenine
Example 90
2-Butoxy-9-(3,4-dimethoxycarbonylbenzyl)-8-hydroxyadenine

Staring from 2-butoxy-9-(3,4-dimethoxycarbonylbenzyl)adenine obtained by Reference example 28, the captioned compound was obtained in accordance with the method of Example 1.


Example 91
2-Butoxy-9-(3,5-dimethoxycarbonylbenzyl)-8-hydroxyadenine

The captioned compound was obtained in accordance with the method of Example 90.


Example 92
2-Butoxy-8-hydroxy-9-{(6-methoxycarbonylmethyl-3-pyridyl)methyl}adenine

The captioned compound was obtained in accordance with the method of Example 81.


Example 93
2-Butoxy-9-{6-(γ-butyrolactonyl)thio-3-pyridyl}methyl}-8-hydroxyadenine

Starting from 2-butoxy-9-{6-(γ-butyrolactonyl)thio-3-pyridyl}methyl)adenine obtained by Reference example 31, the captioned compound was obtained in accordance with the method of Example 1.


Example 94
2-Butoxy-9-{4-(γ-butyrolactonyloxy)benzyl}-8-hydroxyadenine

Starting from 8-bromo-2-butoxy-9-{4-(γ-butyrolactonyloxy)benzyl}adenine obtained by Reference example 32, the captioned compound was obtained in accordance with the method of Example 1.


Example 95
2-Butoxy-9-{4-(1-hydroxy-3-methoxycarbonylprop oxy)benzyl}-8-hydroxyadenine

The captioned compound was obtained in accordance with the method of Example 1.


Example 96
8-Hydroxy-9-(3-methoxycarbonylmethylbenzyl)-2-(2-methoxyethoxy)adenine

9-(3-Carboxymethylbenzyl)-8-hydroxy-2-(2-methoxyethoxy) adenine (81 mg, 0.22 mmol) obtained by Comparative example 27 was dissolved in methanol (3 ml), and thereto was added concentrated sulfuric acid (0.11 g, 1.10 mmol). The mixture was refluxed for 20 minutes. The solution was neutralized with saturated sodium hydrogencarbonate solution, extracted with chloroform, dried over anhydrous magnesium sulfate and concentrated. The residue was washed with diethyl ether to give the captioned compound (33 mg, yield 39%) as a white solid.


Example 97
2-Butylamino-8-hydroxy-9-(3-methoxycarbonyl methylbenzyl)adenine

The captioned compound was obtained in accordance with the method of Example 96.


Example 98
2-Chloro-8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)adenine

8-Bromo-2-chloro-9-(3-methoxycarbonylmethylbenzyl)adenine (1.78 g, 4.34 mmol) obtained by Reference example 39 was suspended in the mixed solvent of 1N sodium hydroxide solution (150 ml) and methanol (150 ml), and the mixture was stirred at 100° C. for 30 minutes. The residue was neutralized with 12N hydrochloric acid. After removing the solvent, to the residue were added methanol (50 ml) and concentrated sulfuric acid (2.45 g, 25.0 mmol) and the mixture was refluxed for 1 hour under heating. The solution was neutralized with saturated sodium hydrogencarbonate solution and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by column chromatography (SiO2 90.0 g, eluting solvent: CHCl3/MeOH=100/0˜50/1) to give the captioned compound (0.84 g, 2.41 mmol, yield: 56%) as a white solid.


Example 99
8-Hydroxy-2-(2-hydroxyethylthio)-9-(3-methoxycarbonylmethylbenzyl)adenine

Sodium (67 mg, 2.90 mmol) was dissolved in 2-mercapt ethanol (2.5 ml) and thereto was added 2-chloro-8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)adenine (100 mg, 0.29 mmol) obtained by Example 98. The mixture was stirred at 120° C. for 4 hours and then neutralized with 12N hydrochloric acid. After removing the solvent, to the residue were added methanol (3.0 ml) and concentrated sulfuric acid (0.14 g, 1.43 mmol), and the mixture was refluxed for 30 minutes. The solution was neutralized with saturated sodium hydrogencarbonate solution and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. To the residue was added water, the mixture was filtered and washed with water to give the captioned compound (55 mg, 0.14 mmol, yield: 49%) as a white solid.


The compounds of Examples 100˜102 below were obtained in accordance with the method of Example 1.


Example 100
2-Butoxy-8-hydroxy-9-[4-(1-methoxycarbonylethyl)benzyl]adenine
Example 101
2-Butoxy-8-hydroxy-9-[3-(2-methoxycarbonyl-2-propyl)benzyl]adenine
Example 102
2-Butoxy-8-hydroxy-9-(4-methoxycarbonylphenethyl)adenine

The compounds of Examples 103˜106 were obtained in accordance with the method of Example 40.


Example 103
9-Benzyl-8-hydroxy-2-[(3-methoxycarbonylbenzyl)thio]adenine
Example 104
9-Benzyl-8-hydroxy-2-[(4-methoxycarbonylbenzyl)thio]adenine
Example 105
9-Benzyl-8-hydroxy-2-[(3-methoxycarbonylmethylbenzyl)thio]adenine
Example 106
9-Benzyl-8-hydroxy-2-[(4-methoxycarbonylmethylbenzyl)thio]adenine

The compounds of Examples 107˜109 below were obtained in accordance with the method of Example 29.


Example 107
9-Benzyl-2-butoxycarbonylmethyl-8-hydroxyadenine
Example 108
9-Benzyl-8-hydroxy-2-(isopropoxycarbonylmethyl)adenine
Example 109
9-Benzyl-2-(2-fluoroethoxycarbonyl)methyl-8-hydroxyadenine
Example 110
9-Benzyl-8-hydroxy-2-(morpholinocarbonylmethyl)adenine

9-Benzyl-2-carboxymethyl-8-hydroxyadenine (15 mg, 0.050 mmol) obtained by Comparative example 8, N-hydroxybenzotriazole (12 mg, 0.075 mmol), morpholine (7 mg, 0.075 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodibide hydrochloride (15 mg, 0.075 mmol) were added to dichloromethane (10 ml), and the mixture was stirred at room temperature for 5 hours. After removing the solvent, the residue was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, concentrated and the residue was purified by column chromatography (SiO2 20 g, eluting solvent: CHCl3/MeOH=100/3˜20/1) to give the captioned compound (8 mg, yield: 43%) as a white solid.


The compounds of Examples 111˜115 below were obtained in accordance with the method of Example 1.


Example 111
2-Butoxy-8-hydroxy-9-[(2-methoxycarbonylmethyl)benzyl]adenine (108 mg, 0.28 mmol)
Example 112
2-Butoxy-8-hydroxy-9 [(4-fluoro-3-methoxycarbonyl)benzyl]adenine) (170 mg, 0.44 mmol)
Example 113
2-Butoxy-8-hydroxy-9-[(4-methoxy-3-methoxycarbonyl)benzyl]adenine (369 mg, 0.92 mmol)
Example 114
2-Butoxy-8-hydroxy-9-[4-(2-methoxycarbonyl-2-methylethyl)benzyl]adenine (305 mg, 0.74 mmol)
Example 115
2-Butoxy-8-hydroxy-9-[3-((2R,S)-methoxycarbonylethyl)benzyl]adenine (287 mg, 0.72 mmol)
Example 116
2-Butoxy-8-hydroxy-9-{3-[methoxy(oxo) acetyl]benzyl}adenine

2-Butoxy-8-hydroxy-9-[3-(oxocarboxymethyl)benzyl]adenine (0.13 g, 0.34 mmol) obtained by Comparative example 43 was dissolved in methanol (3.5 ml), and thereto was added at 0° C. concentrated sulfuric acid (0.2 ml). The solution was stirred at room temperature for 2 hours and neutralized with saturated sodium hydrogencarbonate solution. After adding water, the precipitated solid was filtered, purified by column chromatography (SiO2 5.0 g, eluting solvent: CHCl3/MeOH 10/1) and the obtained compound was washed with water to give the captioned compound (0.086 g, 0.22 mmol, yield: 64%) as a white solid.


Example 117
2-Butoxy-8-hydroxy-9-{3-[(1-hydroxy-2-methoxy)acetyl]benzyl}adenine

The captioned compound was obtained in accordance with the method of Example 116, Yield: 82%.


The compounds of Examples 118˜119 below were obtained in accordance with the method of Example 1.


Example 118
2-Butoxy-8-hydroxy-9-{(2-methoxycarbonyl-4-pyridyl)methyl}adenine
Example 119
2-Butoxy-8-hydroxy-9-{(5-methoxycarbonyl-2-thienyl)methyl}adenine

The compounds of Examples 120˜121 below were obtained in accordance with the method of Example 81.


Example 120
9-{3,5-Bis(methoxycarbonylmethyl)benzyl}-2-butoxy-8-hydroxyadenine
Example 121
2-Butoxy-8-hydroxy-9-{(5-methoxycarbonylmethyl-3-pyridyl)methyl}adenine
Example 122
Interferon Inducing Activity on Cells of Mouse Spleen (In Vitro)

By using a spleen extracted from a C3H/HeJ mouse (male; 8-10 weeks old), a suspension of spleen cells (2×106 cells/ml) was prepared in MEM broth containing 5% FBS. To each well of a 24-well microplate was poured the suspension (0.5 ml). To each well was added 0.5 ml of the test compound (containing 0.2% DMSO) diluted with the same broth, and the microplate was incubated at 37° C. for 24 hours in a 5% CO2 incubator. The culture broth was aseptically filtered by a filter (0.2 micrometer) to give a supernatant. The interferon activity in the supernatant was quantitatively measured by the bioassay method described in J. A. Armstrong, Methods in Enzymology 78, 381˜7. Namely, after mouse fibroblast L929 (1×104 cells/50 μl) were cultured in a 96-well culture plate for 24 hours, thereto was added 50 μl of the diluted culture supernatant and the mixture was further cultivated for 24 hours. And then 100 μl of vesicular stomatitis virus were added to each well. Forty four hours after the virus infection, the effect of the cell denaturation was confirmed by the crystal violet stain. The quantitative analysis was carried out by dissolving the pigment in 2% sodium deoxycholate solution and measuring absorbance at 595 nm. In Table 1, interferon inducting activity on each compound (Minimum effective concentration) was shown.












TABLE 1








Minimum effective



Compound
concentration (μM)



















Example 1
<0.001



Example 6
<0.001



Example 7
<0.001



Example 15
0.003



Example 16
0.003



Example 19
<0.001



Example 20
0.003



Example 21
0.003



Example 24
<0.001



Example 25
0.003



Example 29
0.01



Example 30
0.01



Example 32
0.01



Example 33
0.1



Example 34
0.1



Example 38
0.01



Example 40
0.01



Example 48
0.3



Example 50
0.1



Example 51
0.1



Example 53
0.1



Example 54
0.1



Example 58
0.1



Example 59
0.1



Comparative
0.003



example 1



Comparative
0.1



example 3



Comparative
0.1



example 5



Comparative
0.03



example 6



Comparative
10



example 8



Comparative
1



example 10



Comparative
0.1



example 11



Comparative
10



example 12



Comparative
10



example 13










Example 123
Interferon Inducing Activity on Cells of Rat Spleen (In Vitro)

By using a spleen extracted from a SD rat (male; 8-10 weeks old), a suspension of spleen cells (2×106 cells/ml) was prepared in MEM broth not containing any blood. To each well of a 24-well microplate was poured the suspension (0.5 ml). To each well was added 0.5 ml of the test compound (containing 0.2% DMSO) diluted with the same broth, and the microplate was incubated at 37° C. for 24 hours in a 5% CO2 incubator. The culture broth was aseptically filtered by a filter (0.2 micrometer) to give a supernatant. The interferon activity in the supernatant was quantitatively measured by the bioassay method described in J. A. Armstrong, Methods in Enzymology 78, 381-7. Namely, after mouse fibroblast L929 (1×104 cells/50 μl) were cultured in 96-wells culture plate for 24 hours, thereto was added 50 μl of diluted culture supernatant and the mixture was further cultivated for 24 hours. And then 100 μl of vesicular stomatitis virus were added. Forty four hours after the virus infection, the effect of the cell denaturation was confirmed by crystal violet stain. The quantitative analysis was carried out by extracting the pigment with 50% ethanol and PBS solution and measuring absorbance at 540 nm. In Table 2, interferon inducting activity on each compound (Minimum effective concentration) was shown.












TABLE 2








Minimum effective



Compound
concentration (nM)



















Example 1
0.3



Example 2
1



Example 15
1



Example 17
1



Example 19
0.3



Example 20
0.1



Example 21
1



Example 23
100



Example 24
0.3



Example 29
10



Example 30
10



Example 40
10



Example 54
10



Example 61
3



Example 62
30



Example 63
100



Example 64
3



Example 65
30



Example 66
1



Example 67
1



Example 68
0.3



Example 70
1



Example 71
0.3



Example 73
0.3



Example 74
1



Example 75
3



Example 76
0.1



Example 77
0.3



Example 78
0.03



Example 79
0.3



Example 80
1



Example 81
1



Example 82
100



Example 83
0.3



Example 84
10



Example 87
1



Example 90
0.3



Example 93
3



Example 95
1



Example 96
3



Example 100
0.3



Example 103
10



Example 104
100



Example 105
300



Example 106
100



Example 107
100



Example 108
30



Example 109
30



Example 110
100



Comparative ex. 1
10



Comparative ex. 3
10



Comparative ex. 5
10



Comparative ex. 6
10



Comparative ex. 8
3000



Comparative ex. 12
300



Comparative ex. 13
300



Comparative ex. 15
1000



Comparative ex. 16
1000



Comparative ex. 17
300



Comparative ex. 18
3000



Comparative ex. 19
30



Comparative ex. 20
30



Comparative ex. 21
3



Comparative ex. 23
100



Comparative ex. 26
3



Comparative ex. 27
300



Comparative ex. 31
30



Comparative ex. 34
300



Comparative ex. 35
1000



Comparative ex. 36
3000



Comparative ex. 37
1000










Example 124
Metabolic Stability Test on Serum

Plasma was prepared from fresh blood of a SD rat (male; 8-10 weeks old) and thereto was added the test compound to give the final concentration 10 μM (containing 1% DMSO) After the mixture was metabolized with a plasma esterase at 37° C. for 15 minutes, the test-compound was extracted with ethyl acetate, and was quantitatively analyzed by reverse phase HPLC. The metabolic stability of the test compound was presented by the residual amount (%) per the concentration of pre-metabolization, The result was shown in Table 3.












TABLE 3







Compound
Residual rate (%)









Example 1
32 



Example 2
5



Example 3
20 



Example 4
23 



Example 5
18 



Example 6
14 



Example 7
1



Example 8
16 



Example 9
1



Example 11
13 



Example 12
29 



Example 13
10 



Example 15
0



Example 16
0



Example 17
0



Example 18
0



Example 19
1



Example 20
0



Example 21
 0*



Example 22
0



Example 24
7



Example 25
16 



Example 27
0



Example 29
0



Example 30
0



Example 31
0



Example 32
0



Example 34
11 



Example 37
0



Example 38
2



Example 40
0



Example 41
0



Example 42
0



Example 43
0



Example 44
0



Example 45
0



Example 46
0



Example 47
0



Example 48
0



Example 49
0



Example 53
0



Example 54
0



Example 55
0



Example 56
0



Example 58
0



Example 59
0



Example 61
 0*



Example 62
 0*



Example 64
 0*



Example 65
 0*



Example 68
 0*



Example 70
 0*



Example 71
 0*



Example 73
 4*



Example 74
 0*



Example 75
 0*



Example 80
 0*



Example 103
 6*







*The concentration of the test compound: 1 μM






Example 125
Metabolic Stability on River S9 of Rat

The reaction on river S9 of a rat was carried out on a 96-well plate by using a robot for screening by Tecan Company. S9 solution was prepared by adding to 10 ml of liver S9 of a rat, 20 ml of 250 mM Kpi (pH 7.4) and 20 ml of deionized water. Cofactor solution was prepared by dissolving NADPH (220 mg) in deionized water (40.5 ml) to give finally a 6 mM solution. IS (Internal Standard) solution was prepared by adding 300 μL of IS solution (1 mM DMSO solution) to 30 ml of acetonitrile solution (100 times dilution). The test compound (1 μM DMSO solution) was dissolved in an incubator at 37° C., 35 μL of it was poured into each well of a 96-well plate (24 samples/plate and then, plates (a sample plate, a 96 well-plate for dilution, deep well plates for reaction and recovering, a plate for extraction of the solid phase) and the test samples (S9 solution, Cofactor solution, IS (Internal Standard) solution, Stop solution, acetonitrile for elution) were set to the specified position in the booth of the robot. The reaction started (the concentration of the test compound was 1 μM) and the mixture was incubated at 37° C. under stirring. The solid phase was extracted and at the same time the internal standard for analysis was added. To the recovered sample (200 μL/well) was added 50 μL of acetonitrile per each well and to 2 plates of FALCON Deep well were poured 100 μL of the solution per well. By subjecting to the LC/MS analysis, the chromatogram of the test sample and the internal standard were described and the peak area was calculated. And then, the stability (residual rate after reaction) was calculated by the internal standard method. The result was shown in Table 4.












TABLE 4







Compound
Residual rate (%)









Example 1
7



Example 2
11 



Example 3
19 



Example 4
25 



Example 8
1



Example 14
22 



Example 15
11 



Example 16
0



Example 17
28 



Example 19
0



Example 20
0



Example 21
26 



Example 22
31 



Example 30
4



Example 31
3



Example 33
 2*



Example 34
 1*



Example 41
 2*



Example 42
3



Example 43
2



Example 44
0



Example 45
 8*



Example 46
0



Example 47
0



Example 48
0



Example 49
0



Example 50
7



Example 51
0



Example 52
24 



Example 53
2



Example 55
 4*



Example 56
1



Example 57
3



Example 59
7



Example 61
0



Example 62
0



Example 63
0



Example 64
2



Example 66
0



Example 67
0



Example 68
13 



Example 70
16 



Example 71
0



Example 72
4



Example 73
0



Example 74
7



Example 79
17 



Example 80
0



Example 81
2



Example 82
2



Example 84
1



Example 86
18 



Example 90
3



Example 94
2



Example 95
4



Example 96
0



Example 100
1



Example 103
7



Example 105
1



Example 106
3



Example 107
3



Example 108
3



Example 109
0







*The concentration of the test compound: 10 μM






Example 126
The Measurement of the Amount of Leucocytes and Cytokines in Bronchoalveolar Lavege Fluid (BALF) on an Asthma Modeled Mouse

C57BL/6 mouse was immunized by dermally administering denatured ovalbumin by heating (40 mg). Fourteen days later after the first immunization, ovalbumin (100 μg) was nasally busted. Twenty one days later after the first immunization, the solution (1 ml/kg) prepared by suspending the test compound (10 mg/kg) in physiorogical saline was nasally administered (10 μl/10 g/body weight). After 2 hours ovalbimin (100 μg) was nasally challenged. After 18 hours, bronchoalveolar lavege fluid (BALF) was collected, and the total number of leucocytes in BALF and fractioned leukocyte in the cytospin sample were measured. By ELISA method, IL-4 and IL-5 in the supernatant were measured. The number of leucocytes (inhibition %) was shown in Table 5 and the production inhibition activity of IL-4 and IL-5 (inhibition % to control) was shown in Table 6.














TABLE 5








Number of





Compound
total leukocyte
Acidophile
Netrophile





















Example 15
84
101
−92



Beclometasone
92
89
90



dipropionate





















TABLE 6







Compound
IL-4
IL-5




















Example 15
80
75



Beclometasone dipropionate
97
100










Example 127
Anti Hsv Activity of Antedrug for Herpes Virus (HSV) Infected Vagina of Modeled Rat

On the back of a BALB/c female mouse (6 weeks old: Nippon SLC) 3 mg of Depo-Provera/mouse (Registered Trade Mark) was dermally administered and the mice were fed for 6 days. By doing this the sexual cycle was tuned and the sensitivity between mice to herpes virus was balanced. The slime of mouse vagina was removed by a cotton swab for baby, and the ointment (20 mg) containing 0.5% of compound of Example 20 or the ointment (10 mg) containing 5% of compound of Example 20 was spread to the vagina (corresponding 0.1 mg and 0.5 mg per mouse of the compound of Example). As a control, the placebo ointment not containing the compound was spread as well. As the ointment, the base consisting of 80% Vaseline and 20% liquid paraffin were used. On the next day, the slime of mouse vagina was removed by a cotton swab for baby and then, 2×104 pfu type 2 herpes virus (HSV-2) (10 μl/mouse) was administered to the vagina by pipette. After infection the death or survival of the mice was observed.


The survived rate of mice 9 days later after virus-infection was shown in FIG. 1. The groups spread by the ointments containing 0.5% and 5% of the compound of Example 20, respectively showed clearly higher survived rate comparing with a control group, and the dosage dependency was observed. Furthermore, though the survived rate of the control group was 0%, in the group of 5% ointment its survived rate was 100% and the latter showed clearly anti-viral effect.


Example 128

The aerosol preparation (1 g) containing the following ingredients are prepared.


Compound of Example 15: 0.641 mg (0.06%)
Ethanol: 26.816 mg (2.68%)
1,1,1,2-Tetrafuruoroethane: 972.543 mg (97.25%)
Example 129

The aerosol preparation (1 g) containing the following ingredients are prepared.


Compound of Example 22: 0.641 mg (0.06%)
Ethanol: 26.816 mg (2.68%)
1,1,1,2-Tetrafuruoroethane: 972.543 mg (97.25%)
Example 130

The aerosol preparation (1 g) containing the following ingredients are prepared.


Compound of Example 41: 0.641 mg (0.06%)
Ethanol: 26.816 mg (2.68%)
1,1,1,2-Tetrafuruoroethane: 972.543 mg (97.25%)
Example 131

The aerosol preparation (1 g) containing the following ingredients are prepared.


Compound of Example 19: 0.641 mg (0.06%)
Ethanol: 26.816 mg (2.68%)
1,1,1,2-Tetrafuruoroethane: 972.543 mg (97.25%)
Example 132

The aerosol preparation (1 g) containing the following ingredients are prepared.


Compound of Example 67: 0.641 mg (0.06%)
Ethanol: 26.816 mg (2.68%)
1,1,1,2-Tetrafuruoroethane: 972.543 mg (97.25%)
Comparative Example 1
2-Butoxy-8-hydroxy-9-(3-carboxybenzyl)adenine

2-Butoxy-8-hydroxy-9-(3-methoxycarbonylbenzyl)adenine (0.10 g, 0.27 mmol) obtained by Example 1 was added to 5% sodium hydroxide solution (10 ml) and the solution was stirred at room temperature for 2 hours. After the reaction mixture was neutralized with concentrated hydrochloric acid, the resulting solid was filtered and washed with methanol to give the captioned compound (0.06 g, 0.17 mmol, yield: 61%) as a white solid.


The compounds of Comparative examples 3˜8 below were obtained in accordance with the method of Comparative example 1.


Comparative Example 3
2-Butoxy-8-hydroxy-9-(5-carboxyfurfuryl)adenine
Comparative Example 5
2-Butoxy-8-hydroxy-9-(3-carboxymethylbenzyl)adenine
Comparative Example 6
2-Butoxy-8-hydroxy-9-(4-carboxymethylbenzyl)adenine
Comparative Example 8
9-Benzyl-2 carboxymethyl-8-hydroxyadenine
Comparative Example 9
9-Benzyl-8-hydroxy-2-(2-hydroxyethylamino)adenine

9-Benzyl-8-bromo-2-(2-hydroxyethylamino)adenine 600 mg (1.7 mmol) obtained by Reference example 8 in 6N hydrochloric acid (3 ml) was stirred at 100° C. for 8 hours. After the reaction mixture was neutralized under ice cooling with 40% sodium hydroxide solution, the resulting solid was filtered and washed with water to give the captioned compound (190 mg, 0.63 mmol, yield: 38%) as a white solid.


Comparative Example 10
8-Hydroxy-2-(2-hydroxyethylamino)-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was obtained in accordance with the method of Comparative example 9.


Comparative Example 11
8-Hydroxy-2-(2-hydroxyethoxy)-9-{(6-methyl-3-pyridyl)methyl}adenine

2-Hydroxyethoxy-8-methoxy-9-[(6-methyl-3-pyridyl)methyl]adenine (640 mg, 1.9 mmol) obtained by Reference example 13 in concentrated hydrochloric acid (5 ml) was stirred at room temperature for 6 hours. After the reaction mixture was neutralized under ice cooling with 24% sodium hydroxide solution, the resulting solid was filtered and washed with water to give the captioned compound (440 mg, 1.4 mmol, yield: 73%) as a white solid.


Comparative Example 12
9-Benzyl-8-hydroxy-2-(calboxylmethyl)thioadenine

To sodium hydroxide (500 mg) in methanol (5 ml) was added 9-benzyl-8-hydroxy-2-(methoxycarbonylmethyl)thioprine (64 mg, 0.19 mmol), and the mixture was refluxed for 2 hours. After the reaction mixture was neutralized with 2N hydrochlolic acid, the resulting solid was filtered and washed with water to give the captioned compound (32 mg, yield: 52%) as a white solid.


Comparative Example 13
9-Benzyl-8-hydroxy-2-(2-calboxylethyl)thioadenine

The captioned compound was obtained in accordance with the method of Example 40.


Comparative Example 14
2-(2,3-dihydroxypropylamino)-8-hydroxy-9-{(6-methyl-3-pyridyl)methyl}adenine

The captioned compound was obtained in accordance with the method of Comparative example 10.


Comparative Example 15
9-Benzyl-2-(2-carboxyethyl)-8-hydroxyadenine

To dimethyl malonate (493 mg, 3.73 mmol) in DMF (8 ml) was added in an ice bath sodium hydride (75 mg, 3.13 mmol). Then the mixture was stirred at room temperature for 30 minutes. Thereto was added 9-benzyl-2-chloromethyl-8-hydroxyadenine (0.10 g, 0.37 mmol), and the mixture was stirred at room temperature for 21 hours. After removing the solvent, the residue was poured into water, concentrated, and neutralized with hydrochloric acid. The resulting solid was filtered, washed with water and dried in vacuo under heating to give 9-benzyl-2-(2,2-dimethoxycarbonylethyl)-8-hydroxyadenine (92 mg, 0.24 mmol) as a white solid. Thus obtained 9-benzyl-2-(2,2-dimethoxycarbonylethyl)-8-hydroxyadenine (79 mg, 0.20 mmol) was added to a mixed solvent of concentrated hydrochloric acid (2 ml) and 1,4-dioxane (6 ml), and the mixture was refluxed for 6 hours. After the reaction mixture was neutralized in an ice bath with saturated sodium hydrogencarbonate solution, the resulting solid was filtered, washed with water and dried in vacuo under heating to give the captioned compound (55 mg, 0.18 mmol) as a white solid.


Comparative Example 16
9-Benzyl-8-hydroxy-2-calboxylmethoxyadenine

The captioned compound was obtained in accordance with the method of Comparative example 1.


Comparative Example 17
2-(2-Carbonxylethyl)-8-hydroxy-9-{(6 methyl-3-pyridyl)methyl}adenine)hydrochloride

8-Hydroxy-2-(2-methoxycarbonylethyl)-9-{(6-methyl-3-pyridyl)methyl}adenine (9 mg, 0.026 mmol) obtained by Example 66 was added to concentrated hydrochloric acid (1 ml), and the solution was stirred at 100° C. for 1 hour. After removing the solvent, the residue was dissolved in methanol and the solution was added to diisopropyl ether. The resulting solid was filtered and dried in vacuo under heating to give the captioned compound (7 mg, 0.019 mmol) as a white solid.


The compounds of Comparative examples 18˜26 below were obtained in accordance with the method of Comparative example 1.


Comparative Example 18
2-(2-Carboxylethyl)-9-(4-carboxylmethylbenzyl)-8-hydroxyadenine
Comparative Example 19
2-Butoxy-9-(5-carboxylmethylfurfuryl)-8-hydroxyadenine
Comparative Example 20
2-Butoxy-9-(3-carboxylethylbenzyl-8-hydroxyadenine
Comparative Example 21
2-Butoxy-9-{6-(4-carboxyl-1-piperidyl)-3-pyridylmethyl-8-hydroxyadenine
Comparative Example 22
2-Butoxy-9-{6-(3-carboxyl-1-piperidyl)-3-pyridylmethyl-8-hydroxyadenine
Comparative Example 23
2-Butoxy-9-(3,4-dicarboxylbenzyl)-8-hydroxyadenine
Comparative Example 24
2-Butoxy-9-(3,5-dicarboxylbenzyl)-8-hydroxyadenine
Comparative Example 25
2-Butoxy-9-{(6-carboxylmethyl-3-pyridyl)methyl}-8-hydroxyadenine
Comparative Example 26
2-Butoxy-9-{6-(1-hydroxy-3-carboxylpropyl)thio-3-pyridyl}methyl}-8-hydroxyadenine
Comparative Example 27
9-(3-Carboxymethylbenzyl)-8-hydroxy-2-(2-methoxyethoxy)adenine

8-Bromo-9-(3-methoxycarbonylmethylbenzyl)-2-(2-methoxyethoxy)adenine (0.22 g, 0.50 mmol) obtained by Reference example 35 was suspended in a mixed solvent of 1N sodium hydroxide solution (15 ml) and methanol (15 ml), and the suspension was stirred at 100° C. for 2.5 hours. After removing the solvent, 12N hydrochloric acid (10 ml) was added to the reaction mixture and the mixture was stirred at room temperature for 3.5 hours. After the reaction mixture was neutralized with saturated sodium hydrogencarbonate solution, the resulting solid was successively washed by water and methanol to give the captioned compound (0.14 g, 0.37 mmol, yield: 73%) as a pale red solid.


Comparative Example 28
2-Butylamino-9-(3-carboxymethylbenzyl)-8-hydroxyadenine

The captioned compound was obtained in accordance with the method of Comparative example 27.


Comparative Example 29
9-(3-Carboxymethylbenzyl)-2-chloro-8-hydroxyadenine

2-Chloro-8-hydroxy-9-(3-methoxycarbonylmethylbenzyl)adenine (50 mg, 0.14 mmol) obtained by Example 98 was dissolved in a mixed solvent of 1N sodium hydroxide solution (5 ml) and methanol (5 ml), and the solution was stirred at 100° C. for 5 minutes. The solution was neutralized with 12N hydrochloric acid and the solvent was removed. The residue was added to water, the resulting solid was filtered and washed with water to give the captioned compound (24 mg, 0.072 mmol, yield: 50%) as a pale red solid.


Comparative Example 30
9-(3-Carboxymethylbenzyl)-8-hydroxy-2-(2-hydroxyethylthio)adenine

The captioned compound was obtained in accordance with the method of Comparative example 29.


The compounds of Comparative examples 31˜37 below were obtained in accordance with the method of Comparative example 1.


Comparative Example 31
2-Butoxy-8-hydroxy-9-[4-(1-carboxyethyl)benzyl]adenine
Comparative Example 32
2-Butoxy-8-hydroxy-9-[3-(2-carboxy-2-propyl)benzyl]adenine
Comparative Example 33
2-Butoxy-8-hydroxy-9-(4-carboxyphenethyl)adenine
Comparative Example 34
9-Benzyl-8-hydroxy-2-[(3-carboxybenzyl)thio]adenine
Comparative Example 35
9-Benzyl-8-hydroxy-2-[(4-carboxybenzyl)thio]adenine
Comparative Example 36
9-Benzyl-8-hydroxy-2-[(3-carboxymethylbenzyl)thio]adenine
Comparative Example 37
9-Benzyl-8-hydroxy-2-[(4-carboxymethylbenzyl)thio]adenine

The structures and physical properties of the compounds of Reference examples, Examples and Comparative examples are shown below.











TABLE 7





Refer-




ence




ex.
Structure
Yield







1


embedded image


3.72 g





2


embedded image


1.90 g





3


embedded image


0.50 g





4


embedded image


0.45 g





5


embedded image


0.13 g





6


embedded image


2.08 g
















TABLE 8









embedded image















Reference





ex.
—R2a
—R8a

1H-NMR






 7
—NH(CH2)2OH
—H
(DMSO-d6) δ 7.76 (1H, s), 7.27 (5H,





m), 6.66 (2H, brs), 6.08 (1H, t, J = 5.0





Hz), 5.13 (2H, s), 4.62 (1H, t, J = 5.0





Hz), 3.46 (2H, q, J = 5.0 Hz), 2.46





(2H, q, J = 5.0 Hz).


 8
—NH(CH2)2OH
—Br
(DMSO-d6) δ 7.28 (5H, m), 6.92 (2H,





brs), 6.30 (1H, t, J = 6.0 Hz), 5.17





(2H, s), 3.49 (2H, q, J = 6.0 Hz), 3.31





(2H, q, J = 6.0 Hz).


15
—SH
—H
(DMSO-d6) δ 12.10 (1H, brs), 10.06





(1H, brs), 7.30 (5H, m), 6.74 (2H,





brs), 4.85 (2H, s).
















TABLE 9









embedded image















Refer-





ence





ex.
—R2a
—R8a

1H-NMR






 9
—NH(CH2)2OH
—H
(DMSO-d6) δ 8.48 (1H, s),





7.82 (1H, s), 7.63 (1H, d,





J = 6.8 Hz), 7.21 (1H, d,





J = 6.8 Hz), 6.71 (2H, brs),





6.13 (1H, t, J = 5.6 Hz),





5.12 (2H, s), 4.67 (1H, t,





J = 5.6 Hz), 3.50 (2H, q,





J = 5.6 Hz), 3.30 (2H, q,





J = 5.6 Hz), 2.42 (3H, s).


10
—NH(CH2)2OH
—Br
(DMSO-d6) δ 8.44 (1H, s),





7.54 (1H, d, J = 6.8 Hz),





7.22 (1H, d, J = 6.8 Hz),





6.92 (2H, brs), 6.32 (1H, t,





J = 5.6 Hz), 5.16 (2H, s),





3.50 (2H, t, J = 5.6 Hz),





3.32 (2H, q, J = 5.6 Hz),





2.43 (3H, s).


11
—O(CH2)2OH
—H
(DMSO-d6) δ 8.50 (1H, d,





J = 1.6 Hz), 8.06 (1H, s),





7.63 (1H, dd, J = 7.6, 1.6





Hz), 7.23 (2H, brs), 7.21





(1H, d, J = 7.6 Hz), 5.24





(2H, s), 4.82 (1H, t, J = 5.2





Hz), 4.22 (2H, t, J = 5.2





Hz), 3.67 (2H, q, J = 5.2





Hz), 2.40 (3H, s).


12
—O(CH2)2OH
—Br
(DMSO-d6) δ 12.02 (1H,





brs), 8.53 (1H, d, J = 2.0





Hz), 7.69 (1H, dd, J = 4.0,





2.0 Hz), 7.47 (2H, brs), 7.33





(1H, d, J = 4.0 Hz), 5.28





(2H, s), 4.23 (2H, t, J = 5.6





Hz), 3.67 (2H, t, J = 5.6





Hz), 2.48 (3H, s).


13
—O(CH2)2OH
—OMe
(DMSO-d6) δ 8.41 (1H, d,





J = 2.0 Hz), 7.53 (1H, dd,





J = 8.0, 2.0 Hz), 7.21 (1H,





d, J = 8.0 Hz), 6.87 (2H,





brs), 5.02 (2H, s), 4.80





(1H, t, J = 5.6 Hz), 4.19





(2H, t, J = 5.6 Hz), 4.05





(3H, s), 3.67 (2H, q, J =





5.6 Hz), 2.41 (3H, s).


14
—O(CH2)2OCONMe2
—OMe
(DMSO-d6) δ 8.54 (1H, d,





J = 2.0 Hz), 7.58 (1H, dd,





J = 8.0, 2.0 Hz), 7.09 (1H,





d, J = 8.0 Hz), 5.20 (2H,





brs), 5.06 (2H, s), 4.54





(2H, m), 4.43 (2H, m),





4.11 (3H, s), 2.90 (6H, d,





J = 8.0 Hz), 2.52 (3H, s).


16
—NHCH2CH(OH)CH2OH
—H
(DMSO-d6) δ 8.49 (1H, s),





7.83 (1H, s), 7.64 (1H, d, J =





8.0 Hz), 7.21 (1H, d, J =





8.0 Hz), 6.76 (2H, brs), 6.08





(1H, t, J = 5.6 Hz), 5.16





(2H, s), 4.90 (1H, d, J = 4.8





Hz), 4.62 (1H, t, J = 6.0





Hz), 3.60 (1H, m), 3.40 (3H,





m), 3.20 (1H, m), 2.42 (3H,





s).


17
—NHCH2CH(OH)CH2OH
—Br
(DMSO-d6) δ 8.45 (1H, s),





7.56 (1H, d, J = 7.2 Hz),





7.64 (1H, d, J = 7.2 Hz),





7.02 (2H, brs), 6.27 (1H, t,





J = 6.7 Hz), 5.16 (2H, s),





4.83 (1H, brs), 4.60 (1H,





brs), 3.63 (1H, m), 3.40





(3H, m), 3.20 (1H, m), 2.42





(3H, s).


18
—NHCH2CH(OH)CH2OH
—OMe
(DMSO-d6) δ 8.40 (1H, d,





J = 2.0 Hz), 7.54 (1H, dd,





J = 8.0, 2.0 Hz), 7.20 (1H,





d, J = 8.0 Hz), 6.44 (2H,





brs), 5.94 (1H, t, J = 5.6





Hz), 4.95 (2H, s), 4.90





(1H, d, J = 4.4 Hz), 4.60





(1H, t, J = 5.6 Hz), 4.00





(3H, s), 3.60 (1H, m),





3.39 (3H, m), 3.19 (1H,





m), 2.42 (3H, s).





19


embedded image


—OMe

1H NMR (DMSO-d6) δ 8.39 (1H, d, J = 1.4 Hz), 7.53 (1H, dd, J = 8.0, 1.4 Hz), 7.20 (1H, d, J = 8.0 Hz), 6.52 (1H, t, J = 5.6 Hz), 6.47 (2H, brs), 4.97 (2H, s), 4.93 (1H, m), 4.52 (1H, t, J = 8.4 Hz), 4.37 (1H, m), 4.01 (3H, s), 3.60 (1H, m), 3.50 (1H, m), 2.42 (3H, s).



















TABLE 10





Reference




ex.
Structure
Yield


















20


embedded image


0.12
g





21


embedded image


0.10
g





22


embedded image


0.23
g





23


embedded image


358
mg





24


embedded image


31
mg





25


embedded image


50
mg





26


embedded image


31
mg





27


embedded image


2.05
g





28


embedded image


775
mg





29


embedded image


78
mg





30


embedded image


0.98
g





31


embedded image


0.31
g





32


embedded image


0.19
g





33


embedded image


3.06
g
















TABLE 11









embedded image















Refer-





ence





ex.
—R2a
—R8a

1H-NMR






34
—O(CH2)2OMe
—H
(DMSO-d6) δ 8.04 (1H, s), 7.29 (1H, dd,





J = 7.6 Hz, 7.6 Hz), 7.24-7.17 (5H, m),





5.24 (2H, s), 4.32 (2H, t, J = 4.8 Hz),





3.65 (2H, s), 3.61 (2H, t, J = 4.8 Hz),





3.58 (3H, s), 3.28 (3H, s).


35
—O(CH2)2OMe
—Br
(CDCl3) δ 7.29-7.20 (4H, m), 6.44 (2H,





brs), 5.28 (2H, s), 4.49 (2H, t, J = 4.4





Hz), 3.75 (2H, t, J = 4.4 Hz), 3.67 (3H,





s), 3.60 (2H, s), 3.43 (3H, s).


36
—NH-Butyl
—H
(DMSO-d6) δ 7.44 (1H, s), 7.31-7.18





(4H, m), 5.66 (2H, brs), 5.19 (2H, s),





4.97 (1H, brs), 3.66 (3H, s), 3.60 (2H,





s), 3.40 (2H, dt, J = 6.0 Hz, 7.2 Hz),





1.56 (2H, tt, J = 7.6 Hz, 7.2 Hz), 1.39





(2H, tq, J = 7.6 Hz, 7.2 Hz), 0.93 (3H,





t, J = 7.2 Hz).


37
—NH-Butyl
—Br
(CDCl3) δ 7.29-7.19 (4H, m), 5.75 (2H,





brs), 5.20 (2H, s), 5.07 (1H, brs), 3.67





(3H, s), 3.60 (2H, s), 3.39 (2H, dt, J =





6.8 Hz, 6.8 Hz), 1.56 (2H, tt, J = 6.8





Hz, 7.6 Hz), 1.38 (2H, tq, J = 7.6 Hz,





7.2 Hz), 0.92 (3H, t, J = 7.2 Hz).


38
—Cl
—H
(DMSO-d6) δ 8.24 (1H, s), 7.80 (2H,





brs), 7.31 (1H, dd, J = 7.6 Hz, 7.6 Hz),





7.19 (1H, d, 7.6 Hz), 7.18 (1H, s), 7.14





(1H, d, 7.6 Hz), 5.32 (2H, s), 3.66 (2H,





s), 3.59 (3H, s).


39
—Cl
—Br
(CDCl3) δ 7.32 (1H, dd, J = 8.0 Hz, 7.6





Hz), 7.26-7.19 (3H, m), 5.72 (2H, brs),





5.34 (2H, s), 3.70 (3H, s), 3.61 (2H, s).


















TABLE 12





Reference




ex.
Structure
Yield







40


embedded image


4.71 g





41


embedded image


4.92 g





42


embedded image


4.62 g





43


embedded image


4.79 g





44


embedded image


4.36 g





45


embedded image


4.42 g





46


embedded image


3.07 g





47


embedded image


3.43 g





48


embedded image


2.26 g





49


embedded image


2.97 g





50


embedded image


2.90 g





51


embedded image


2.80 g





52


embedded image


2.84 g





53


embedded image


2.48 g





54


embedded image


2.16 g





55


embedded image


3.75 g


















TABLE 13





Reference




ex.
Structure

1H-NMR (ppm)








56


embedded image


(CDCl3) δ 7.64 (1H, s), 7.60-7.51 (1H, m), 7.42- 7.34 (2H, m), 4.50 (2H, s), 3.74 (3H, s), 3.27 (6H, s).





57


embedded image



1H NMR (CDCl3) δ 7.65 (1H, s), 7.61 (1H, s), 7.53 (1H, d, J = 7.7 Hz), 7.35 (1H, dd, J = 7.7 Hz, 7.7 Hz), 7.26 (1H, d, J = 7.7 Hz), 6.41 (2H, brs), 5.29 (2H, s), 4.34 (2H, t, J = 6.6 Hz), 3.71 (3H, s), 3.25 (6H, s), 1.78 (2H, tt, J = 6.6 Hz, 5.8 Hz), 1.52 (2H, tq, J = 5.8 Hz, 7.4 Hz), 0.97 (3H, t, J = 7.4 Hz).






58


embedded image



1H NMR (CDCl3) δ 7.70 (1H, s), 7.53 (1H, d, J = 7.5 Hz), 7.33 (1H, dd, J = 7.6 Hz, 7.5 Hz), 7.29 (1H, d, J = 7.6 Hz), 5.95 (2H, brs), 5.31 (2H, s), 4.35 (2H, t, J = 6.6 Hz), 3.71 (3H, s), 3.25 (6H, s), 1.77 (2H, tt, J = 6.6 Hz, 5.8 Hz), 1.50 (2H, tq, J = 5.8 Hz, 7.4 Hz), 0.97 (3H, t, J = 7.4 Hz).

















TABLE 14









embedded image














Ex.
—R9a

1H-NMR






 1
—OMe
(DMSO-d6) δ 10.02 (1H, brs), 7.93 (1H, s),




7.87 (1H, d, J = 7.3 Hz), 7.59 (1H, d, J =




7.6 Hz), 7.49 (1H, t, J = 7.6 Hz), 6.48 (2H,




brs), 4.93 (2H, s), 4.14 (2H, t, J = 6.5 Hz),




3.84 (3H, s), 1.63 (2H, 5, J = 7.0 Hz), 1.36




(2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).


 2
—OEt
(DMSO-d6) δ 10.16 (1H, brs), 7.93 (1H, s),




7.86 (1H, d, J = 7.3 Hz), 7.58 (1H, d, J =




7.8 Hz), 7.48 (1H, t, J = 7.6 Hz), 6.52 (2H,




brs), 4.92 (2H, s), 4.27 (2H, q, J = 7.0 Hz),




4.14 (2H, t, J = 6.5 Hz), 1.63 (2H, 5, J =




7.0 Hz), 1.36 (5H, m), 0.59 (3H, t, J =




7.3 Hz).


 3
—OiPr
(DMSO-d6) δ 10.03 (1H, brs), 7.92 (1H,




s), 7.84 (1H, d, J = 7.3 Hz), 7.55 (1H, d,




J = 7.8 Hz), 7.47 (1H, t, J = 7.6 Hz), 6.48




(2H, brs), 5.11 (1H, 7, J = 6.5 Hz), 4.92




(2H, s), 4.14 (2H, t, J = 6.8 Hz), 1.60 (2H,




5, J = 6.2 Hz), 1.34 (2H, 6, J = 7.0 Hz),




1.30 (6H, d, J = 6.2 Hz), 0.89 (3H, t, J =




7.3 Hz).


 4
—OCH2CF3
(DMSO-d6) δ 10.03 (1H, brs), 7.96 (1H, s),




7.90 (1H, d, J = 7.8 Hz), 7.65 (1H, d, J =




7.8 Hz), 7.55 (1H, t, J = 7.8 Hz), 6.49 (2H,




brs), 4.97 (4H, m), 4.13 (2H, t, J = 6.5 Hz),




1.61 (2H, 5, J = 7.6 Hz), 1.37 (2H, 6, J =




7.6 Hz), 0.89 (3H, t, J = 7.3 Hz).


 5
—O(CH2)2OBzl
(DMSO-d6) δ 10.32 (1H, brs), 7.94 (1H,




s), 7.86 (1H, d, J = 7.6 Hz), 7.58 (1H, d,




J = 7.6 Hz), 7.50 (1H, t, J = 7.6 Hz), 7.28




(5H, m), 6.56 (2H, brs), 4.93 (2H, s), 4.54




(2H, s), 4.42 (2H, t, J = 4.6 Hz), 4.13 (2H,




t, J = 6.5 Hz), 3.74 (2H, t, J = 4.6 Hz), 1.60




(2H, 5, J = 7.6 Hz), 1.34 (2H, 6, J = 7.6 Hz),




0.87 (3H, t, J = 7.6 Hz).


 6
—O(CH2)2OH
(DMSO-d6) δ 9.99 (1H, brs), 7.96 (1H, s),




7.89 (1H, d, J = 7.6 Hz), 7.57 (1H, d, J =




7.6 Hz), 7.49 (1H, t, J = 7.6 Hz), 6.48 (2H,




brs), 4.93 (2H, s), 4.89 (1H, m), 4.27 (2H,




t, J = 5.1 Hz), 4.14 (2H, t, J = 6.8 Hz), 3.67




(2H, q, J = 5.4 Hz), 1.62 (2H, 5, J = 7.6 Hz),




1.36 (2H, 6, J = 7.6 Hz), 0.89 (3H, t, J =




7.6 Hz).


 7
—O(CH2)2NMe2
(DMSO-d6) δ 10.01 (1H, brs), 7.87 (1H, s),




7.85 (1H, d, J = 7.8 Hz), 7.59 (1H, d, J =




7.8 Hz), 7.50 (1H, t, J = 7.6 Hz), 6.49 (2H,




brs), 4.93 (2H, s), 4.33 (2H, t, J = 5.4 Hz),




4.14 (2H, t, J = 6.5 Hz), 2.58 (2H, m), 2.18




(6H, s), 1.62 (2H, 5, J = 7.6 Hz), 1.36 (2H,




6, J = 7.6 Hz), 0.89 (3H, t, J = 7.6 Hz).





 8


embedded image


(DMSO-d6) δ 10.10 (1H, brs), 7.89 (1H, s), 7.86 (1H, d, J = 7.8 Hz), 7.60 (1H, d, J = 7.6 Hz), 7.50 (1H, t, J = 7.8 Hz), 6.51 (2H, brs), 4.93 (2H, s), 4.36 (2H, t, J = 7.6 Hz), 4.14 (2H, t, J = 6.8 Hz), 3.53 (4H, t, J = 4.6 Hz), 2.65 (2H, t, J = 5.1 Hz), 2.43 (4H, t, J = 4.6 Hz), 1.62 (2H, 5, J = 7.6 Hz), 1.36 (2H, 6, J = 7.6 Hz), 0.89 (3H, t, J = 7.6 Hz).





 9


embedded image


(DMSO-d6) δ 10.16 (1H, brs), 8.68 (1H, d, J = 1.6 Hz), 8.57 (1H, dd, J = 4.6, 1.6 Hz), 7.96 (1H, s), 7.86 (2H, m), 7.50 (3H, m), 6.52 (2H, s), 5.38 (2H, s), 4.93 (2H, s), 4.11 (2H, t, J = 6.5 Hz), 1.57 (2H, 5, J = 6.5 Hz), 1.34 (2H, 6, J = 7.0 Hz), 0.87 (3H, t, J = 7.3 Hz).





10
—SMe
(DMSO-d6) δ 10.21 (1H, brs), 7.87 (1H, s),




7.83 (1H, d, J = 7.8 Hz), 7.60 (1H, d, J =




7.6 Hz), 7.52 (1H, t, J = 7.6 Hz), 6.54 (2H,




brs), 4.94 (2H, s), 4.15 (2H, t, J = 6.5 Hz),




2.43 (3H, s), 1.63 (2H, 5, J = 7.0 Hz), 1.36




(2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).
















TABLE 15









embedded image














Ex.
—R9a

1H-NMR






11
—OMe
(DMSO-d6) δ 10.21 (1H, brs), 7.92 (2H, d, J =




8.4 Hz), 7.39 (2H, d, J = 11.1 Hz), 6.54 (2H,




brs), 4.93 (2H, s), 4.11 (2H, t, J = 6.8 Hz),




3.83 (3H, s), 1.62 (2H, 5, J = 6.8 Hz), 1.36




(2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).


12
—OiPr
(DMSO-d6) δ 10.02 (1H, brs), 7.90 (2H, d, J =




7.8 Hz), 7.40 (2H, d, J = 8.4 Hz), 6.48 (2H,




brs), 5.11 (1H, 7, J = 6.2 Hz), 4.93 (2H, s),




4.12 (2H, t, J = 6.8 Hz), 1.59 (2H, 5, J =




6.2 Hz), 1.36 (8H, m), 0.88 (3H, t, J = 7.3




Hz).





13


embedded image


(DMSO-d6) δ 10.04 (1H, brs), 8.68 (1H, d, J = 1.4 Hz), 8.55 (1H, dd, J = 2.1, 1.6 Hz), 7.96 (2H, d, J = 8.4 Hz), 7.88 (1H, d, J = 8.4 Hz), 7.43 (3H, m), 6.49 (2H, s), 5.38 (2H, s), 4.94 (2H, s), 4.11 (2H, t, J = 6.8 Hz), 1.62 (2H, 5, J = 6.8 Hz), 1.34 (2H, 6, J = 7.0 Hz), 0.87 (3H, t, J = 7.3 Hz).





14
—OBzl
(DMSO-d6) δ 10.09 (1H, brs), 7.96 (2H, d, J =




8.4 Hz), 7.39 (7H, m), 6.50 (2H, s), 5.34 (2H,




s), 4.94 (2H, s), 4.11 (2H, t, J = 6.8 Hz), 1.62




(2H, 5, J = 6.8 Hz), 1.34 (2H, 6, J = 7.0 Hz),




0.87 (3H, t, J = 7.3 Hz).
















TABLE 16









embedded image














Ex.
—R10a

1H-NMR






15


embedded image


(DMSO-d6) δ 10.05 (1H, brs), 7.24 (1H, d, J = 3.8 Hz), 6.51 (3H, m), 4.93 (2H, s), 4.13 (2H, t, J = 6.5 Hz), 3.78 (3H, s), 1.64 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).





16


embedded image


(DMSO-d6) δ 10.05 (1H, brs), 7.18 (1H, d, J = 3.5 Hz), 6.47 (3H, m), 5.08 (1H, 7, J = 6.2 Hz), 4.93 (2H, s), 4.13 (2H, t, J = 6.8 Hz), 1.60 (2H, 5, J = 6.2 Hz), 1.34 (2H, 6, J = 7.0 Hz), 1.18 (6H, d, J = 7.6 Hz), 0.90 (3H, t, J = 7.3 Hz).





17


embedded image


(DMSO-d6) δ 10.10 (1H, brs), 8.69 (1H, d, J = 1.9 Hz), 8.02 (1H, d, J = 8.4 Hz), 8.83 (1H, dd, J = 1.9, 8.4 Hz), 6.50 (2H, brs), 4.99 (2H, s), 4.12 (2H, t, J = 6.8 Hz), 3.86 (3H, s), 1.62 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).





18


embedded image


(DMSO-d6) δ 10.14 (1H, brs), 8.69 (1H, d, J = 2.2 Hz), 8.00 (1H, d, J = 7.8 Hz), 7.83 (1H, dd, J = 2.2, 8.4 Hz), 6.52 (2H, brs), 5.15 (1H, 7, J = 6.2 Hz), 4.98 (2H, s), 4.12 (2H, t, J = 6.8 Hz), 1.62 (2H, 5, J = 6.8 Hz), 1.36 (8H, m), 0.90 (3H, t, J = 7.3 Hz).





19


embedded image


(DMSO-d6) δ 10.01 (1H, brs), 7.19 (4H, m), 6.47 (2H, brs), 4.83 (2H, s), 4.14 (2H, t, J = 6.8 Hz), 3.64 (2H, s), 3.59 (3H, s), 1.62 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).





20


embedded image


(DMSO-d6) δ 10.11 (1H, brs), 7.22 (4H, m), 6.49 (2H, brs), 4.83 (2H, s), 4.14 (2H, t, J = 6.5 Hz), 3.63 (2H, s), 3.58 (3H, s), 1.62 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).





21


embedded image


(DMSO-d6) δ 9.98 (1H, brs), 7.20 (4H, m), 6.45 (2H, brs), 4.87 (1H, 7, J = 6.2 Hz), 4.83 (2H, s), 4.14 (2H, t, J = 6.8 Hz), 3.57 (2H, s), 1.64 (2H, 5, J = 6.2 Hz), 1.34 (2H, 6, J = 7.0 Hz), 1.18 (6H, d, J = 6.5 Hz), 0.87 (3H, t, J = 7.3 Hz).





22


embedded image


(DMSO-d6) δ 9.98 (1H, brs), 7.24 (2H, d, J = 8.4 Hz), 6.87 (2H, d, J = 8.6 Hz), 6.45 (2H, brs), 4.78 (2H, s), 4.76 (2H, s), 4.15 (2H, t, J = 6.2 Hz), 3.68 (3H, s), 1.63 (2H, 5, J = 66.8 Hz), 1.38 (2H, 6, J = 7.0 Hz), 0.91 (3H, t, J = 7.3 Hz).





23


embedded image


(DMSO-d6) δ 9.96 (1H, brs), 7.58 (1H, d, J = 1.9 Hz), 7.24 (1H, dd, J = 1.9, 8.4 Hz), 6.97 (1H, d, J = 8.4 Hz), 6.45 (2H, brs), 4.89 (2H, s), 4.78 (2H, s), 4.16 (2H, t, J = 6.2 Hz), 3.68 (3H, s), 1.64 (2H, 5, J = 6.8 Hz), 1.38 (2H, 6, J = 7.0 Hz), 0.91 (3H, t, J = 7.3 Hz).





24


embedded image


(DMSO-d6) δ 9.92 (1H, brs), 8.11 (1H, d, J = 1.9 Hz), 7.49 (1H, dd, J = 2.4, 8.4 Hz), 6.79 (1H, d, J = 8.9 Hz), 6.42 (2H, s), 4.71 (2H, s), 4.01 (7H, brm), 2.90 (2H, t, J = 10.8 Hz), 1.56 (8H, brm), 1.17 (3H, t, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).





25


embedded image


(DMSO-d6) δ 9.99 (1H, brs), 8.11 (1H, d, J = 1.9 Hz), 7.49 (1H, dd, J = 2.4, 8.4 Hz), 6.79 (1H, d, J = 8.9 Hz), 6.44 (2H, s), 4.71 (2H, s), 4.01 (6H, brm), 3.04 (2H, m), 1.91 (1H, m), 1.66 (4H, m), 1.40 (3H, m), 1.16 (3H, t, J = 6.8 Hz), 0.92 (3H, t, J = 7.3 Hz).





26


embedded image


(DMSO-d6) δ 9.97 (1H, brs), 7.75 (3H, m), 7.44 (1H, dd, J = 1.6 Hz, J = 8.4 Hz), 7.22 (2H, m), 6.47 (2H, s), 4.98 (2H, s), 4.88 (2H, s), 4.15 (4H, m), 1.62 (2H, 5, J = 6.8 Hz), 1.39 (2H, 6, J = 7.3 Hz), 1.21 (3H, t, J = 7.0 Hz), 0.88 (3H, t, J = 7.3 Hz).
















TABLE 17









embedded image















Ex.
—R2a
—R10a

1H-NMR






27
—NHBu


embedded image


(DMSO-d6) δ 9.94 (1H, brs), 7.90 (2H, d, J = 8.4 Hz), 7.38 (2H, d, J = 8.4 Hz), 6.20 (1H, t, J = 5.6 Hz), 6.10 (2H, brs), 4.88 (2H, s), 3.83 (3H, s), 3.13 (2H, t, J = 6.8 Hz), 1.43 (2H, 5, J = 7.0 Hz), 1.25 (2H, 6, J = 7.0 Hz), 0.84 (3H, t, J = 7.0 Hz).





28
—NHBu


embedded image


(DMSO-d6) δ 9.70 (1H, brs), 7.21 (1H, d, J = 3.2 Hz), 6.45 (1H, d, J = 3.5 Hz), 6.26 (1H, t, J = 5.6 Hz), 6.08 (2H, brs), 4.87 (2H, s), 4.25 (2H, q, J = 7.3 Hz), 3.14 (2H, t, J = 5.9 Hz), 1.43 (2H, 5, = 7.0 Hz), 1.26 (5H, m), 0.86 (3H, t, J = 7.3 Hz).





29
—CH2COOMe


embedded image


(DMSO-d6) δ 10.28 (1H, brs), 7.30 (5H, m), 6.52 (2H, s), 4.89 (2H, s), 3.65 (2H, s), 3.60 (3H, s).





30
—CH2COOEt


embedded image


(DMSO-d6) δ 10.26 (1H, brs), 7.29 (5H, m), 6.51 (2H, s), 4.89 (2H, s), 4.06 (2H, q, J = 7.0 Hz), 3.63 (2H, s), 1.15 (3H, t, J = 7.0 Hz). (DMSO-d6) d 9.76 (1H, s), 7.29 (5H, m), 6.64 (1H, t, J = 6.2 Hz), 6.12 (2H, brs), 4.78 (2H, s), 3.90 (1H, d, J = 4.3 Hz), 3.57 (3H, s).





31
—NHCH2COOMe


embedded image


(DMSO-d6) d 9.76 (1H, s), 7.29 (5H, m), 6.64 (1H, t, J = 6.2 Hz), 6.12 (2H, brs), 4.78 (2H, s), 3.90 (1H, d, J = 4.3 Hz), 3.57 (3H, s).





32
—NHCH2COOMe


embedded image


(DMSO-d6) δ 9.70 (1H, brs), 8.40 (1H, d, J = 2.0 Hz), 7.53 (1H, dd, J = 8.0, 2.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 6.65 (1H, t, J = 7.1 Hz), 6.11 (2H, brs), 4.79 (2H, s), 3.92 (2H, d, J = 7.1 Hz), 3.60 (3H, s), 2.42 (3H, s).





33
—NH(CH2)2OCOMe


embedded image


(DMSO-d6) δ 9.68 (1H, s), 8.42 (1H, d, J = 2.0 Hz), 7.59 (1H, dd, J = 8.0, 2.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 6.38 (1H, t, J = 5.2 Hz), 6.08 (2H, brs), 4.79 (2H, s), 4.07 (2H, t, J = 5.2 Hz), 3.40 (2H, q, J = 5.2 Hz), 2.41 (3H, s), 1.99 (3H, s).





34
—NH(CH2)2OCOOMe


embedded image


(DMSO-d6) δ 9.68 (1H, s), 8.42 (1H, d, J = 2.0 Hz), 7.58 (1H, dd, J = 8.0, 2.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 6.42 (1H, t, J = 5.6 Hz), 6.08 (2H, brs), 4.79 (2H, s), 4.15 (2H, t, J = 5.6 Hz), 3.68 (3H, s), 3.40 (2H, q, J = 5.6 Hz), 2.42 (3H, s).





35
—NH(CH2)2OCOMe


embedded image


(DMSO-d6) δ 9.73 (1H, s), 7.26 (5H, m), 6.36 (1H, t, J = 6.0 Hz), 6.09 (2H, brs), 4.80 (2H, s), 4.07 (2H, t, J = 6.0 Hz), 3.40 (2H, q, J = 6.0 Hz), 1.98 (3H, s).





36
—O(CH2)2OCOMe


embedded image


(DMSO-d6) δ 9.95 (1H, brs), 8.43 (1H, d, J = 1.6 Hz), 7.59 (1H, dd, J = 8.0, 1.6 Hz), 7.20 (1H, d, J = 8.0 Hz), 6.51 (1H, brs), 4.85 (2H, s), 4.35 (2H, m), 4.29 (2H, m), 2.42 (3H, s), 2.03 (3H, s).





37
—O(CH2)2OCOEt


embedded image


(DMSO-d6) δ 9.86 (1H, brs), 8.43 (1H, d, J = 2.0 Hz), 7.58 (1H, dd, J = 8.0, 2.0 Hz), 7.21 (1H, d, J = 8.0 Hz), 6.51 (1H, brs), 4.84 (2H, s), 4.35 (2H, m), 4.29 (2H, m), 2.42 (3H, s), 2.33 (2H, q, J = 7.6 Hz), 1.01 (3H, t, J = 7.6 Hz).





38
—O(CH2)2OCOOMe


embedded image


(DMSO-d6) δ 10.00 (1H, s), 8.43 (1H, d, J = 2.0 Hz), 7.60 (1H, dd, J = 8.0, 2.0 Hz), 7.21 (1H, d, J = 8.0 Hz), 6.52 (1H, brs), 4.85 (2H, s), 4.36 (4H, s), 3.70 (3H, s), 2.42 (3H, s).





39
—O(CH2)2OCONMe2


embedded image


(DMSO-d6) δ 8.42 (1H, d, J = 1.6 Hz), 7.56 (1H, dd, J = 8.0, 1.6 Hz), 7.58 (1H, d, J = 8.0 Hz), 7.11 (1H, brs), 6.56 (2H, brs), 4.84 (2H, s), 4.34 (2H, m), 4.24 (2H, m), 2.82 (6H, s), 2.42 (3H, s).
















TABLE 18









embedded image














Ex.
R2a

1H-NMR






40
—SCH2COOMe
(DMSO-d6) δ 10.12 (1H, brs), 7.30 (5H,




m), 6.57 (2H, brs), 4.84 (2H, s), 3.91




(3H, s), 3.56 (2H, s).


41
—SCH2COOEt
(DMSO-d6) δ 10.12 (1H, brs), 7.31 (5H,




m), 6.57 (2H, brs), 4.85 (2H, s), 4.01




(2H, q, J = 7.1 Hz), 3.90 (2H, s), 1.12




(3H, t, J = 7.1 Hz).


42
—SCH2COO(CH2)7CH3
(DMSO-d6) δ 10.12 (1H, brs), 7.28 (5H,




m), 6.56 (2H, brs), 4.84 (2H, s), 3.96




(2H, t, J = 6.5 Hz), 3.90 (2H, s), 1.45




(2H, m), 1.24 (2H, m), 1.11 (8H, m),




0.83 (3H, t, J = 7.3 Hz).


43
—SCH2COOtBu
(DMSO-d6) δ 10.13 (1H, brs), 7.29 (5H,




m), 6.55 (2H, brs), 4.87 (2H, s), 3.82




(2H, s), 1.37 (9H, s).


44
—SCH2COOCH2CH═CH2
(DMSO-d6) δ 10.13 (1H, brs), 7.28 (5H,




m), 6.58 (2H, brs), 5.86 (1H, m), 5.70




(2H, m), 4.84 (2H, s), 4.51 (2H, m),




3.96 (2H, s).


45
—SCH2COOBzl
(DMSO-d6) δ 10.11 (1H, brs), 7.28 (10H,




m), 6.57 (2H, brs), 5.06 (2H, s), 4.72




(2H, s), 3.97 (2H, s).


46
—SCH2COO(CH2)2F
(DMSO-d6) δ 10.13 (1H, brs), 7.29 (5H,




m), 6.56 (2H, brs), 4.84 (2H, s), 4.54




(2H, dt, J = 47.7 Hz, 7.0 Hz), 4.23 (2H,




dt, J = 30.2 Hz, 7.0 Hz), 3.96 (2H, s).


47
—SCH2COOCH2CF2H
(DMSO-d6) δ 10.14 (1H, brs), 7.28 (5H,




m), 6.57 (2H, brs), 6.20 (1H, m), 4.84




(2H, s), 4.27 (2H, m), 4.00 (2H, s).


48
—SCH2COOCH2CF3
(DMSO-d6) δ 10.14 (1H, brs), 7.28 (5H,




m), 6.58 (2H, brs), 4.81 (2H, s), 4.63




(2H, m), 4.04 (2H, s).


49
—SCH2COO(CH2)2OMe
(DMSO-d6) δ 10.13 (1H, brs), 7.28 (5H,




m), 6.56 (2H, brs), 4.85 (2H, s), 4.10




(2H, t, J = 4.7 Hz), 3.92 (2H, s), 3.46




(2H, t, J = 4.7 Hz), 3.19 (3H, s).


50
—SCH2CONHEt
(DMSO-d6) δ 10.13 (1H, brs), 7.95 (1H,




brs), 7.28 (5H, m), 6.58 (2H, s), 4.88




(2H, s), 3.71 (2H, s), 3.02 (2H, m), 0.94




(3H, t, J = 7.2 Hz).





51


embedded image


(DMSO-d6) δ 10.13 (1H, brs), 7.30 (5H, m), 6.57 (2H, brs), 4.88 (2H, s), 4.21 (2H, s), 3.43 (2H, m), 3.38 (2H, m), 1.54 (2H, m), 1.46 (2H, m), 1.38 (2H, m).





52


embedded image


(DMSO-d6) δ 10.13 (1H, brs), 7.30 (5H, m), 6.57 (2H, brs), 4.88 (2H, s), 4.05 (2H, s), 3.44 (8H, m).





53


embedded image


(DMSO-d6) δ 10.13 (1H, brs), 7.29 (5H, m), 6.59 (2H, brs), 4.89 (1H, d, J = 15.3 Hz), 4.82 (1H, d, J = 15.3 Hz), 4.36 (1H, d, J = 7.3 Hz), 4.03 (2H, q, J = 7.1 Hz), 1.47 (3H, d, J = 7.3 Hz), 1.11 (3H, t, J = 7.1 Hz).





54
—S(CH2)2COOMe
(DMSO-d6) δ 10.12 (1H, s), 7.30 (5H, m),




6.55 (2H, brs), 4.87 (2H, s), 3.60 (3H,




s), 3.19 (2H, t, J = 7.2 Hz), 2.74 (2H, t,




J = 7.2 Hz).


55
—S(CH2)2COOEt
(DMSO-d6) δ 10.12 (1H, brs), 7.27 (5H,




m), 6.55 (2H, brs), 4.87 (2H, s), 4.07




(2H, q, J = 7.1 Hz), 3.20 (2H, t, 7.0 Hz),




2.70 (2H, t, J = 7.0 Hz), 1.17 (3H, t, J =




7.1 Hz).


56
—S(CH2)3COOEt
(DMSO-d6) δ 10.11 (1H, brs), 7.30 (5H,




m), 6.53 (2H, brs), 4.89 (2H, s), 4.04




(2H, q, J = 7.1 Hz), 3.04 (2H, t, J =




7.3 Hz), 2.38 (2H, t, J = 7.4 Hz), 1.88




(2H, m), 1.16 (3H, t, J = 7.1 Hz).


57
—S(CH2)4COOEt
(DMSO-d6) δ 10.11 (1H, brs), 7.28 (5H,




m), 6.52 (2H, brs), 4.89 (2H, s), 4.03




(2H, q, J = 7.1 Hz), 3.00 (2H, t, J =




6.6 Hz), 2.28 (2H, t, J = 7.0 Hz), 1.61




(4H, m), 1.16 (3H, t, J = 7.1 Hz).


58
—SCH2COCH2COOEt
(DMSO-d6) δ 10.14 (1H, brs), 7.30 (5H,




m), 6.58 (2H, brs), 4.87 (2H, s), 4.10




(2H, q, J = 7.1 Hz), 3.92 (2H, s), 3.71




(2H, s), 1.15 (3H, t, J = 7.1 Hz).





59


embedded image


(DMSO-d6) δ 10.17 (1H, brs), 7.29 (5H, m), 6.61 (2H, brs), 4.90 (1H, d, J = 15.4 Hz), 4.84 (1H, d, J = 15.4 Hz), 4.40 (1H, t, J = 9.9 Hz), 4.22 (2H, m), 2.61 (1H, m), 2.41 (1H, m).
















TABLE 19









embedded image















Ex.
R2a
R10a

1H-NMR






60


embedded image




embedded image


(DMSO-d6) δ 9.73 (1H, brs), 8.42 (1H, d, J = 2.0 Hz), 7.57 (1H, dd, J = 8.0, 2.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 6.60 (1H, t, J = 6.0 Hz), 6.14 (2H, brs), 4.89 (1H, m), 4.80 (2H, s), 4.50 (1H, t, J = 8.0 Hz), 4.33 (1H, dd, J = 8.4, 6.0 Hz), 3.56 (1H, m), 3.45 (1H, m), 2.42 (3H, s).





61
—(CH2)2COOMe


embedded image


(DMSO-d6) δ 10.21 (1H, brs), 7.28 (5H, m), 6.40 (2H, s), 4.87 (2H, s), 3.53 (3H, s), 2.87 (2H, d, J = 6.9 Hz), 2.71 (2H, d, J = 6.9 Hz).





62
—(CH2)2COOEt


embedded image


(DMSO-d6) δ 10.14 (1H, brs), 7.28 (5H, m), 6.39 (2H, s), 4.87 (2H, s), 3.98 (2H, q, J = 7.1 Hz), 2.88 (2H, d, J = 7.0 Hz), 2.69 (2H, d, J = 7.0 Hz), 1.11 (3H, d, J = 7.1 Hz).





63
—(CH2)2COSMe


embedded image


(DMSO-d6) δ 10.18 (1H, brs), 7.27 (5H, m), 6.42 (2H, s), 4.88 (2H, s), 2.87 (2H, d, J = 6.6 Hz), 2.71 (2H, d, J = 6.6 Hz), 2.20 (3H, s).





64
—OCH2COOMe


embedded image


(DMSO-d6) δ 10.06 (1H, brs), 7.28 (5H, m), 6.57 (2H, brs), 4.82 (2H, s), 4.78 (2H, s), 3.61 (3H, s).





65
—OCH2COOEt


embedded image


(DMSO-d6) δ 10.02 (1H, brs), 7.29 (5H, m), 6.54 (2H, brs), 4.83 (2H, s), 4.75 (2H, s), 4.07 (2H, q, J = 7.1 Hz), 1.14 (3H, d, J = 7.1 Hz).





66
—(CH2)2COOMe


embedded image


(DMSO-d6) δ 10.14 (1H, brs), 8.43 (1H, d, J = 2.0 Hz), 7.59 (1H, dd, J = 8.0, 2.3 Hz), 7.19 (1H, d, J = 8.0 Hz), 6.40 (2H, brs), 4.85 (2H, s), 3.56 (3H, s), 2.88 (2H, d, J = 6.9 Hz), 2.72 (2H, d, J = 6.9 Hz), 2.41 (3H, s).





67
—(CH2)2COOMe


embedded image


(DMSO-d6) δ 10.16 (1H, brs), 7.24 (2H, d, J = 8.2 Hz), 7.19 (2H, d, J = 8.2 Hz), 6.39 (2H, brs), 4.85 (2H, s), 3.64 (2H, s), 3.58 (3H, s), 3.53 (3H, s), 2.87 (2H, d, J = 6.9 Hz), 2.71 (2H, d, J = 6.9 Hz).
















TABLE 20









embedded image














Ex.
R10a

1H-NMR






68


embedded image


(DMSO-d6) δ 9.95 (1H, brs), 7.23 (2H, d, J = 8.3 Hz), 7.20 (2H, d, J = 8.3 Hz), 6.46 (2H, brs), 4.83 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 4.04 (2H, q, J = 7.1 Hz), 3.61 (2H, s), 1.62 (2H, 5, J = 6.6 Hz), 1.36 (2H, 6, J = 6.6 Hz), 1.16 (3H, t, J = 7.1 Hz), 0.90 (3H, t, J = 7.3 Hz).





69


embedded image


(DMSO-d6) δ 10.01 (1H, brs), 7.25 (2H, d, J = 8.6 Hz), 7.22 (2H, d, J = 8.5 Hz), 6.47 (2H, brs), 4.83 (2H, s), 4.13 (2H, q, J = 9.1 Hz), 4.13 (2H, t, J = 6.6 Hz), 3.79 (2H, s), 1.62 (2H, 5, J = 7.0 Hz), 1.37 (2H, 6, J = 7.5 Hz), 0.90 (3H, t, J = 7.4 Hz).





70


embedded image


(DMSO-d6) δ 10.00 (1H, brs), 7.24 (2H, d, J = 8.6 Hz), 7.21 (2H, d, J = 8.8 Hz), 6.46 (2H, brs), 4.83 (2H, s), 4.66 (1H, t, J = 4.0 Hz), 4.54 (1H, t, J = 4.0 Hz), 4.30 (1H, t, J = 4.0 Hz), 4.23 (1H, t, J = 4.0 Hz), 4.13 (2H, t, J = 6.6 Hz), 3.68 (2H, s), 1.62 (2H, 5, J = 6.7 Hz), 1.36 (2H, 6, J = 7.6 Hz), 0.90 (3H, t, J = 7.3 Hz).





71


embedded image


(DMSO-d6) δ 9.98 (1H, brs), 7.24 (2H, d, J = 8.5 Hz), 7.21 (2H, d, J = 8.5 Hz), 6.46 (2H, brs), 4.83 (2H, s), 4.81 (1H, t, J = 5.5 Hz), 4.13 (2H, t, J = 6.6 Hz), 4.02 (2H, t, J = 5.2 Hz), 3.64 (2H, s), 3.55 (2H, q, J = 5.4 Hz), 1.62 (2H, 5, J = 6.7 Hz), 1.36 (2H, 6, J = 7.5 Hz), 0.90 (3H, t, J = 7.4 Hz).





72


embedded image


(DMSO-d6) δ 10.13 (1H, brs), 9.78 (1H, brs), 7.25 (4H, m), 6.56 (2H, brs), 4.84 (2H, s), 4.33 (2H, t, J = 5.0 Hz), 4.14 (2H, t, J = 6.6 Hz), 3.70 (2H, s), 3.35 (2H, q, J = 5.0 Hz), 2.76 (3H, s), 2.75 (3H, s), 1.62 (2H, 5, J = 7.9 Hz), 1.37 (2H, 6, J = 7.6 Hz), 0.90 (3H, t, J = 7.4 Hz).





73


embedded image


(DMSO-d6) δ 9.97 (1H, brs), 7.23 (4H, m), 6.45 (2H, brs), 4.83 (2H, s), 4.12 (4H, m), 3.62 (2H, s), 3.48 (4H, t, J = 4.7 Hz), 2.48 (2H, t, J = 5.7 Hz), 2.32 (4H, t, J = 4.8 Hz), 1.62 (2H, 5, J = 7.8 Hz), 1.36 (2H, 6, J = 7.3 Hz), 0.90 (3H, t, J = 7.3 Hz).





74


embedded image


(DMSO-d6) δ 10.00 (1H, brs), 7.23 (4H, m), 6.46 (2H, brs), 4.83 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.87 (2H, s), 2.20 (2H, s), 1.62 (2H, 5, J = 7.8 Hz), 1.37 (2H, 6, J = 7.4 Hz), 0.90 (3H, t, J = 7.4 Hz).





75


embedded image


(DMSO-d6) δ 9.99 (1H, brs), 7.24 (2H, d, J = 8.4 Hz), 7.21 (2H, d, J = 8.4 Hz), 6.46 (2H, brs), 4.83 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.85 (2H, s), 2.78 (2H, q, J = 7.4 Hz), 1.62 (2H, 5, J = 6.7 Hz), 1.36 (2H, 6, J = 7.3 Hz), 1.12 (3H, t, J = 7.4 Hz), 0.90 (3H, t, J = 7.4 Hz).





76


embedded image


(DMSO-d6) δ 9.93 (1H, brs), 7.43 (1H, s), 7.21 (2H, d, J = 8.4 Hz), 7.18 (2H, d, J = 8.3 Hz), 6.85 (1H, s), 6.44 (2H, brs), 4.81 (2H, s), 4.14 (2H, t, J = 6.7 Hz), 3.32 (2H, s), 1.62 (2H, 5, J = 6.6 Hz), 1.37 (2H, 6, J = 7. 5 Hz), 0.90 (3H, t, J = 7.3 Hz).





77


embedded image


(DMSO-d6) δ 9.96 (1H, brs), 7.91 (1H, d, J = 4.3 Hz), 7.21 (2H, d, J = 8.3 Hz), 7.18 (2H, d, J = 8.3 Hz), 6.45 (2H, brs), 4.81 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 2.54 (2H, s), 2.53 (3H, s), 1.62 (2H, 5, J = 6.7 Hz), 1.37 (2H, 6, J = 7.6 Hz), 0.90 (3H, t, J = 7.3 Hz).





78


embedded image


(DMSO-d6) δ 9.99 (1H, brs), 7.21 (2H, d, J = 8.1 Hz), 7.15 (2H, d, J = 8.1 Hz), 6.46 (2H, brs), 4.82 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.63 (2H, s), 2.97 (3H, s), 2.80 (3H, s), 1.62 (2H, 5, J = 6.6 Hz), 1.37 (2H, 6, J = 7.6 Hz), 0.90 (3H, t, J = 7.3 Hz).





79


embedded image


(DMSO-d6) δ 9.95 (1H, brs), 7.22 (2H, d, J = 8.0 Hz), 7.15 (2H, d, J = 8.0 Hz), 6.45 (2H, brs), 4.82 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.67 (2H, s), 3.46 (8H, m), 1.62 (2H, 5, J = 7.7 Hz), 1.37 (2H, 6, J = 7.4 Hz), 0.90 (3H, t, J = Hz).





80


embedded image


(DMSO-d6) δ 9.98 (1H, brs), 7.27 (1H, t, J = 8.0 Hz), 7.16 (3H, m), 6.46 (2H, brs), 4.83 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 4.03 (2H, q, J = 7.1 Hz), 3.58 (2H, s), 1.62 (2H, 5, J = 6.6 Hz), 1.36 (2H, 6, J = 7.5 Hz), 1.14 (3H, t, J = 7.1 Hz), 0.90 (3H, t, J = 7.3 Hz).





81


embedded image


(DMSO-d6) δ 9.99 (1H, brs), 6.46 (2H, brs), 6.19 (2H, m), 4.79 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.72 (2H, s), 3.60 (3H, s), 1.62 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.4 Hz), 0.90 (3H, t, J = 7.3 Hz).





82


embedded image


(DMSO-d6) δ 10.08 (1H, brs), 8.69 (1H, d, J = 0.9 Hz), 7.89 (2H, m), 6.51 (2H, brs), 5.00 (2H, s), 4.12 (2H, t, J = 6.6 Hz), 2.35 (3H, s), 1.62 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.3 Hz), 0.88 (3H, t, J = 7.4 Hz).





83


embedded image


(DMSO-d6) δ 10.01 (1H, brs), 8.61 (1H, d, J = 1.7 Hz), 8.09 (1H, brs), 7.98 (1H, d, J = 8.0 Hz), 7.83 (1H, dd, J = 2.1, 8.0 Hz), 7.63 (1H, brs), 6.49 (2H, brs), 4.98 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 1.61 (2H, 5, J = 6.6 Hz), 1.35 (2H, 6, J = 7.5 Hz), 0.89 (3H, t, J = 7.4 Hz).





84


embedded image


(DMSO-d6) δ 9.99 (1H, brs), 7.15 (4H, m), 6.46 (2H, brs), 4.81 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.54 (3H, s), 2.80 (2H, t, J = 7.6 Hz), 2.58 (2H, t, J = 7.6 Hz), 1.62 (2H, 5, J = 6.6 Hz), 1.36 (2H, 6, J = 7.6 Hz), 0.90 (3H, t, J = 7.3 Hz).





85


embedded image


(DMSO-d6) δ 9.93 (1H, brs), 7.21 (2H, d, J = 8.3 Hz), 7.15 (2H, d, J = 8.3 Hz), 6.44 (2H, brs), 4.80 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.56 (3H, s), 2.80 (2H, t, J = 7.7 Hz), 2.59 (2H, t, J = 7.5 Hz), 1.62 (2H, 5, J = 6.6 Hz), 1.36 (2H, 6, J = 7.3 Hz), 0.90 (3H, t, J = 7.3 Hz).





86


embedded image


(DMSO-d6) δ 9.97 (1H, brs), 7.20 (2H, d, J = 8.3 Hz), 7.15 (2H, d, J = 8.3 Hz), 6.45 (2H, brs), 4.80 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 4.01 (2H, q, J = 7.1 Hz), 2.79 (2H, t, J = 7.4 Hz), 2.56 (2H, t, J = 7.7 Hz), 1.62 (2H, 5, J = 7.0 Hz), 1.36 (2H, 6, J = 7.6 Hz), 1.12 (3H, t, J = 7.1 Hz), 0.90 (3H, t, J = 7.3 Hz).





87


embedded image


(DMSO-d6) δ 9.90 (1H, brs), 8.10 (1H, d, J = 2.1 Hz), 7.49 (1H, dd, J = 2.3, 8.9 Hz), 6.79 (1H, d, J = 8.8 Hz), 6.42 (2H, brs), 4.71 (2H, s), 4.15 (4H, m), 3.59 (3H, s), 2.86 (2H, t, J = 11.0 Hz), 2.58 (2H, m), 1.84 (1H, m), 1.63 (2H, 5, J = 7.8 Hz), 1.48 (2H, m), 1.38 (2H, 6, J = 7.3 Hz), 0.92 (3H, t, J = 7.3 Hz).





88


embedded image


(DMSO-d6) δ 9.93 (1H, brs), 8.11 (1H, d, J = 2.3 Hz), 7.49 (1H, dd, J = 2.4, 8.8 Hz), 6.79 (1H, d, J = 8.8 Hz), 6.43 (2H, s), 4.71 (2H, s), 4.31 (1H, m), 4.16 (2H, t, J = 6.6 Hz), 3.94 (1H, m), 2.99 (2H, m), 2.45 (1H, m), 1.93 (1H, m), 1.62 (4H, m), 1.39 (3H, m), 0.92 (3H, t, J = 7.3 Hz).





89


embedded image


(DMSO-d6) δ 9.97 (1H, brs), 7.81 (1H, d, J = 9.0 Hz), 7.75 (1H, d, J = 8.6 Hz), 7.71 (1H, s), 7.43 (1H, d, J = 7.2 Hz), 7.26 (1H, d, J = 2.2 Hz), 7.19 (1H, dd, J = 2.5, 9.0 Hz), 6.46 (2H, s), 4.98 (2H, s), 4.90 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.71 (3H, s), 1.61 (2H, 5, J = 7.1 Hz), 1.35 (2H, 6, J = 7.6 Hz), 0.88 (3H, t, J = 7.4 Hz).





90


embedded image


(DMSO-d6) δ 10.03 (1H, brs), 7.72 (1H, d, J = 8.0 Hz), 7.64 (1H, d, J = 1.5 Hz), 7.59 (1H, dd, J = 1.7, 8.0 Hz), 6.49 (2H, brs), 4.95 (2H, s), 4.12 (2H, t, J = 6.6 Hz), 3.80 (6H, s), 1.60 (2H, 5, J = 6.6 Hz), 1.35 (2H, 6, J = 7.5 Hz), 0.89 (3H, t, J = 7.4 Hz).





91


embedded image


(DMSO-d6) δ 10.10 (1H, brs), 8.38 (1H, m), 8.18 (2H, d, J = 1.6 Hz), 6.52 (2H, brs), 5.00 (2H, s), 4.15 (2H, t, J = 6.6 Hz), 3.88 (6H, s), 1.62 (2H, 5, J = 6.6 Hz), 1.36 (2H, 6, J = 7.5 Hz), 0.89 (3H, t, J = 7.4 Hz).





92


embedded image


(DMSO-d6) δ 9.98 (1H, brs), 8.47 (1H, d, J = 1.8 Hz), 7.66 (1H, dd, J = 2.3, 8.0 Hz), 7.31 (1H, d, J = 7.9 Hz), 6.46 (2H, brs), 4.87 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.59 (2H, s), 3.43 (3H, s), 1.62 (2H, 5, J = 7.0 Hz), 1.36 (2H, 6, J = 7.6 Hz), 0.90 (3H, t, J = 7.3 Hz).





93


embedded image


(DMSO-d6) δ 9.99 (1H, brs), 8.38 (1H, d, J = 1.6 Hz), 7.60 (1H, dd, J = 2.2, 8.3 Hz), 7.34 (1H, d, J = 8.3 Hz), 6.47 (2H, brs), 4.84 (2H, s), 4.64 (1H, t, J = 9.6 Hz), 4.39 (1H, dt, J = 3.2, 8.7 Hz), 4.31 (1H, q, J = 8.7 Hz), 4.14 (2H, t, J = 6.6 Hz), 2.69 (1H, m), 2.33 (1H, m), 1.62 (2H, 5, J = 7.0 Hz), 1.37 (2H, 6, J = 7.5 Hz), 0.91 (3H, t, J = 7.3 Hz).





94


embedded image


(DMSO-d6) δ 9.96 (1H, brs), 7.26 (2H, d, J = 8.3 Hz), 6.98 (2H, d, J = 8.3 Hz), 6.45 (2H, brs), 5.29 (1H, t, J = 8.7 Hz), 4.79 (2H, s), 4.39 (1H, dt, J = 2.3, 8.8 Hz), 4.31 (1H, m), 4.15 (2H, t, J = 6.6 Hz), 2.74 (1H, m), 2.22 (1H, m), 1.63 (2H, 5, J = 6.6 Hz), 1.37 (2H, 6, J = 7.6 Hz), 0.91 (3H, t, J = 7. 3 Hz).





95


embedded image


(DMSO-d6) δ 9.96 (1H, brs), 7.22 (2H, d, J = 8.7 Hz), 6.81 (2H, d, J = 8.7 Hz), 6.44 (2H, brs), 4.86 (1H, m), 4.76 (2H, s), 4.67 (1H, t, J = 5.1 Hz), 4.14 (2H, t, J = 6.7 Hz), 3.65 (3H, s), 3.53 (2H, m), 1.94 (2H, m), 1.63 (2H, 5, J = 6.6 Hz), 1.37 (2H, 6, J = 7.4 Hz), 0.91 (3H, t, J = 7.3 Hz).


















TABLE 21





Ex.
Structure

1H-NMR








 96


embedded image


(DMSO-d6) δ 9.96 (1H, s), 7.27 (1H, dd, J = 7.6 Hz, 7.6 Hz), 7.20 (1H, s), 7.17 (1H, d, J = 7.6 Hz), 7.15 (1H, d, J = 7.6 Hz), 6.47 (2H, brs), 4.83 (2H, s), 4.25 (2H, t, J = 4.8 Hz), 3.65 (2H, s), 3.58 (3H, s), 3.58 (2H, t, J = 4.8 Hz), 3.26 (3H, s).





 97


embedded image


(DMSO-d6) δ 9.63 (1H, s), 7.26 (1H, dd, J = 7.6 Hz, 7.6 Hz), 7.19 (1H, s), 7.16-7.13 (2H, m), 6.20 (1H, t, J = 5.6 Hz), 6.00 (2H, s), 4.83 (2H, s), 3.77 (2H, s), 3.59 (3H, s), 3.15 (2H, dt, J = 5.6 Hz, 6.8 Hz), 1.43 (2H, tt, J = 7.6 Hz, 6.8 Hz), 1.28 (2H, tq, J = 7.6 Hz, 7.6 Hz), 0.86 (3H, t, J = 7.6 Hz).





 98


embedded image


(DMSO-d6) δ 10.37 (1H, brs), 7.29 (1H, dd, J = 8.0 Hz, 4.8 Hz), 7.18-7.12 (3H, m), 6.91 (2H, brs), 4.88 (2H, s), 3.65 (2H, s), 3.58 (3H, s).





 99


embedded image


(DMSO-d6) δ 10.12 (1H, s), 7.28 (1H, dd, J = 7.6 Hz, 7.6 Hz), 7.23 (1H, s), 7.21 (1H, d, J = 7.6 Hz), 7.16 (1H, d, J = 7.6 Hz), 6.53 (2H, brs), 4.88 (1H, brs), 4.85 (2H, s), 3.65 (2H, s), 3.61-3.57 (2H, m), 3.59 (3H, s), 3.12 (2H, t, J = 6.8 Hz).





100


embedded image


(DMSO-d6) δ 9.93 (1H, brs), 7.26-7.19 (4H, m), 6.43 (2H, brs), 4.81 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.75 (1H, q, J = 6.9 Hz), 3.54 (3H, s), 1.61 (2H, 5, J = 6.9 Hz), 1.36 (2H, 6, J = 7.0 Hz), 1.26 (3H, d, J = 6.9 Hz), 0.90 (3H, t, J = 7.3 Hz).





101


embedded image


(DMSO-d6) δ 9.93 (1H, brs), 7.30-7.11 (4H, m), 6.43 (2H, brs), 4.83 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.52 (2H, s), 3.58 (3H, s), 1.62 (2H, 5, J = 6.9 Hz), 1.45 (6H, s), 1.36 (2H, 6, J = 7.0 Hz), 0.89 (3H, t, J = 7.2 Hz).





102


embedded image


(DMSO-d6) δ 9.81 (1H, brs), 7.82 (2H, d, J = 8.3 Hz), 7.29 (2H, d, J = 8.2 Hz), 6.37 (2H, brs), 4.09 (2H, t, J = 6.6 Hz), 3.93 (2H, t, J = 7.0 Hz), 3.81 (3H, s), 3.06 (2H, t, J = 7.1 Hz), 1.61 (2H, 5, J = 7.0 Hz), 1.37 (2H, 6, J = 7.4 Hz), 0.90 (3H, t, J = 7.3 Hz).
















TABLE 22









embedded image














Ex.
—R2a

1H-NMR






103


embedded image


(DMSO-d6) δ 10.14 (1H, brs), 8.05 (1H, s), 7.79 (1H, d, J = 7.8 Hz), 7.64 (1H, d, J = 7.8 Hz), 7.34 (1H, t, J = 7.8 Hz), 7.28 (5H, m), 6.60 (2H, brs), 4.92 (2H, s), 4.36 (2H, s), 3.82 (3H, s).





104


embedded image


(DMSO-d6) δ 10.15 (1H, brs), 7.77 (2H, d, J = 8.2 Hz), 7.49 (2H, d, J = 8.2 Hz) 7.28 (5H, m), 6.61 (2H, brs), 4.92 (2H, s), 4.35 (2H, s), 3.83 (3H, s).





105


embedded image


(DMSO-d6) δ 10.13 (1H, brs), 7.29 (7H, m), 7.18 (1H, t, J = 7.6 Hz), 7.09 (2H, d, J = 7.6 Hz), 6.59 (2H, brs), 4.91 (2H, s), 4.27 (2H, s), 3.60 (2H, s), 3.58 (3H, s).





106


embedded image


(DMSO-d6) δ 10.13 (1H, brs), 7.27 (7H, m), 7.09 (2H, d, J = 8.0 Hz), 6.58 (2H, brs), 4.91 (2H, s), 4.27 (2H, s), 3.61 (2H, s), 3.59 (3H, s).





107


embedded image


(DMSO-d6) δ 10.11 (1H, s), 7.18 (5H, m), 6.40 (2H, s), 4.80 (2H, s), 3.93 (2H, t, J = 6.6 Hz), 3.55 (2H, s), 1.42 (2H, m), 1.17 (2H, m), 0.74 (3H, t, J = 7.4 Hz).





108


embedded image


(DMSO-d6) δ 10.26 (1H, brs), 7.32 (5H, m), 6.53 (2H, s), 4.94 (3H, m), 3.64 (2H, s), 1.19 (6H, t, J = 6.3 Hz).





109


embedded image


(DMSO-d6) δ 10.03 (1H, brs), 7.09 (5H, m), 6.32 (2H, s), 4.70 (2H, s), 4.39 (2H, m), 4.08 (2H, m), 3.50 (2H, s).





110


embedded image


(DMSO-d6) δ 10.13 (1H, s), 7.24 (5H, m), 6.40 (2H, brs), 4.83 (2H, s), 3.63 (2H, s), 3.44-3.32 (8H, m).
















TABLE 23









embedded image














Ex.
—R10a

1H-NMR






111


embedded image


(DMSO-d6) δ 9.97 (1H, brs), 7.21 (4H, s), 6.43 (2H, brs), 4.85 (2H, s), 4.12 (2H, t, J = Hz), 4.01 (2H, s), 3.58 (3H, s), 1.61 (2H, 5, J = 6.6 Hz), 1.36 (2H, 6, J = 7.3 Hz), 0.89 (3H, t, J = 7.3 Hz).





112


embedded image


(DMSO-d6) δ 9.98 (1H, brs), 7.87-7.84 (1H, m), 7.60-7.58 (1H, m), 7.34-7.27 (1H, m), 6.45 (2H, brs), 4.88 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.82 (3H, s), 1.61 (2H, 5, J = 6.8 Hz), 1.35 (2H, 6, J = 7.5 Hz), 0.88 (3H, t, J = 7.3 Hz).





113


embedded image


(DMSO-d6) δ 9.93 (1H, brs), 7.63 (1H, d, J = 2.4 Hz), 7.48 (1H, dd, J = 2.4 Hz, 8.6 Hz), 7.10 (1H, d, J = 8.8 Hz), 6.43 (2H, brs), 4.80 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.77 (3H, s), 3.75 (3H, s), 1.62 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.5 Hz), 0.89 (3H, t, J = 7.3 Hz).





114


embedded image


(DMSO-d6) δ 9.96 (1H, brs), 7.24 (4H, s), 6.44 (2H, brs), 4.81 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.55 (3H, s), 1.61 (2H, 5, J = 6.8 Hz), 1.45 (6H, s), 1.36 (2H, 6, J = 7.5 Hz), 0.90 (3H, t, J = 7.3 Hz).





115


embedded image


(DMSO-d6) δ 9.96 (1H, brs), 7.29-7.12 (4H, m), 6.44 (2H, brs), 4.82 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.75 (1H, q, J = 7.1 Hz), 3.54 (3H, s), 1.61 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.5 Hz), 1.33 (3H, d, J = 7.1), 0.89 (3H, t, J = 7.3 Hz).





116


embedded image


(DMSO-d6) δ 10.05 (1H, brs), 7.91 (1H, s), 7.88 (1H, d, J = 7.7 Hz), 7.69 (1H, d, J = 7.6 Hz), 7.58 (1H, dd, J = 7.7 Hz, 7.6 Hz), 6.50 (2H, brs), 4.96 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.91 (3H, s), 1.61 (2H, tt, J = 7.4 Hz, 6.6 Hz), 1.37 (2H, tq, J = 7.4 Hz, 7.4 Hz), 0.89 (3H, t, J = 7.4 Hz).





117


embedded image


(DMSO-d6) δ 9.97 (1H, s), 7.34 (1H, s), 7.32- 7.28 (2H, m), 7.24-7.20 (1H, m), 6.46 (2H, brs), 6.07 (1H, d, J = 5.1 Hz), 5.10 (1H, d, J = 5.1 Hz), 4.84 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.57 (3H, s), 1.62 (2H, tt, J = 7.4 Hz, 6.6 Hz), 1.38 (2H, tq, J = 7.4 Hz, 7.4 Hz), 0.90 (3H, t, J = 7.4 Hz).





118


embedded image


(DMSO-d6) δ 10.11 (1H, brs), 8.65 (1H, dd, J = 0.6, 5.0 Hz), 7.93 (1H, d, J = 0.9 Hz), 7.31 (1H, dd, J = 0.6, 5.0 Hz), 6.53 (2H, brs), 4.98 (2H, s), 4.11 (2H, t, J = 6.8 Hz), 3.86 (3H, s), 1.58 (2H, 5, J = 6.6 Hz), 1.33 (2H, 6, J = 7.3 Hz), 0.87 (3H, t, J = 7.3 Hz).





119


embedded image


(DMSO-d6) δ 10.11 (1H, brs), 7.65 (1H, d, J = 3.8 Hz), 7.14 (1H, d, J = 3.8 Hz), 6.53 (2H, brs), 5.06 (2H, s), 4.16 (2H, t, J = 6.6 Hz), 3.78 (3H, s), 1.63 (2H, 5, J = 6.6 Hz), 1.37 (2H, 6, J = 7.3 Hz), 0.90 (3H, t, J = 7.3 Hz).





120


embedded image


(DMSO-d6) δ 10.00 (1H, brs), 7.09 (2H, s), 7.05 (1H, s), 6.47 (2H, brs), 4.81 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.63 (4H, s), 3.58 (6H, s), 1.62 (2H, 5, J = 6.6 Hz), 1.37 (2H, 6, J = 7.3 Hz), 0.90 (3H, t, J = 7.3 Hz).





121


embedded image


(DMSO-d6) δ 10.09 (1H, brs), 8.45 (1H, d, J = 2.0 Hz), 8.38 (1H, d, J = 2.0 Hz), 7.60 (1H, m), 6.50 (2H, brs), 4.88 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.73 (2H, s), 3.60 (3H, s), 1.62 (2H, 5, J = 6.6 Hz), 1.37 (2H, 6, J = 7.4 Hz), 0.90 (3H, t, J = 7.3 Hz).


















TABLE 24





Comp.




ex.
Structure

1H-NMR








 1


embedded image


(DMSO-d6) δ 12.99 (1H, brs), 10.03 (1H, s), 7.88 (1H, s), 7.84 (1H, d, J = 7.8 Hz), 7.55 (1H, d, J = 7.8 Hz), 7.45 (1H, t, J = 7.8 Hz), 6.48 (2H, brs), 4.91 (2H, s), 4.14 (2H, t, J = 6.5 Hz), 1.60 (2H, 5, J = 7.0 Hz), 1.36 (2H, 6, J = 7.0 Hz), 0.89 (3H, t, J = 7.3 Hz).





 3


embedded image


(DMSO-d6) δ 13.08 (1H, brs), 10.02 (1H, brs), 7.09 (1H, d, J = 2.4 Hz), 6.45 (3H, m), 4.91 (2H, s), 4.13 (2H, t, J = 6.5 Hz), 1.64 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).





 5


embedded image


(DMSO-d6) δ 12.31 (1H, brs), 10.03 (1H, brs), 7.22 (4H, m), 6.47 (2H, brs), 4.83 (2H, s), 4.14 (2H, t, J = 6.8 Hz), 3.50 (2H, s), 1.60 (2H, 5, J = 6.8 Hz), 1.38 (2H, 6, J = 7.6 Hz), 0.90 (3H, t, J = 7.0 Hz).





 6


embedded image


(DMSO-d6) δ 13.14 (1H, brs), 10.01 (1H, brs), 7.22 (4H, m), 6.49 (2H, brs), 4.83 (2H, s), 4.14 (2H, t, J = 6.5 Hz), 3.53 (2H, s), 1.62 (2H, 5, J = 6.8 Hz), 1.36 (2H, 6, J = 7.0 Hz), 0.90 (3H, t, J = 7.3 Hz).





 8


embedded image


(DMSO-d6) δ 12.40 (1H, brs), 10.23 (1H, brs), 7.29 (5H, m), 6.50 (2H, s), 4.90 (2H, s), 3.53 (2H, s).





 9


embedded image


(DMSO-d6) δ 9.68 (1H, s), 7.29 (5H, m), 6.06 (3H, brs), 4.80 (2H, s), 4.60 (1H, t, J = 4.4 Hz), 3.46 (2H, q, J = 4.4 Hz), 3.23 (2H, q, J = 4.4 Hz).





10


embedded image


(DMSO-d6) δ 9.70 (1H, brs), 8.42 (1H, s), 7.59 (1H, d, J = 8.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 6.10 (1H, t, J = 6.0 Hz), 6.06 (2H, brs), 4.78 (2H, s), 4.62 (1H, t, J = 6.0 Hz), 3.50 (1H, q, J = 6.0 Hz), 3.25 (2H, q, J = 6.0 Hz), 2.42 (3H, s).





11


embedded image


(DMSO-d6) δ 10.13 (1H, s), 8.43 (1H, d, J = 2.0 Hz), 7.60 (1H, dd, J = 8.0, 2.0 Hz), 7.22 (1H, d, J = 8.0 Hz), 6.55 (2H, brs), 4.84 (2H, s), 4.80 (1H, t, J = 4.8 Hz), 4.16 (2H, t, J = 4.8 Hz), 3.64 (2H, q, J = 4.8 Hz), 2.42 (3H, s).





12


embedded image


(DMSO-d6) δ 10.44 (1H, brs), 7.34 (5H, m), 6.64 (2H, brs), 4.85 (2H, s), 3.82 (2H, s).





13


embedded image


(DMSO-d6) δ 12.26 (br s, 1H), 8.16 (s, 1H), 7.39-7.17 (m, 5H), 5.29 (s, 2H), 3.22 (t, 2H, J = 7.2 Hz), 2.66 (t, 2H, J = 6.9 Hz).





14


embedded image


(DMSO-d6) δ 9.70 (1H, s), 8.43 (1H, d, J = 2.0 Hz), 7.60 (1H, dd, J = 8.0, 2.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 6.11 (2H, brs), 6.02 (1H, t, J = 5.7 Hz), 4.81 (1H, brs), 4.78 (2H, s), 4.56 (1H, t, J = 8.3 Hz), 3.57 (1H, m), 3.33 (3H, m), 3.12 (1H, m), 2.42 (3H, s).





15


embedded image


(DMSO-d6) δ 12.04 (1H, brs), 10.20 (1H, brs), 7.26 (5H, m), 6.42 (2H, s), 4.88 (2H, s), 2.83 (2H, d, J = 7.2 Hz), 2 .65 (2H, d, J = 7.2 Hz).





16


embedded image


(DMSO-d6) δ 12.80 (1H, brs), 10.00 (1H, brs), 7.28 (5H, m), 6.52 (2H, s), 4.83 (2H, s), 4.70 (2H, s).





17


embedded image


(DMSO-d6) δ 10.57 (1H, brs), 8.70 (1H, s), 8.17 (1H, s), 7.68 (1H, d, J = 7.0 Hz), 6.83 (2H, brs), 5.04 (2H, s), 2.87 (2H, d, J = 7.1 Hz), 2.66 (2H, d, J = 6.9 Hz), 2.61 (3H, s).





18


embedded image


(DMSO-d6) δ 10.76 (1H, brs), 7.28 (2H, d, J = 8.1 Hz), 7.19 (2H, d, J = 8.1 Hz), 4.91 (2H, s), 3.52 (2H, s), 2.93 (2H, d, J = 7.1 Hz), 2.72 (2H, d, J = 6.9 Hz).





19


embedded image


(DMSO-d6) δ 12.50 (1H, brs), 9.97 (1H, brs), 6.46 (2H, brs), 6.19 (1H, d, J = 3.1 Hz), 6.16 (1H, d, J = 3.1 Hz), 4.79 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.59 (2H, s), 1.63 (2H, 5, J = 6.6 Hz), 1.38 (2H, 6, J = 7.4 Hz), 0.90 (3H, t, J = 7.3 Hz).





20


embedded image


(DMSO-d6) δ 11.16 (1H, brs), 9.86 (1H, brs), 7.16 (1H, t, J = 7.6 Hz), 7.13 (1H, s), 7.08 (1H, d, J = 7.5 Hz), 7.03 (1H, d, J = 7.5 Hz), 6.76 (2H, brs), 4.79 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 2.70 (2H, t, J = 7.7 Hz), 2.15 (2H, t, J = 7.7 Hz), 1.62 (2H, 5, J = 6.6 Hz), 1.36 (2H, 6, J = 7.5 Hz), 0.89 (3H, t, J = 7.4 Hz).





21


embedded image


(DMSO-d6) δ 11.10 (1H, brs), 9.90 (1H, brs), 8.07 (1H, d, J = 2.2 Hz), 7.42 (1H, dd, J = 2.4, 8.8 Hz), 6.74 (3H, m), 4.68 (2H, s), 4.15 (2H, t, J = 6.6 Hz), 4.04 (2H, m), 2.85 (2H, t, J = 10.8 Hz), 2.08 (1H, m), 1.73 (2H, m), 1.64 (2H, 5, J = 6.6 Hz), 1.46 (2H, m), 1.38 (2H, 6, J = 7.3 Hz), 0.92 (3H, t, J = 7.3 Hz).





22


embedded image


(DMSO-d6) δ 11.51 (1H, brs), 8.06 (1H, d, J = 2.3 Hz), 7.43 (1H, dd, J = 2.4, 8.8 Hz), 6.87 (2H, s), 6.79 (1H, d, J = 8.8 Hz), 4.67 (2H, s), 4.14 (4H, m), 2.75 (3H, m), 1.93 (2H, m), 1.50 (6H, m), 0.92 (3H, t, J = 7.3 Hz).





23


embedded image


(DMSO-d6) δ 13.14 (2H, brs), 10.00 (1H, brs), 7.64 (1H, d, J = 7.9 Hz), 7.59 (1H, d, J = 1.5 Hz), 7.45 (1H, dd, J = 1.7, 7.9 Hz), 6.48 (2H, brs), 4.93 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 1.61 (2H, 5, J = 6.6 Hz), 1.35 (2H, 6, J = 7.3 Hz), 0.89 (3H, t, J = 7.4 Hz).





24


embedded image


(DMSO-d6) δ 13.31 (1H, brs), 10.08 (1H, brs), 8.36 (1H, s), 8.11 (2H, s), 6.52 (2H, brs), 4.98 (2H, s), 4.15 (2H, t, J = 6.6 Hz), 1.61 (2H, 5, J = 6.7 Hz), 1.35 (2H, 6, J = 7.3 Hz), 0.89 (3H, t, J = 7.4 Hz).





25


embedded image


(DMSO-d6) δ 12.44 (1H, brs), 9.98 (1H, brs), 8.46 (1H, d, J = 1.9 Hz), 7.65 (1H, dd, J = 2.3, 8.0 Hz), 7.29 (1H, d, J = 7.8 Hz), 6.46 (2H, brs), 4.87 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 3.43 (2H, s), 1.62 (2H, 5, J = 7.7 Hz), 1.37 (2H, 6, J = 7.6 Hz), 0.91 (3H, t, J = 7.4 Hz).





26


embedded image


(DMSO-d6) δ 10.65 (1H, brs), 8.32 (1H, s), 7.60 (1H, d, J = 7.1 Hz), 7.34 (1H, d, J = 8.3 Hz), 6.66 (2H, brs), 5.70 (1H, brs), 4.78 (2H, s), 4.15 (4H, m), 3.51 (1H, t, J = 8.7 Hz), 3.14 (1H, m), 1.90 (2H, m), 1.63 (2H, 5, J = 7.0 Hz), 1.37 (2H, 6, J = 7.5 Hz), 0.91 (3H, t, J = 7.3 Hz).





27


embedded image


(DMSO-d6) δ 12.32 (1H, brs), 9.97 (1H, s), 7.26 (1H, dd, J = 7.6 Hz, 7.6 Hz), 7.20 (1H, s), 7.17-7.14 (2H, m), 6.47 (2H, brs), 4.83 (2H, s), 4.26 (2H, t, J = 4.8 Hz), 3.58 (2H, t, J = 4.8 Hz), 3.53 (2H, s), 3.26 (3H, s).





28


embedded image


(DMSO-d6) δ 12.29 (1H, brs), 9.98 (1H, brs), 7.26 (1H, dd, J = 7.6 Hz, 7.6 Hz), 7.21 (1H, s), 7.18-7.15 (2H, m), 6.74 (2H, brs), 4.81 (2H, s), 3.69 (2H, s), 3.40-3.17 (2H, m), 1.48 (2H, tt, J = 7.2 Hz, 7.2 Hz), 1.30 (2H, tq, J = 7.2 Hz, 7.2 Hz), 0.88 (3H, t, J = 7.2 Hz).





29


embedded image


(DMSO-d6) δ 12.39 (1H, brs), 10.39 (1H, brs), 7.27-7.25 (1H, m), 7.17 (1H, s), 7.17-7.11 (2H, m), 6.91 (2H, brs), 4.92 (2H, s), 3.53 (2H, s).





30


embedded image


(DMSO-d6) δ 12.29 (1H, brs), 10.11 (1H, s), 7.28 (1H, dd, J = 7.6 Hz, 7.6 Hz), 7.23 (1H, s), 7.19 (1H, d, J = 7.6 Hz), 7.15 (1H, d, J = 7.6 Hz), 6.52 (2H, brs), 4.90 (1H, brs), 4.85 (2H, s), 3.60 (2H, t, J = 6.8 Hz), 3.54 (2H, s), 3.12 (2H, t, J = 6.8 Hz).





31


embedded image


(DMSO-d6) δ 12.27 (1H, brs), 9.95 (1H, brs), 7.26-7.19 (4H, m), 6.43 (2H, brs), 4.81 (2H, s), 4.13 (2H, t, J = 6.6 Hz), 3.62 (1H, q, J = 6.9 Hz), 1.61 (2H, 5, J = 6.9 Hz), 1.36 (2H, 6, J = 7.0 Hz), 1.30 (3H, d, J = 6.9 Hz), 0.89 (3H, t, J = 7.3 Hz).





32


embedded image


(DMSO-d6) δ 12.32 (1H, brs), 9.94 (1H, brs), 7.37-7.10 (4H, m), 6.43 (2H, brs), 4.83 (2H, s), 4.14 (2H, t, J = 6.6 Hz), 1.62 (2H, 5, J = 6.9 Hz), 1.42 (6H, s), 1.36 (2H, 6, J = 7.0 Hz), 0.89 (3H, t, J = 7.3 Hz).





33


embedded image


(DMSO-d6) δ 9.84 (1H, brs), 7.80 (2H, d, J = 8.1 Hz), 7.26 (2H, d, J = 8.1 Hz), 6.39 (2H, brs), 4.10 (2H, t, J = 6.6 Hz), 3.93 (2H, t, J = 6.9 Hz), 3.05 (2H, t, J = 7.3 Hz), 1.61 (2H, 5, J = 7.0 Hz), 1.37 (2H, 6, J = 7.4 Hz), 0.91 (3H, t, J= 7.3 Hz).





34


embedded image


(DMSO-d6) δ 10.16 (1H, brs), 8.01 (1H, s), 7.77 (1H, d, J = 7.8 Hz), 7.59 (1H, d, J = 7.8 Hz), 7.27 (6H, m), 6.60 (2H, brs), 4.91 (2H, s), 4.35 (2H, s).





35


embedded image


(DMSO-d6) δ 10.18 (1H, brs), 7.76 (2H, d, J = 8.2 Hz), 7.45 (2H, d, J = 8.2 Hz) 7.28 (5H, m), 6.62 (2H, brs), 4.91 (2H, s), 4.34 (2H, s).





36


embedded image


(DMSO-d6) δ 12.32 (1H, brs), 10.16 (1H, brs), 7.33-7.09 (9H, m), 6.59 (2H, brs), 4.91 (2H, s), 4.28 (2H, s), 3.49 (2H, s).





37


embedded image


(DMSO-d6) δ 12.30 (1H, brs), 10.13 (1H, brs), 7.28 (7H, m), 7.09 (2H, d, J = 8.0 Hz), (2H, brs), 4.91 (2H, s), 4.27 (2H, s), 3.50 (2H, s).









The preferable compounds of the present invention are illustrated below.









TABLE 25









embedded image















No.
—R9







201


embedded image









202


embedded image









203


embedded image









204


embedded image









205


embedded image









206


embedded image









207


embedded image









208


embedded image









209


embedded image









210


embedded image









211


embedded image









212


embedded image









213


embedded image









214


embedded image









215


embedded image









216


embedded image









217


embedded image









218


embedded image









219


embedded image









220


embedded image









221


embedded image









222


embedded image









223


embedded image









224


embedded image









225


embedded image









226


embedded image









227


embedded image









228


embedded image









229


embedded image









230


embedded image









231


embedded image









232


embedded image









233


embedded image









234


embedded image









235


embedded image









236


embedded image









237


embedded image









238


embedded image









239


embedded image









240


embedded image









241


embedded image









242


embedded image









243


embedded image









244


embedded image









245


embedded image









246


embedded image









247


embedded image









248


embedded image









249


embedded image









250


embedded image









251


embedded image









252


embedded image









253


embedded image









254


embedded image









255


embedded image









256


embedded image









257


embedded image









258


embedded image









259


embedded image









260


embedded image









261


embedded image









262


embedded image









263


embedded image









264


embedded image









265


embedded image









266


embedded image









267


embedded image









268


embedded image









269


embedded image









270


embedded image









271


embedded image









272


embedded image









273


embedded image









274


embedded image









275


embedded image









276


embedded image









277


embedded image









278


embedded image









279


embedded image









280


embedded image









281


embedded image









282


embedded image









283


embedded image









284


embedded image









285


embedded image









286


embedded image









287


embedded image









288


embedded image









289


embedded image









290


embedded image









291


embedded image









292


embedded image









293


embedded image









294


embedded image









295


embedded image









296


embedded image









297


embedded image









298


embedded image









299


embedded image









300


embedded image









301


embedded image









302


embedded image









303


embedded image









304


embedded image









305


embedded image









306


embedded image









307


embedded image









308


embedded image









309


embedded image









310


embedded image









311


embedded image









312


embedded image









313


embedded image









314


embedded image









315


embedded image









316


embedded image









317


embedded image









318


embedded image









319


embedded image









320


embedded image









321


embedded image









322


embedded image









323


embedded image









324


embedded image









325


embedded image









326


embedded image









327


embedded image









328


embedded image









329


embedded image









330


embedded image



















TABLE 26









embedded image















No.
—Y1—Q1
X
—R9





331
—Bu



embedded image







332
—CH2OH



embedded image







333
—(CH2)2OH



embedded image







334
—(CH)2OMe



embedded image







335
—Bu



embedded image







336
—CH2OH



embedded image







337
—(CH2)2OH



embedded image







338
—(CH2)2OH



embedded image







339
—(CH)2OMe



embedded image







340
—Bu



embedded image







341
—CH2OH



embedded image







342
—(CH2)2OH



embedded image







343
—(CH)2OMe



embedded image







344
—Bu



embedded image







345
—CH2OH



embedded image







346
—(CH2)2OH



embedded image







347
—(CH)2OMe



embedded image







348
—Bu



embedded image







349
—CH2OH



embedded image







350
—(CH2)2OH



embedded image







351
—(CH)2OMe



embedded image







352
—Bu



embedded image







353
—CH2OH



embedded image







354
—(CH2)2OH



embedded image







355
—CH2OMe



embedded image







356
—Bu



embedded image







357
—CH2OH



embedded image







358
—(CH2)2OH



embedded image







359
—(CH2)OMe
NH


embedded image







360
—Bu
NH


embedded image







361
—(CH2)3OH
NMe


embedded image







362
—(CH)2OH
NH


embedded image







363
—(CH2)3OEt
NH


embedded image







364
—(CH2)OMe
NMe


embedded image







365
—Bu
NH


embedded image







366
—(CH2)3OH
NH


embedded image







367
—CH2OH
NH


embedded image







368
—(CH2)3OEt
NMe


embedded image







369
—CH2OMe
NH


embedded image







370
—Bu
NH


embedded image







371
—(CH2)3OH
NMe


embedded image







372
—CH2OH
NH


embedded image







373
—(CH2)3OEt
NH


embedded image







374
—CH2OMe
NH


embedded image







375
—Bu
NMe


embedded image







376
—(CH2)3OH
NH


embedded image







377
—CH2OH
NH


embedded image







378
—(CH2)3OEt
NMe


embedded image







379
—CH2OMe
NH


embedded image







380
—Bu
NH


embedded image







381
—(CH2)3OH
NH


embedded image







382
—(CH)2OH
NMe


embedded image







383
—(CH2)3OEt
NH


embedded image







384
—CH2OMe
NH


embedded image







385
—Bu
NMe


embedded image







386
—(CH2)3OH
NH


embedded image







387
—CH2OH
NH


embedded image







388
—(CH2)3OEt
NH


embedded image







389
—CH2OMe
NMe


embedded image







390
—Bu
NH


embedded image







391
—(CH2)2OH
NH


embedded image







392
—(CH2)2OMe
NMe


embedded image







393
—Bu
NH


embedded image







394
—(CH2)2OH
NH


embedded image







395
—(CH2)2OMe
NH


embedded image







396
—Bu
NMe


embedded image







397
—(CH2)2OH
NH


embedded image







398
—(CH2)2OMe
NH


embedded image







399
—Bu
NMe


embedded image







400
—(CH2)2OH
NH


embedded image







401
—(CH2)2OMe
NH


embedded image







402
—Bu
NH


embedded image







403
—(CH2)2OH
NMe


embedded image







404
—Bu
S


embedded image







405
—(CH2)3OH
S


embedded image







406
—CH2OH
S


embedded image







407
—(CH2)3OEt
S


embedded image







408
—CH2OMe
S


embedded image







409
—Bu
S


embedded image







410
—(CH2)3OH
S


embedded image







411
—CH2OH
S


embedded image







412
—(CH2)3OEt
S


embedded image







413
—CH2OMe
S


embedded image







414
—Bu
S


embedded image







415
—(CH2)3OH
S


embedded image







416
—CH2OH
S


embedded image







417
—(CH2)3OH
S


embedded image







418
—(CH)2OH
S


embedded image







419
—(CH2)3OEt
S


embedded image







420
—CH2OMe
S


embedded image







421
—Bu
S


embedded image







422
—(CH2)3OH
S


embedded image







423
—CH2OH
S


embedded image







424
—(CH2)3OEt
S


embedded image







425
—CH2OMe
S


embedded image







426
—Bu
S


embedded image







427
—(CH2)3OH
S


embedded image







428
—CH2OH
S


embedded image







429
—(CH2)3OEt
S


embedded image







430
—CH2OMe
S


embedded image







431
—Bu
S


embedded image







432
—(CH2)3OH
S


embedded image







433
—CH2OH
S


embedded image







434
—(CH2)3OEt
S


embedded image







435
—CH2OMe
S


embedded image







436
—Bu
S


embedded image







437
—(CH2)2OH
S


embedded image







438
—(CH2)2OMe
S


embedded image







439
—Bu
S


embedded image







440
—(CH2)2OH
S


embedded image







441
—(CH2)2OMe
S


embedded image







442
—Bu
S


embedded image







443
—(CH2)2OH
S


embedded image







444
—(CH2)2OMe
S


embedded image







445
—Bu
S


embedded image







446
—(CH2)2OH
S


embedded image







447
—(CH2)2OMe
S


embedded image







448
—CH2OH
O


embedded image







449
—(CH2)3OEt
O


embedded image







450
—(CH2)3OH
O


embedded image







451
—CH2OMe
O


embedded image







452
—CH2OH
O


embedded image







453
—(CH2)3OEt
O


embedded image







454
—(CH2)3OH
O


embedded image







455
—CH2OMe
O


embedded image







456
—CH2OH
O


embedded image







457
—(CH2)3OEt
O


embedded image







458
—(CH2)3OH
O


embedded image







459
—CH2OMe
O


embedded image







460
—CH2OH
O


embedded image







461
—(CH2)3OEt
O


embedded image







462
—(CH2)3OH
O


embedded image







463
—CH2OMe
O


embedded image







464
—CH2OH
O


embedded image







465
—(CH2)3OEt
O


embedded image







466
—(CH2)3OH
O


embedded image







467
—CH2OMe
O


embedded image







468
—CH2OH
O


embedded image







469
—(CH2)3OEt
O


embedded image







470
—(CH2)3OH
O


embedded image







471
—CH2OMe
O


embedded image







472
—CH2OH
O


embedded image







473
—(CH2)3OEt
O


embedded image







474
—(CH2)2OH
O


embedded image







475
—(CH2)2OMe
O


embedded image







476
—(CH2)2OH
O


embedded image







477
—(CH2)2OMe
O


embedded image







478
—(CH2)2OH
O


embedded image







479
—(CH2)2OMe
O


embedded image







480
—(CH2)2OH
O


embedded image







481
—(CH2)2OMe
O


embedded image







482
—(CH2)2OH
O


embedded image







483
—(CH2)2OMe
O


embedded image


















TABLE 27









embedded image
















No.
—Y1—Q1
X







484
—CO2Me




485
—CO2CH2CH═CH2




486
—CO2CH2CF3




487
—CO2(CH2)2OMe




488
—CO2(CH2)2OH




489
—CO2(CH2)NMe2




490
—CO2Bn








491


embedded image










492


embedded image










493
—CH2CO2CH2Cl




494
—CH2CO2(CH2)3OEt




495
—CH2CO2(CH2)4OH








496


embedded image










497


embedded image










498


embedded image










499
—(CH2)2CO2Bn




500
—(CH2)3CO2CH2Cl




501
—(CH2)4CO2(CH2)3OEt




502
—(CH2)2CO2(CH2)2OH








503


embedded image










504


embedded image










505


embedded image










506
—COS—iPr




507
—COS(CH2)2OH




508
—CH2COS(CH2)2OMe








509


embedded image










510
—CH2OCO2Et




511
—(CH2)3OCO2(CH2)2OMe




512
—CH2OCOEt




513
—(CH2)2OCOBn








514


embedded image










515
—CONMe2




516
—CH2CONH(CH2)NMe2








517


embedded image










518
— (CH2)3CONH(CH2)OMe




519
—CH2OCONMe2








520


embedded image










521


embedded image










522


embedded image


NH







523
—CH2CO2CH2CF3
NMe



524
—CH2CO2(CH2)3OEt
NEt



525
—CH2CO2(CH2)4OH
NH







526


embedded image


NMe







527


embedded image


NEt







528


embedded image


NH







529
—(CH2)2CO2Bn
NMe



530
—(CH2)3CO2CH2Cl
NEt



531
—(CH2)4CO2(CH2)3OEt
NH



532
—(CH2)2CO2(CH2)2OH
NMe







533


embedded image


NEt







534


embedded image


NH







535


embedded image


NMe







536
—CH2COSBu
NEt



537
—CH2COS(CH2)2OH
NH



538
—CH2COS(CH2)2OMe
NMe



539
—(CH2)2COS(CH2)2NMeEt
NEt



540
—CH2OCO2Et
NH



541
—(CH2)3OCO2(CH2)2OMe
NMe



542
—CH2OCOEt
NEt



543
—(CH2)2OCOBn
NH







544


embedded image


NMe







545
—CH2CONMe2
NEt



546
—CH2CONH(CH2)NMe2
NH







547


embedded image


NMe







548
—(CH2)3CONH(CH2)OMe
NEt



549
—CH2OCONMe2
NH







550


embedded image


NMe







551


embedded image


NEt







552


embedded image


S







553
—CH2CO2CH2CF3
S



554
—CH2CO2(CH2)4OH
S







555


embedded image


S







556


embedded image


S







557
—(CH2)2CO2Bn
S



558
—(CH2)4CO2(CH2)3OEt
S







559


embedded image


S







560


embedded image


S







561
—CH2COSBu
S



562
—CH2COS(CH2)2OMe
S



563
—(CH2)2COS(CH2)2NMeEt
S



564
—(CH2)3OCO2(CH2)2OMe
S



565
—CH2OCOEt
S







566


embedded image


S







567
—CH2CONMe2
S







568


embedded image


S







569
—(CH2)3CONH(CH2)OMe
S







570


embedded image


S







571


embedded image


S







572


embedded image


O







573
—CH2CO2(CH2)3OEt
O



574
—CH2CO2(CH2)4OH
O







575


embedded image


O







576


embedded image


O







577
—(CH2)3CO2CH2Cl
O



578
—(CH2)4CO2(CH2)3OEt
O







579


embedded image


O







580


embedded image


O







581
—CH2COSBu
O



582
—CH2COS(CH2)2OH
O



583
—(CH2)2COS(CH2)2NMeEt
O



584
—CH2OCO2Et
O



585
—CH2OCOEt
O



586
—(CH2)2OCOBn
O



587
—CH2CONMe2
O



588
—CH2CONH(CH2)NMe2
O



589
—(CH2)3CONH(CH2)OMe
O



590
—CH2OCONMe2
O







591


embedded image


O

















TABLE 28









embedded image















No.
—Y1—Q1
X
—R9





592
—CO2Me



embedded image







593
—CO2CH2CF3



embedded image







594
—CO2(CH2)2OH



embedded image







595
—CO2Bn



embedded image







596


embedded image





embedded image







597
—CH2CO2(CH2)3OEt



embedded image







598


embedded image





embedded image







599


embedded image





embedded image







600
—(CH2)3CO2CH2Cl



embedded image







601
—(CH2)2CO2(CH2)2OH



embedded image







602


embedded image





embedded image







603
—COS—iPr



embedded image







604
—CH2COS(CH2)2OMe



embedded image







605
—CH2OCO2Et



embedded image







606
—CH2OCOEt



embedded image







607


embedded image





embedded image







608
—CH2CONH(CH2)NMe2



embedded image







609
—(CH2)3CONH(CH2)OMe



embedded image







610


embedded image





embedded image







611
—CH2CO2CH2CF3
NMe


embedded image







612
—CH2CO2(CH2)4OH
NH


embedded image







613


embedded image


NEt


embedded image







614
—(CH2)2CO2Bn
NMe


embedded image







615
—(CH2)4CO2(CH2)3OEt
NH


embedded image







616


embedded image


NEt


embedded image







617


embedded image


NMe


embedded image







618
—CH2COS(CH2)2OH
NH


embedded image







619
—(CH2)2COS(CH2)2NMeEt
NEt


embedded image







620
—(CH2)3OCO2(CH2)2OMe
NMe


embedded image







621
—(CH2)2OCOBn
NH


embedded image







622
—CH2CONMe2
NEt


embedded image







623


embedded image


NMe


embedded image







624
—CH2OCONMe2
NH


embedded image







625


embedded image


NEt


embedded image







626


embedded image


S


embedded image







627
—CH2CO2(CH2)4OH
S


embedded image







628


embedded image


S


embedded image







629
—(CH2)4CO2(CH2)3OEt
S


embedded image







630


embedded image


S


embedded image







631
—CH2COS(CH2)2OMe
S


embedded image







632
—(CH2)3OCO2(CH2)2OMe
S


embedded image







633


embedded image


S


embedded image







634


embedded image


S


embedded image







635


embedded image


S


embedded image







636
—CH2CO2(CH2)3OEt
O


embedded image







637


embedded image


O


embedded image







638
—(CH2)3CO2CH2Cl
O


embedded image







639


embedded image


O


embedded image







640
—CH2COSBu
O


embedded image







641
—(CH2)2COS(CH2)2NMeEt
O


embedded image







642
—CH2OCOEt
O


embedded image







643
—CH2CONMe2
O


embedded image







644
—(CH2)3CONH(CH2)OMe
O


embedded image







645


embedded image


O


embedded image







646
—CO2Me



embedded image







647
—CO2CH2CH═CH2



embedded image







648
—CO2(CH2)2OMe



embedded image







649
—CO2(CH2)2OH



embedded image







650
—CO2Bn



embedded image







651


embedded image





embedded image







652
—CH2CO2CH2Cl



embedded image







653
—CH2CO2(CH2)3OEt



embedded image







654


embedded image





embedded image







655


embedded image





embedded image







656
—(CH2)2CO2Bn



embedded image







657
—(CH2)3CO2CH2Cl



embedded image







658
—(CH2)2CO2(CH2)2OH



embedded image







659


embedded image





embedded image







660


embedded image





embedded image







661
—COS—iPr



embedded image







662
—CH2COS(CH2)2OMe



embedded image







663
—(CH2)2COS(CH2)2NMeEt



embedded image







664
—(CH2)3OCO2(CH2)2OMe



embedded image







665
—(CH2)2OCOBn



embedded image







666


embedded image





embedded image







667
—CH2CONH(CH2)NMe2



embedded image







668


embedded image





embedded image







669
—CH2OCONMe2



embedded image







670


embedded image





embedded image







671
—CH2CO2CH2CF3
NMe


embedded image







672
—CH2CO2(CH2)4OH
NH


embedded image







673


embedded image


NEt


embedded image







674
—(CH2)2CO2Bn
NMe


embedded image







675
—(CH2)4CO2(CH2)3OEt
NH


embedded image







676


embedded image


NEt


embedded image







677


embedded image


NMe


embedded image







678
—CH2COS(CH2)2OH
NH


embedded image







679
—(CH2)2COS(CH2)2NMeEt
NEt


embedded image







680
—(CH2)3OCO2(CH2)2OMe
NMe


embedded image







681
—(CH2)2OCOBn
NH


embedded image







682
—CH2CONMe2
NEt


embedded image







683


embedded image


NMe


embedded image







684
—CH2OCONMe2
NH


embedded image







685


embedded image


NEt


embedded image







686


embedded image


S


embedded image







687
—CH2CO2Me
S


embedded image







688


embedded image


S


embedded image







689
—(CH2)4CO2(CH2)3OEt
S


embedded image







690


embedded image


S


embedded image







691
—CH2COS(CH2)2OMe
S


embedded image







692
—(CH2)3OCO2(CH2)2OMe
S


embedded image







693


embedded image


S


embedded image







694


embedded image


S


embedded image







695


embedded image


S


embedded image







696


embedded image


O


embedded image







697
—CH2CO2(CH2)4OH
O


embedded image







698


embedded image


O


embedded image







699
—(CH2)4CO2Et
O


embedded image







700


embedded image


O


embedded image







701
—CH2COS(CH2)2OH
O


embedded image







702
—CH2OCO2Et
O


embedded image







703
—(CH2)2OCOMe
O


embedded image







704
—CH2CONH(CH2)NMe2
O


embedded image







705
—CH2OCONMe2
O


embedded image







706
—CO2(CH2)2OMe



embedded image







707
—(CH2)2CO2Et



embedded image







708


embedded image





embedded image







709
—CH2COSMe



embedded image







710
—CH2OAc



embedded image







711
—CH2OCO2Me



embedded image







712
—CH2CO2Me



embedded image







713
—CH2CO2(CH2)2NMe2



embedded image







714
—(CH2)2CO2Bn



embedded image







715


embedded image





embedded image







716


embedded image





embedded image







717


embedded image





embedded image







718
—CH2CHMeCO2Me



embedded image







719


embedded image





embedded image







720


embedded image





embedded image







721
—CO2(CH2)2OMe



embedded image







722
—(CH2)2CO2Et



embedded image







723


embedded image





embedded image







724
—CH2CONMe2



embedded image







725
—CH2OCO(CH2)2OH



embedded image







726
—CH2OCONMe2



embedded image







727
—(CH2)2CO2Bn



embedded image







728


embedded image





embedded image







729


embedded image





embedded image







730


embedded image





embedded image







731
—CH2CHMeCO2Me



embedded image







732


embedded image





embedded image







733


embedded image





embedded image







734
—COS(CH2)2OMe



embedded image







735
—CO2(CH2)2OH



embedded image







736
—CHMeCO2CH2CF3



embedded image







737


embedded image





embedded image







738
—CH2COSMe



embedded image







739
—CH2OAc



embedded image







740
—CH2OCO2Et



embedded image







741
—(CH2)2CO2Bn



embedded image







742


embedded image





embedded image







743


embedded image





embedded image







744


embedded image





embedded image







745
—CH2CHMeCO2Me



embedded image







746


embedded image





embedded image







747
—(CH2)2OCO2CH2CF3



embedded image







748
—CH2CONMe(CH2)2OH



embedded image







749
—CO2(CH2)2OMe



embedded image







750
—(CH2)2CO2Et



embedded image







751


embedded image





embedded image







752
—CH2COSMe



embedded image







753
—CH2OAc



embedded image







754
—CH2OCO2Me



embedded image







755


embedded image





embedded image







756


embedded image





embedded image







757
—CH2CHMeCO2Me



embedded image







758


embedded image





embedded image







759
—(CH2)2OCO2CH2CF3



embedded image







760
—CH2OCO(CH2)2OMe



embedded image







761
—CH2OCONMe2



embedded image







762
—(CH2)2CO2Bn



embedded image







763


embedded image





embedded image







764
—CH2CO2(CH2)2NMe2



embedded image







765
—(CH2)2CO2Bn



embedded image







766


embedded image





embedded image







767
—CH2COSMe



embedded image







768
—CH2OCO2Et



embedded image







769
—CHMeCO2CH2CF3



embedded image







770
—CO2(CH2)2OMe



embedded image







771


embedded image





embedded image







772
—CH2OAc



embedded image







773


embedded image





embedded image







774
—CH2CHMeCO2Me



embedded image







775
—(CH2)2OCO2CH2CF3



embedded image







776
—CH2OCONMe2



embedded image







777


embedded image





embedded image







778
—(CH2)2CO2Bn



embedded image







779
—CO2(CH2)2OMe



embedded image







780


embedded image





embedded image







781
—CH2OCO(CH2)2OH



embedded image







782
—CO2(CH2)2OMe



embedded image







783


embedded image





embedded image







784
—CH2OCO(CH2)2OEt



embedded image







785
—(CH2)2CO2Bn



embedded image







786
—CH2CO2(CH2)2OMe
NH


embedded image







787


embedded image


NEt


embedded image







788
—(CH2)2OAc
NMe


embedded image







789
—CH2CO2Me
NH


embedded image







790
—(CH2)2CO2Bn
NEt


embedded image







791


embedded image


NMe


embedded image







792
—CH2CHMeCO2Me
NH


embedded image







793


embedded image


NEt


embedded image







794
—CH2CO2(CH2)2OMe
NH


embedded image







795


embedded image


NEt


embedded image







796
—(CH2)3OCO(CH2)2OH
NMe


embedded image







797
—(CH2)2CO2Bn
NH


embedded image







798


embedded image


NEt


embedded image







799
—CH2CHMeCO2Me
NMe


embedded image







800


embedded image


NMe


embedded image







801
—CH2CO2(CH2)2OH
NH


embedded image







802


embedded image


NEt


embedded image







803
—(CH2)2OCOPr
NMe


embedded image







804
—(CH2)2CO2Bn
NH


embedded image







805


embedded image


NEt


embedded image







806
—CH2CHMeCO2Me
NMe


embedded image







807
—(CH2)2OCO2CH2CF3
NMe


embedded image







808
—CH2CO2Me
NH


embedded image







809


embedded image


NEt


embedded image







810
—(CH2)4OAc
NMe


embedded image







811


embedded image


NH


embedded image







812
—CH2CHMeCO2Me
NEt


embedded image







813
—(CH2)2OCO2CH2CF3
NMe


embedded image







814
—(CH2)3OCONMe2
NH


embedded image







815


embedded image


NEt


embedded image







816
—(CH2)2CO2Bn
NMe


embedded image







817
—CH2COSMe
NH


embedded image







818
—CHMeCO2CH2CF3
NEt


embedded image







819


embedded image


NMe


embedded image







820


embedded image


NH


embedded image







821
—(CH2)2OCO2CH2CF3
NEt


embedded image







822


embedded image


NMe


embedded image







823
—CH2CO2Bu
NH


embedded image







824
—(CH2)2OCO(CH2)2OH
NEt


embedded image







825


embedded image


NH


embedded image







826
—(CH2)2CO2Bn
NEt


embedded image







827
—CH2CO2iPr
S


embedded image







828
—(CH2)2CO2Et
S


embedded image







829
—CH2COSMe
S


embedded image







830
—(CH2)2OCOEt
S


embedded image







831
—CH2CO2Me
S


embedded image







832
—CH2CO2(CH2)2NMe2
S


embedded image







833


embedded image


S


embedded image







834


embedded image


S


embedded image







835
—CH2CHMeCO2Me
S


embedded image







836


embedded image


S


embedded image







837
—CH2CO2(CH2)2OMe
S


embedded image







838
—(CH2)2CO2Et
S


embedded image







839
—CH2CONMe2
S


embedded image







840
—CH2OCO(CH2)2OH
S


embedded image







841
—(CH2)2CO2Bn
S


embedded image







842


embedded image


S


embedded image







843


embedded image


S


embedded image







844
—CH2CHMeCO2Me
S


embedded image







845


embedded image


S


embedded image







846
—CH2COS(CH2)2NMe2
S


embedded image







847
—(CH2)4CO2Me
S


embedded image







848
—CHMeCO2CH2CF3
S


embedded image







849
—CH2COSMe
S


embedded image







850
—(CH2)3OAc
S


embedded image







851
—(CH2)2CO2Bn
S


embedded image







852


embedded image


S


embedded image







853


embedded image


S


embedded image







854
—CH2CHMeCO2Me
S


embedded image







855
—(CH2)4OCO2CH2CF3
S


embedded image







856
—CH2CONMe(CH2)2OH
S


embedded image







857
—CH2CO2(CH2)2OMe
S


embedded image







858
—(CH2)3CO2Et
S


embedded image







859
—CH2COSMe
S


embedded image







860
—(CH2)2OCO(CH2)2OMe
S


embedded image







861


embedded image


S


embedded image







862


embedded image


S


embedded image







863


embedded image


S


embedded image







864
—(CH2)2OCO2CH2CF3
S


embedded image







865
—(CH2)2OCONMe2
S


embedded image







866
—(CH2)2CO2Bn
S


embedded image







867
—CH2CO2(CH2)2NMeEt
S


embedded image







868
—(CH2)2CO2Bn
S


embedded image







869
—CH2COSMe
S


embedded image







870
—(CH2)3OCO2Et
S


embedded image







871
—CHMeCH2CO2(CH2)2OMe
S


embedded image







872


embedded image


S


embedded image







873


embedded image


S


embedded image







874
—CH2CHMeCO2Me
S


embedded image







875
—(CH2)2OCONMe2
S


embedded image







876


embedded image


S


embedded image







877
—CH2CO2(CH2)2OMe
S


embedded image







878


embedded image


S


embedded image







879
—CH2CO2(CH2)2NMe2
S


embedded image







880


embedded image


S


embedded image







881
—(CH2)2CO2Bn
S


embedded image







882
—(CH2)2CO2Et
O


embedded image







883
—CH2COSMe
O


embedded image







884
—(CH2)2OCO2Me
O


embedded image







885
—CH2CO2(CH2)2NMe2
O


embedded image







886


embedded image


O


embedded image







887


embedded image


O


embedded image







888


embedded image


O


embedded image







889
—(CH2)2CO2Et
O


embedded image







890
—CH2CONMe2
O


embedded image







891
—(CH2)2OCONMe2
O


embedded image







892


embedded image


O


embedded image







893


embedded image


O


embedded image







894


embedded image


O


embedded image







895
—CH2COS(CH2)2OMe
O


embedded image







896
—CHMeCO2CH2CF3
O


embedded image







897
—CH2COSMe
O


embedded image







898
—(CH2)5OCO2Et
O


embedded image







899


embedded image


O


embedded image







900


embedded image


O


embedded image







901


embedded image


O


embedded image







902
—CH2CONMe(CH2)2OH
O


embedded image







903
—CH2CO2Bu
O


embedded image







904


embedded image


O


embedded image







905
—(CH2)3OAc
O


embedded image







906


embedded image


O


embedded image







907
—CH2CHMeCO2Me
O


embedded image







908
—(CH2)2OCO2CH2CF3
O


embedded image







909
—(CH2)2OCONMe2
O


embedded image







910


embedded image


O


embedded image







911
—(CH2)2CO2Bn
O


embedded image







912
—CH2COSMe
O


embedded image







913
—CHMeCO2CH2CF3
O


embedded image







914


embedded image


O


embedded image







915


embedded image


O


embedded image







916
—(CH2)2OCO2CH2CF3
O


embedded image







917


embedded image


O


embedded image







918
—(CH2)3CO2(CH2)2OMe
O


embedded image







919
—(CH2)2OCO(CH2)2OH
O


embedded image







920


embedded image


O


embedded image







921
—(CH2)2CO2Bn
O


embedded image











INDUSTRIAL APPLICABILITY

The present invention provides an adenine compound useful as a medicament for the topical administration which is characterized in showing the medical effect by the topical administration and showing none of the systemically pharmacological activity. The therapy and prevention for allergic diseases such as asthma and atopic dermatitis, viral diseases such as herpes, etc. becomes possible.

Claims
  • 1. A topically administrable medicament containing an adenine compound represented by a general formula (1):
  • 2. A topically administrable medicament containing an adenine compound represented by a general formula (1):
  • 3. The topically administrable medicament according to claim 2, wherein in the general formula (1), the substituent(s), by which alkyl group, alkenyl group or alkynyl group in R10, R11 and R12 is substituted, are the same or different and at least one substituent selected from the group consisting of halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heterocyclic group.
  • 4. The topically administrable medicament according to claim 2, wherein in the general formula (1), Z is methylene and Ring A is benzene.
  • 5. The topically administrable medicament according to claim 2, wherein in the general formula (1), Y1 is C1-5 alkylene, Q1 is hydrogen atom, hydroxy group or alkoxy group, Y2 is a single bond, and Q2 is —COOR10.
  • 6. The topically administrable medicament according to claim 2, wherein in the general formula (1), Z is methylene, Ring A is benzene, R10 is alkyl group substituted by hydroxy group, amino group, alkylamino group or dialkylamino group, and m is 1.
  • 7. The topically administrable medicament according to claim 2, wherein in the general formula (1), Y1 is C1-5 alkylene, Q1 is hydrogen atom, hydroxy group or alkoxy group, Y2 is C1-3 alkylene, Q2 is —COOR10, and m is 1.
  • 8. The topically administrable medicament according to claim 2, wherein in the general formula (1), m is 0, Y1 is C1-6 alkylene which may be substituted with oxo group, and Q1 is —COOR10, —COSR10, —OCOR10, —OCOOR10, —CONR11R12 or —OCONR11R12.
  • 9. The topically administrable medicament according to claim 2, wherein in the general formula (1) X1 is oxygen atom, sulfur atom or NR1 (wherein R1 is hydrogen atom or alkyl group).
  • 10. The topically administrable medicament according to claim 2, wherein in the general formula (1), m is 0, X1 is a single bond, Y1 is C1-4 alkylene which may be substituted by oxo group, and Q1 is —COOR10.
  • 11. The topically administrable medicament according to claim 2, wherein in the general formula (1), the limitation is either 1) or 2) below: 1) n is 0;2) n is 1 or 2, and R is alkyl group, alkoxy group or halogen atom.
  • 12. The adenine compound or its pharmaceutically acceptable salt of claim 1, wherein in the general formula (1), Z is methylene, Ring A is a 5 to 10 membered mono or bicyclic hetero ring containing 1 to 3 heteroatoms selected from the group consisting of 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom.
  • 13. The adenine compound or its pharmaceutically acceptable salt of claim 1, wherein in the general formula (1), the heteroaromatic ring in Ring A is furan, thiophene, or pyridine.
  • 14. The adenine compound or its pharmaceutically acceptable salt according to claim 12, wherein in the general formula (1), Q1 is hydrogen atom, hydroxy group or alkoxy group, Y1 is C1-5 alkylene, Q2 is —COOR10 (wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group), and m is 1.
  • 15. The adenine compound or its pharmaceutically acceptable salt according to claim 12, wherein in the general formula (1), Y2 is a single bond.
  • 16. The adenine compound, its tautomer or its pharmaceutically acceptable salt according to claim 12, wherein in the general formula (1), m is 0, Y1 is C1-6 alkylene which may be substituted by oxo group, and Q1 is —COOR10, —COSR10, —OCOR10, —OCOOR10, —CONR11R12 or —OCONR11R12 (wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R11 and R12 are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R11 and R12 may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s)); and any group selected from the following formulas (3)˜(6):
  • 17. The adenine compound or its pharmaceutically acceptable salt according to claim 12, wherein in the general formula (1), the substituent(s) by which alkyl group, alkenyl group or alkynyl group in R10, R11, R12, R20, R21 and R22 is substituted, are at least one substituent selected from the group consisting of halogen atom, hydroxy group, substituted or unsubstituted alkoxy group, substituted or unsubstituted amino group, substituted or unsubstituted aryl group, and substituted or unsubstituted heterocyclic group.
  • 18. The adenine compound or its pharmaceutically acceptable salt according to claim 12, wherein R is hydrogen atom, alkyl group, alkoxy group, or halogen atom.
  • 19. The adenine compound or its pharmaceutically acceptable salt according to claim 1, wherein in the general formula (1), Z is methylene, Ring A is benzene, Q1 is hydrogen atom, hydroxy group or alkoxy group, Y1 is C1-5 alkylene, Y2 is a single bond, Q2 is —COOR23 (wherein R23 is alkyl group substituted by amino group, alkylamino group or dialkylamino group), and m is 1.
  • 20. The adenine compound or its pharmaceutically acceptable salt according to claim 12 or 19, wherein in the general formula (1), X1 is oxygen atom, sulfur atom or NR1 (wherein R1 is hydrogen atom or alkyl group).
  • 21. The topically administrable preparation according to claim 2, wherein the preparation is a prophylactic or therapeutic agent for viral diseases, dermal diseases or allergic diseases.
  • 22. The topically administrable preparation according to claim 2 wherein the allergic disease is asthma.
  • 23. The topically administrable preparation according to claim 2 wherein the allergic disease is atopic dermatosis.
  • 24. The topically administrable preparation according to claim 2, wherein the half-life in serum on the compound of the general formula (1) is less than 1 hour.
  • 25. The topically administrable preparation according to claim 2, wherein the half-life in liver S9 of the compound of the general formula (1) is less than 1 hour.
  • 26. The topically administrable preparation according to claim 2, wherein the interferon concentration in serum is less than 10 IU/ml after said compound is topically administered.
  • 27. The topically administrable preparation according to claim 2, wherein the preparation is an inhalation formulation.
  • 28. A method for regulating immune response, comprising topically administering to a patient in need an effective amount of an adenine compound of claim 1.
  • 29. A method for regulating immune response, comprising: topically administering to a patient in need an effective amount of the medicament comprising an adenine compound represented by the formula (1) of claim 2.
  • 30. A method for regulating immune response, comprising topically administering to a patient in need an effective amount of an adenine compound in claim 12 or 19.
  • 31. A method for treatment or prophylaxis of viral diseases, dermal diseases or allergic diseases, comprising topically administering to a patient in need an effective amount of an adenine compound of claim 1.
  • 32. The method according to claim 31 wherein the allergic disease is asthma or atopic dermatosis.
  • 33. A method for treatment or prophylaxis of viral diseases, dermal diseases or allergic diseases, comprising topically administering to a patient in need an effective amount of the medicament of claim 2.
  • 34. A method for treatment or prophylaxis of viral diseases, dermal diseases or allergic diseases, comprising topically administering to a patient in need an effective amount of an adenine compound in claim 12 or 19.
  • 35. The method according to claim 31 wherein the half-life in serum on the compound of the formula (1) is less than 1 hour after said compound is locally administered.
  • 36. The method according to claim 31 wherein the half-life in liver S9 on the compound of the formula (1) is less than 1 hour after said compound is locally administered.
  • 37. The method according to claim 31 wherein the interferon concentration in serum is less than 10 IU/ml after said compound is topically administered.
  • 38. The method according to claim 31, wherein the compound is administered by inhalation formulation.
  • 39. The adenine compound or its pharmaceutically acceptable salt according to claim 17, in which, in formula (1), at least one of Q1 and Q2 is —COSR10, —OCOOR10, —OCOR10 or —OCONR11R12 (wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R11 and R12 are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R11 and R12 may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s)); and any group selected from the following formulas (3)˜(6):
  • 40. The adenine compound or its pharmaceutically acceptable salt according to claim 20, in which, in formula (1), at least one of Q1 and Q2 is —COSR10, —OCOOR10, —OCOR10 or —OCONR11R12 (wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R11 and R12 are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R11 and R12 may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s)); and any group selected from the following formulas (3)˜(6):
  • 41. The method of claim 30, in which in the compound of the formula (1), at least one of Q1 and Q2 is —COSR10, —OCOOR10, —OCOR10 or —OCONR11R12 (wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R11 and R12 are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R11 and R12 may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s)); and any group selected from the following formulas (3)˜(6):
  • 42. The method of claim 34, in which in the compound of the formula (1), at least one of Q1 and Q2 is —COSR10, —OCOOR10, —OCOR10 or —OCONR11R12 (wherein R10 is substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, R11 and R12 are independently hydrogen atom, substituted or unsubstituted alkyl group, substituted or unsubstituted cycloalkyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted cycloalkenyl group, or substituted or unsubstituted alkynyl group, or R11 and R12 may be taken together to form with the adjacent nitrogen atom a 5 to 7 membered heterocycle containing a nitrogen atom(s)); and any group selected from the following formulas (3)˜(6):
Priority Claims (2)
Number Date Country Kind
2002-283428 Sep 2002 JP national
2002-301213 Oct 2002 JP national
Parent Case Info

This application is a Continuation of the U.S. application Ser. No. 12/793,649 filed Jun. 3, 2010, which is a Continuation of the U.S. application Ser. No. 10/528,343 filed Mar. 18, 2005, which is the national stage of International Application PCT/JP2003/012320, filed Sep. 26, 2003, which claims priority under 35 USC §119(a)-(d) of Japanese Application No. 2002-283428, filed Sep. 27, 2002 and of Japanese Application No. 2002-301213, filed Oct. 16, 2002.

Continuations (2)
Number Date Country
Parent 12793649 Jun 2010 US
Child 13402850 US
Parent 10528343 Mar 2005 US
Child 12793649 US